

Please type a plus sign (+) inside this box ☐

08-2205

AF 17W
1547

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/991,854
Filing Date	November 14, 2001
First Named Inventor	AVI ASHKENAZI
Group/Art Unit	1647
Examiner Name	Landsman, Robert S.
Attorney Docket Number	39780-2730P1C24

Total Number of Pages in This Submission

86

ENCLOSURES (check all that apply)

☒ **Fee Transmittal Form**

☐ Fee Attached

☐ **AMENDMENT / RESPONSE**

☐ After Final

☐ Version With Markings Showing Changes

☐ Affidavits/declaration(s)

☒ **Extension of Time Request**

☐ INFORMATION DISCLOSURE STATEMENT WITH FORM PTO-1449

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Copy of Notice

☐ **DECLARATION**

☐ DECLARATION ON INCORPORATION BY REFERENCE

☐ AMENDMENT UNDER 37 CFR §1.48(b)

☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers

☐ Terminal Disclaimer

☐ Small Entity Statement

☐ Request for Refund

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☒ **Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)**

☐ Proprietary Information

☐ Status Letter

☒ **ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW):**

☒ **EVIDENCE APPENDIX ITEMS A-E; STAMPED RETURN POSTCARD**

Remarks

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39780-2730 P1C24.

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	HELLER EHRMAN LLP	BARRIE D. GREENE (Reg. No. 46,740)
	275 Middlefield Road, Menlo Park, California 94025	Telephone: (650) 324-7000 Facsimile: (650) 324-0638
Signature	<i>Barrie D. Greene</i>	
Date	August 19, 2005	Customer Number: 35489

CERTIFICATE OF EXPRESS MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: **MAIL STOP APPEAL BRIEFS-PATENTS**, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: **August 19, 2005**

Express Mail Label **EL 993 631 050 US**

Typed or printed name	ELENA TORRES		
Signature	<i>Elena Torres</i>	Date	August 19, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop APPEAL BRIEFS-PATENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



FREE TRANSMITTAL for FY 2005

Effective 12/08/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 2,660.00

Complete if Known

Application Number **09/991,854**
Filing Date **November 14, 2001**
First Named Inventor **Ashkenazi, et al.**
Examiner Name **Landsman, Robert S.**
Art Unit **1647**
Attorney Docket No. **39780-2730P1C24**

METHOD OF PAYMENT (check one)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number **08-1641 (Docket No. 39780-2730P1C24)**

Deposit Account Name **Heller Ehrman LLP**

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1001	300	2001	150	Utility filing fee	
1002	350	2002	175	Design filing fee	
1003	550	2003	275	Plant filing fee	
1004	790	2004	395	Reissue filing fee	
1005	200	2005	100	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
20** =			
Independent Claims	-3** =		0
Multiple Dependent			0

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
1202	50	2202	25	Claims in excess of 20
1201	200	2201	100	Independent claims in excess of 3
1203	360	2203	180	Multiple dependent claim, if not paid
1204	200	2204	100	**Reissue independent claims over original patent
1205	50	2205	25	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1,020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1,080	Extension for reply within fifth month	2,160.00
1401	500	2401	250	Notice of Appeal	
1402	500	2402	250	Filing a brief in support of an appeal	500.00
1403	1,000	2403	500	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	500	2452	250	Petition to revive - unavoidable	
1453	1,500	2453	750	Petition to revive - unintentional	
1501	1,400	2501	700	Utility issue fee (or reissue)	
1502	800	2502	400	Design issue fee	
1503	1,100	2503	550	Plant issue fee	
1460		1460		Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 2,660.00

SUBMITTED BY

Name (Print/Type) **Barrie D. Greene**

Signature *Barrie D. Greene*

Registration No. (Attorney/Agent) **46,740**

Date **AUGUST 19, 2005**

Complete (if applicable)

Telephone **650-324-7000**

Customer No. **35489**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Examiner: Landsman, Robert S.
Avi ASHKENAZI, <i>et al.</i>)
) Art Unit: 1647
)
Application Serial No. 09/991,854) Confirmation No: 3241
)
Filed: November 14, 2001) Attorney's Docket No. 39780-2730 P1C24
)
For: ANTIBODIES TO PRO1346) Customer No. 35489
POLYPEPTIDES)
)

EXPRESS MAIL LABEL NO.: EL 993 631 050 US
DATE MAILED: August 19, 2005

ON APPEAL TO THE BOARD OF PATENT APPEALS AND INTERFERENCES

APPELLANTS' BRIEF

MAIL STOP APPEAL BRIEF - PATENTS

Commissioner for Patents -
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

On October 21, 2004, the Examiner made a final rejection to pending Claims 119-121 and 123. A Notice of Appeal was filed on January 20, 2005.

Appellants hereby appeal to the Board of Patent Appeals and Interferences from the last decision of the Examiner. A request for a 5 month extension of time is filed concurrently herewith.

The following constitutes Appellants' Brief on Appeal.

08/23/2005 EFLORES 00000129 081641 09991854

01 FC:1255 2160.00 DA

08/23/2005 EFLORES 00000129 081641 09991854

02 FC:1402 500.00 DA

1. REAL PARTY IN INTEREST

The real party in interest is Genentech, Inc., South San Francisco, California, by an assignment of the patent application U.S. Serial No. 09/941,992, recorded November 16, 2001, at Reel 012176 and Frame 0450.

2. RELATED APPEALS AND INTERFERENCES

The claims pending in the current application are directed to a polypeptide referred to herein as "PRO1346". There exist two related patent applications, (1) U.S. Serial No. 09/993,748, filed November 14, 2001 (containing claims directed to the PRO1346 polypeptides), and (2) U.S. Serial No. 09/989,729, filed November 19, 2001 (containing claims directed to polynucleotides encoding the PRO1346 polypeptides). Both applications are also under final rejection from the same Examiner and based upon the same outstanding rejection, and appeal of these final rejections is being pursued independently and concurrently herewith.

3. STATUS OF CLAIMS

Claims 119-121 and 123 are in this application.

Claims 1-118, 122 and 124 are canceled.

Claims 119-121 and 123 stand rejected and Appellants appeal the rejection of these claims.

A copy of the rejected claims involved in the present Appeal is provided in the Appendix.

4. STATUS OF AMENDMENTS

The claims involved in the appeal have been amended by an amendment filed August 15, 2005. The claims listed in the Appendix incorporate this amendment.

5. SUMMARY OF CLAIMED SUBJECT MATTER

The invention claimed in the present application concerns an isolated antibody, or fragment thereof, that specifically binds to the polypeptide of SEQ ID NO: 314 (Claim 119). The invention further provides monoclonal antibodies (Claim 120), humanized antibodies (Claim 121), and labeled antibodies (Claim 123) that specifically bind to the polypeptide of SEQ ID NO:314.

Support for the preparation and uses of antibodies is found throughout the specification, including, for example, pages 390-398. The preparation of antibodies is described in Example 144, while Example 145 describes the use of the antibodies for purifying the polypeptides to which they bind. Isolated antibodies are defined in the specification at page 315, line 31, to page 316, line 3. Support for monoclonal antibodies is found in the specification at, for example, page 390, line 17, to page 392, line 3, and Example 144. Support for humanized antibodies is found in the specification at, for example, page 392, line 4, to page 393, line 5. Support for antibody fragments is found in the specification at, for example, page 314, line 30, to page 315, line 24, and page 394, lines 10-28. Support for labeled antibodies is found in the specification at, for example, page 316, lines 3-6, and page 397, line 31, to page 398, line 3.

The polypeptide of SEQ ID NO:314 is designated PRO346, and its amino acid sequence is shown in Figure 228, while the encoding nucleic acid sequence (SEQ ID NO:313) is shown in Figure 227. PRO1346 is described as a TIE ligand homolog (see, for example, page 31 lines 6-7, and page 361, lines 24-26). The isolation of cDNA clones encoding PRO1346 of SEQ ID NO:314 is described in Example 100. Examples 140-143 describe the expression of PRO polypeptides in various host cells, including *E. coli*, mammalian cells, yeast and Baculovirus-infected insect cells. Finally, Example 143, in the specification at page 525, lines 1-32, line 28, shows that PRO1346 tested positive in the mixed lymphocyte reaction (MLR) assay, demonstrating that PRO1346 is active as a stimulator of the proliferation of stimulated T-lymphocytes, and therefore would have utility in the treatment of conditions where the enhancement of an immune response would be beneficial.

The specification discloses that antibodies to PRO polypeptides may be used, for example, in purification of PRO (page 398, lines 4-10 and Example 145), in diagnostic assays for

PRO expression (page 380, lines 22-28, and page 397, line 31 to page 398, line 3), as antagonists to PRO (page 388, lines 33-37), and as elements of pharmaceutical compositions for the treatment of various disorders (page 396, line 27, to page 397, line 26).

6. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL

- I. Whether Claims 119-121 and 123 satisfy the utility requirement of 35 U.S.C. §101.
- II. Whether Claims 119-121 and 123 satisfy the enablement requirement of 35 U.S.C. §112, first paragraph.
- III. Whether Claims 119-121 and 123 are patentable under 35 U.S.C. §102(b) over Fernandez *et al.* (WO 00/61754, published October 19, 2000).

7. ARGUMENT

Summary of the Arguments:

Issue I: Utility

Appellants have previously explained that patentable utility of the PRO1346 polypeptide and the antibodies which bind it is based upon the data derived from the mixed leukocyte reaction (MLR) assay. The specification discloses that PRO1346 showed positive activity in the MLR assay (see Example 151). The MLR is a well-established assay for evaluating test compounds for their ability to stimulate T-lymphocyte proliferation *in vitro*. The specification explains that compounds which stimulate proliferation of lymphocytes in this assay, such as PRO1346, "are useful therapeutically where enhancement of an immune response is beneficial." Stimulators of T-cell proliferation find utility in fighting viral infections, including retroviral infections, such as HIV infection or Epstein-Barr infection, as well as in the treatment of cancers such as melanoma.

Appellants have also submitted, with their Response filed September 9, 2004, the Declaration of Dr. Sherman Fong. Dr. Fong provides examples of important clinical applications for immune stimulants which have been shown to stimulate T-cell proliferation in the MLR assay, such as the chemokine IL-12, used in the treatment of melanoma. Dr. Fong concludes that "a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present

invention with an activity at least 180% of the control, as specified in the present application, is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant."

Appellants submit that the Examiner applied an improper legal standard when making this rejection. The applicant does not have to prove that a correlation exists between a particular activity and an asserted therapeutic use of a compound as a matter of statistical certainty. The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the totality of the evidence under consideration. Thus, to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the Examiner has made a proper *prima facie* showing of lack of utility, does the burden of rebuttal shift to the applicant.

The Examiner takes issue with Dr. Fong's statement that "[t]he MLR assay of the present application is designed to measure the ability of a test substance to 'drive' the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously," asserting that this statement is not supported in the specification as filed. Appellants submit that one of skill in the art would have understood at the time of filing that (i) molecules which enhanced the proliferation of stimulated T-cells would increase the ability of dendritic cells to convert antigens to immunogens, and (ii) such stimulatory molecules would allow antigens that were not usually immunogenic, such as known melanoma or viral antigens, to become immunogenic. This conclusion would have been apparent to the skilled artisan based solely upon knowledge about dendritic cells and their role in antigen presentation that was widely known in the art at the time of filing.

Appellants submit that the Examiner has not shown that it is more likely than not that one of ordinary skill in the art would doubt the truth of Appellants' statement of utility. Appellants have provided a Declaration from an expert in the art which supports the statements in the specification as filed that molecules such as PRO1346, which test positive in the MLR assay, have therapeutic utility as immunostimulants. The art of record, such as Gubler *et al.*,

confirms that in vitro assays such as the MLR assay can be successfully used to identify compounds having immunomodulatory activity in vivo. The Patent Office has not cited any references or other evidence to demonstrate that one of ordinary skill in the art would find it more likely than not that molecules which test positive in the disclosed MLR assay would not have real-world therapeutic utility. Thus the Patent Office has failed to meet its initial burden of proof that Appellants' claims of utility are not substantial or credible.

Accordingly, Appellants submit that when the proper legal standard is applied, one should reach the conclusion that the present application discloses at least one patentable utility for the PRO1346 polypeptide and the claimed antibodies which bind it.

Issue II: Enablement

Claims 119-121 and 123 stand rejected under 35 U.S.C. §112, first paragraph, allegedly "since the claimed invention is not supported by a specific, substantial and credible asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention." (Page 6 of the Office Action mailed March 9, 2004).

Appellants submit that, as discussed above, the MLR assay demonstrates utility for the PRO1346 polypeptide for the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable, including viral infections such as HIV and Epstein-Barr, and cancers such as melanoma. Based on such a utility, one of skill in the art would know exactly how to use the claimed antibodies that bind the PRO1346 polypeptide, for example in the purification of PRO1346 to be used in the therapeutic applications described above, without any undue experimentation.

Issue III: Anticipation by Fernandez *et al.*, WO 00/61754

Claims 119-121 and 123 stand rejected under 35 U.S.C. §102 as allegedly being anticipated by Fernandez *et al.* (WO 00/61754, published October 19, 2000).

The instant application claims priority to PCT/US00/05841, which discloses data generated in an MLR assay that establish a patentable utility for the claimed invention. PCT/US00/05841 was filed March 2, 2000, over seven months before the publication date of Fernandez *et al.* The instant application has not been granted the earlier priority date on the grounds that "a review of the instant application and this assay do not lead to a conclusion of

utility based on this assay", and therefore, priority to the PCT application is not afforded (Page 2 of the Office Action mailed October 21, 2004). Appellants respectfully submit that as discussed above under Issues I and II, the presently claimed invention is supported by a specific, substantial and credible utility and, therefore, the present specification teaches one of ordinary skill in the art "how to use" the claimed invention without undue experimentation. Accordingly, the instant application is entitled to at least the effective filing date of March 2, 2000, and thus Fernandez et al. is not prior art.

These arguments are all discussed in further detail below under the appropriate headings.

ISSUE I: Claims 119-121 and 123 satisfy the utility requirement of 35 USC §101

Claims 119-121 and 123 stand rejected under 35 U.S.C. §101 because allegedly "the claimed invention is not supported by a specific, substantial and credible asserted utility or a well established utility." (Page 3 of the Office Action mailed March 9, 2004).

Appellants submit, for the reasons set forth below, that the specification discloses at least one credible, substantial and specific asserted utility for the claimed antibodies that bind the PRO1346 polypeptide.

A. The Legal Standard for Utility

According to 35 U.S.C. § 101:

Whoever invents or discovers any new and *useful* process, machine, manufacture, or composition of matter, or any new and *useful* improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. (Emphasis added.)

In interpreting the utility requirement, in *Brenner v. Manson*,¹ the Supreme Court held that the *quid pro quo* contemplated by the U.S. Constitution between the public interest and the interest of the inventors required that a patent applicant disclose a "substantial utility" for his or her invention, *i.e.* a utility "where specific benefit exists in currently available form."² The Court concluded that "a patent is not a hunting license. It is not a reward for the search, but

¹ *Brenner v. Manson*, 383 U.S. 519, 148 U.S.P.Q. (BNA) 689 (1966).

² *Id.* at 534, 148 U.S.P.Q. (BNA) at 695.

compensation for its successful conclusion. A patent system must be related to the world of commerce rather than the realm of philosophy."³

Later, in *Nelson v. Bowler*,⁴ the C.C.P.A. acknowledged that tests evidencing pharmacological activity of a compound may establish practical utility, even though they may not establish a specific therapeutic use. The court held that "since it is crucial to provide researchers with an incentive to disclose pharmaceutical activities in as many compounds as possible, we conclude adequate proof of any such activity constitutes a showing of practical utility."⁵

In *Cross v. Iizuka*,⁶ the C.A.F.C. reaffirmed *Nelson*, and added that *in vitro* results might be sufficient to support practical utility, explaining that "*in vitro* testing, in general, is relatively less complex, less time consuming, and less expensive than *in vivo* testing. Moreover, *in vitro* results with the particular pharmacological activity are generally predictive of *in vivo* test results, i.e. there is a reasonable correlation there between."⁷ The court perceived "No insurmountable difficulty" in finding that, under appropriate circumstances, "*in vitro* testing, may establish a practical utility."⁸

Furthermore, M.P.E.P. §2107.03 (III) states that:

"If reasonably correlated to the particular therapeutic or pharmacological utility, data generated using *in vitro* assays, or from testing in an animal model or a combination thereof almost invariably will be sufficient to establish therapeutic or pharmacological utility for a compound, composition or process."

Thus, the legal standard recognizes that *in vitro* or animal model data is acceptable to establish utility as long as the data is "reasonably correlated" to the pharmacological utility described.

³ *Id.* at 536, 148 U.S.P.Q. (BNA) at 696.

⁴ *Nelson v. Bowler*, 626 F.2d 853, 206 U.S.P.Q. (BNA) 881 (C.C.P.A. 1980).

⁵ *Id.* at 856, 206 U.S.P.Q. (BNA) at 883.

⁶ *Cross v. Iizuka*, 753 F.2d 1047, 224 U.S.P.Q. (BNA) 739 (Fed. Cir. 1985).

⁷ *Id.* at 1050, 224 U.S.P.Q. (BNA) at 747.

⁸ *Id.*

The case law has also clearly established that applicants' statements of utility are usually sufficient, unless such statement of utility is unbelievable on its face.⁹ The PTO has the initial burden to prove that applicants' claims of usefulness are not believable on their face.¹⁰ In general, an Applicant's assertion of utility creates a presumption of utility that will be sufficient to satisfy the utility requirement of 35 U.S.C. §101, "unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope."^{11, 12}

Compliance with 35 U.S.C. §101 is a question of fact.¹³ The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the totality of the evidence under consideration.¹⁴ Thus, to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the Examiner made a proper *prima facie* showing of lack of utility, does the burden of rebuttal shift to the applicant. The issue will then be decided on the totality of evidence.

The well established case law is clearly reflected in the Utility Examination Guidelines ("Utility Guidelines")¹⁵, which acknowledge that an invention complies with the utility requirement of 35 U.S.C. §101, if it has at least one asserted "specific, substantial, and credible utility" or a "well-established utility." Under the Utility Guidelines, a utility is "specific" when it is particular to the subject matter claimed. For example, it is generally not enough to state that a nucleic acid is useful as a diagnostic without also identifying the conditions that are to be diagnosed.

⁹ *In re Gazave*, 379 F.2d 973, 154 U.S.P.Q. (BNA) 92 (C.C.P.A. 1967).

¹⁰ *Ibid.*

¹¹ *In re Langer*, 503 F.2d 1380,1391, 183 U.S.P.Q. (BNA) 288, 297 (C.C.P.A. 1974).

¹² See also *In re Jolles*, 628 F.2d 1322, 206 USPQ 885 (C.C.P.A. 1980); *In re Irons*, 340 F.2d 974, 144 USPQ 351 (1965); *In re Sichert*, 566 F.2d 1154, 1159, 196 USPQ 209, 212-13 (C.C.P.A. 1977).

¹³ *Raytheon v. Roper*, 724 F.2d 951, 956, 220 U.S.P.Q. (BNA) 592, 596 (Fed. Cir. 1983) *cert. denied*, 469 US 835 (1984).

¹⁴ *In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d (BNA) 1443, 1444 (Fed. Cir. 1992).

¹⁵ 66 Fed. Reg. 1092 (2001).

In explaining the “substantial utility” standard, M.P.E.P. §2107.01 cautions, however, that Office personnel must be careful not to interpret the phrase “immediate benefit to the public” or similar formulations used in certain court decisions to mean that products or services based on the claimed invention must be “currently available” to the public in order to satisfy the utility requirement. “Rather, any reasonable use that an applicant has identified for the invention that can be viewed as providing a public benefit should be accepted as sufficient, at least with regard to defining a ‘substantial’ utility.”¹⁶ Indeed, the Guidelines for Examination of Applications for Compliance With the Utility Requirement,¹⁷ gives the following instruction to patent examiners: “If the applicant has asserted that the claimed invention is useful for any particular practical purpose . . . and the assertion would be considered credible by a person of ordinary skill in the art, do not impose a rejection based on lack of utility.”

B. Proper Application of the Legal Standard

Appellants submit that the mixed lymphocyte reaction (MLR) assay described in Example 74 is sufficient to establish patentable utility under 35 U.S.C. §101 for the PRO1346 polypeptide and the claimed antibodies that bind it. The positive result for PRO1346 in the MLR assay, described in Example 151, at page 525 of the specification, demonstrates that PRO1346 is active as a stimulator of the proliferation of stimulated T-lymphocytes.

The MLR is a well-established assay for evaluating test compounds, such as the PRO1346 polypeptide, for their ability to stimulate T-lymphocyte proliferation *in vitro*, and consequently, for assessing the immune response of an individual. The MLR assay is well-described in standard textbooks, including, for example, *Current Protocols in Immunology*, unit 3.12; edited by J E Coligan, A M Kruisbeek, D H Marglies, E M Shevach, W Strober, National Institutes of Health, Published by John Wiley & Sons, Inc., which is referenced in Example 74, and the entire content of which is expressly incorporated by reference into the disclosure of the present application (see page 525, lines 6-8). In brief, in this method, an immune response results upon mixing T-cells from antigenically distinct individuals under cell culture conditions.

¹⁶ M.P.E.P. §2107.01.

¹⁷ M.P.E.P. §2107 II (B)(1).

An MLR reaction can be monitored quantitatively by, for example, following the incorporation of tritiated thymidine during DNA synthesis, or by observing blast formation, or by other methods well known in the art.

According to the specification, positive increases over control in this assay are considered to be positive results, with increases of greater than or equal to 180% being preferred. However, any value greater than control indicates a stimulatory effect for the test protein. PRO1346 (SEQ ID NO:314) tested positive in this assay, using the described criteria. Example 151 further explains that compounds which stimulate proliferation of lymphocytes in this assay "are useful therapeutically where enhancement of an immune response is beneficial." Accordingly, PRO1346 has utility in the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable.

In further support of utility based upon the MLR assay, Appellants have submitted (with their Response filed September 9, 2004) the Declaration of Sherman Fong, Ph.D. Dr. Fong is an inventor of the above-identified patent application, and an experienced scientist familiar with the MLR assay, which was used by him and others under his supervision, to test the immune stimulatory or immune inhibitory activity of novel polypeptides discovered in Genentech's Secreted Protein Discovery Initiative project, including PRO1346.

The Fong Declaration explains how the MLR reaction was performed in the instant application using peripheral blood mononuclear cells (PBMCs), which contain responder T-cells, and allogenic, pre-treated (irradiated) PBMCs, which predominantly contained dendritic cells. Dr. Fong proceeds to explain (paragraph 7 of the Declaration) that dendritic cells are potent antigen-presenting cells that are able to "prime native T cells *in vivo*." Once activated by dendritic cells, the T-cells are capable of interacting with other antigen-presenting cells (B cells and macrophages) to produce additional immune responses from these cells.

As Dr. Fong states, the MLR assay of the present application, is designed to measure the ability of a test substance to "drive" the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously. (Paragraph 8 of the Declaration.)

As Dr. Fong emphasizes, immunostimulants are important and highly desirable in the treatment of cancer and in enhancing the effectiveness of previously identified treatments for cancer. Supportive evidence also comes from teachings in the art such as Steinman *et al.* (submitted as Exhibit B with the Response filed September 9, 2004) who state that "...**medicine needs therapies that enhance immunity or resistance to infections and tumors**" (page 1, column 1, line 7; emphasis added).

In paragraph 9 of his Declaration, Dr. Fong provides examples of important clinical applications for immune stimulants which have been shown to stimulate T-cell proliferation in the MLR assay. As Dr. Fong explains,

IL-12 is a known immune stimulant, which has been shown to stimulate T-cell proliferation in the MLR assay. IL-12 was first identified in just such an MLR [Gubler et al. PNAS 88, 4143 (1991) (Exhibit C)]. In a recent cancer vaccine trial, researchers from the University of Chicago and Genetics Institute (Cambridge, MA) have demonstrated the efficacy of the approach, relying on the immune stimulatory activity of IL-12, for the treatment of melanoma. [Peterson et al. Journal of Clinical Oncology 21 (12). 2342-48 (2003) (Exhibit D)] They extracted circulating white blood cells carrying one or more markers of melanoma cells, isolated the antigen, and returned them to the patients. Normally patients would not have an immune response to his or her own human antigens. The patients were then treated with different doses of IL-12, an immune stimulant capable of inducing the proliferation of T cells that have been co-stimulated by dendritic cells. Due to the immune stimulatory effect of IL-12, the treatment provided superior results in comparison to earlier work, where patients' own dendritic cells were prepared from peripheral blood mononuclear cells (PBMCs), treated with antigens, then cultured *in vitro* and returned to the patient to stimulate anti-cancer response. [Turner et al. J. Exp. Med. 190 (11), 1669-78 (1999) (Exhibit E)].

Dr. Fong concludes that (paragraph 10):

It is my considered scientific opinion that a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present invention with an activity at least 180% of the control, as specified in the present application, is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant."

Accordingly, the positive results obtained in this assay clearly establish the immunostimulant utility for the polypeptides claimed in the present application, and the

specification, in turn, enables one skilled in the art to use the compounds for the asserted purpose.

Appellants further submit that the teachings of the specification are properly evaluated through the eyes of one skilled in the pertinent art at the effective filing date of the present application. In 1998 it was well known in the art, as it is today, that T-cells are highly important in the body's natural defense mechanisms for fighting infections. For example, viral infections, such as HIV infection, are well known to result in reduced T cell count. Indeed, the count of T-cell lymphocytes is a generally accepted measure of the extent and seriousness of HIV infection and resultant AIDS. Accordingly, stimulators of T-cell proliferation find utility in fighting viral infections, including retroviral infections, such as HIV infection or Epstein-Barr infection.

It was also well known at the time of filing that T cells can recognize tumor antigens and kill tumors. See, for example, Thurner *et al.*, J. Exp. Med. 190:1669-1678 (1999) (submitted as Exhibit E with the Response filed September 9, 2004), which describes experimental procedures designed to treat melanoma by boosting the immune response. Accordingly, one of skill in the art at the time of filing would have expected immunostimulant molecules such as PRO1346 to also have utility in the treatment of cancers such as melanoma.

The claimed antibodies that bind PRO1346 would therefore have utility in the purification of PRO1346 (see the specification at page 398, lines 4-10 and Example 145), to be used in the therapeutic applications discussed above. Antibodies that bind PRO1346 could also be used as antagonists (see the specification at, for example, page 388, lines 33-37). Such antagonists to PRO1346 would find practical utility when an inhibition of the immune response is desirable, such as in autoimmune disorders (see, for example, paragraph 10 of the Fong Declaration).

As discussed above, the legal standard is that *in vitro* results are acceptable to demonstrate utility. Further, the data derived from the MLR assay is "reasonably correlated" to the asserted pharmacological utility, because one of ordinary skill in the art would understand, based upon the discussion above, that molecules showing immunostimulant activity as measured in the MLR assay would be useful in the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable, including viral infections such as HIV and Epstein-

Barr, and cancers such as melanoma. Accordingly, a valid case for utility has been made and would be considered credible by a person of ordinary skill in the art.

C. A prima facie case of lack of utility has not been established

As a preliminary matter, Appellants submit that, as discussed above, the evidentiary standard to be used throughout *ex parte* examination of a patent application is a preponderance of the totality of the evidence under consideration. Accordingly, Appellants submit that in order to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that **it is more likely than not** that one of ordinary skill in the art would doubt the truth of the statement of utility. With respect to asserted therapeutic utilities based upon *in vitro* data, an applicant "does not have to prove that a correlation exists between a particular activity and an asserted therapeutic use of a compound as a matter of statistical certainty."¹⁸ The law requires only that one skilled in the art should accept that such a correlation is **more likely than not to exist**. Appellants respectfully submit that when the proper evidentiary standard is applied, a correlation must be acknowledged.

The Examiner has asserted that "this [Fong] Declaration is insufficient to overcome the holding of lack of utility based on results of the MLR assay." In particular, the Examiner takes issue with Dr. Fong's statement that "[t]he MLR assay of the present application is designed to measure the ability of a test substance to "drive" the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously." The Examiner states that "[t]his is not what the instant specification asserts at pages 204-206. There is no mention in the instant specification about boosting the immune system 'to respond to a particular antigen that may not have been immunologically active previously'." The Examiner asserts that "Dr. Fong is reading the results of the Peterson et al. reference into the disclosure of the instant specification," and that because this reference was not available at the time the instant application was filed, "reliance on the methods and results of this reference is improper." (Page 3 of the Office Action mailed October

¹⁸ M.P.E.P. 2107.03

21, 2004.)

Appellants submit that the statements of Dr. Fong regarding the purpose of the MLR assay described in the instant specification are not based upon the Peterson *et al.* reference, but upon evidence regarding the properties of antigens and antigen presenting cells that was well known in the immunological art at the time the instant application was filed.

The specification discloses that the stimulator cells used in the MLR assay were treated with 3000 Rads of radiation. As explained in the Fong Declaration,

This irradiation is done in order to create a sample of cells that has mainly dendritic cells. It is known that the dendritic cell population among the PBMCs are differentially affected by irradiation. At low doses (500-1000 Rad), the proliferation of most cells, including the B cells in the PBMCs, is preserved, however, at doses above 2000 Rad, this function of B cells is abolished. Dendritic cells on the other hand, maintain their antigen presentation function even at a 3000 Rad dose of radiation.

Thus one of ordinary skill in the art, upon reading that the cells were treated with 3000 Rads, would have understood that, as a consequence of that treatment, the stimulator cells would be predominantly dendritic cells (DCs).

It was well known at the time of filing that, as disclosed in Steinman *et al.*, "[t]he best studied function of DCs is to convert antigens into immunogens for T cells" (Abstract). Appellants note that article by Steinman *et al.*, published December 2000, is a review article that provides an accurate indication as to what was known in the art at the instant application's asserted priority date of March 2000. It was also the case that "protein antigens often are known for a tumor-like melanoma, or for a virus like HIV-1 whose genetic sequence has been available," but that **these antigens needed to become immunogenic, that is, capable of inducing a T cell response** (Steinman *et al.*, page 585, col. 1; emphasis added). The use of DCs in therapeutic treatment for melanoma was already being tested in clinical trials around priority date of the instant application, as evidenced, for example, by Thurner *et al.*, whose results were completed and published by 1999. Steinman *et al.* further disclose that "[i]n order for an antigen to become a strong immunogen, one needs to provide a stimulus for the final maturation of the DCs," explaining that most DCs in the body **"are in an immature state and lack features leading to a strong T cell response"** (page 585, col. 2; emphasis added).

Thus one of skill in the art would have understood at the time of filing that (i) molecules which enhanced the proliferation of stimulated T-cells would increase the ability of DCs to convert antigens to immunogens, and (ii) such stimulatory molecules would allow antigens that were not usually immunogenic, such as the melanoma or viral antigens described above, to become immunogenic. Therefore, while the specification does not use the precise language that the purpose of the MLR assay was to identify molecules capable of boosting the immune system "to respond to a particular antigen that may not have been immunologically active previously," the structure of the assay, which is designed to find molecules that increase DC-induced T-cell proliferation, is clearly intended to find precisely such molecules. This conclusion would have been apparent to the skilled artisan based solely upon knowledge about DCs and their role in antigen presentation that was widely known in the art at the time of filing.

The Examiner has also disputed the relevance of the Gubler *et al.* article, cited by Dr. Fong in his Declaration as providing an example in which the MLR assay was used to identify a molecule, IL-12, that was proven to also have *in vivo* immunostimulant activity. The Examiner has asserted that "a review of Gubler *et al.* does not reveal the use of MLR in evaluating the biological effects of IL-12" and adds that "further work of researchers regarding IL-12 was not based on the results of a single assay, being the MLR, but rather by a body of work which provides for a number of biological activities of IL-12, which are not disclosed for the claimed invention". (Page 3 of the Office Action mailed October 20, 2004).

Gubler *et al.* identified CLMF (Cytokine Lymphocyte Maturation Factor), a heterodimeric lymphokine, and designated it as interleukin 12. Gubler *et al.* reported the molecular cloning and expression of CLMF (see column 1, last line and Materials and Methods), and performed two biological assays: (i) the T-cell growth factor assay (see Table 1 and Fig. 3 (upper panel) and (ii) the LAK (lymphokine activated killer) cell induction assay. In the T-cell growth factor assay, PHA-activated lymphoblasts prepared from human PBMCs were used to measure lymphoblast proliferation in a tritiated thymidine assay very similar to the instant MLR assay (see legend of Table 1). Table 1 summarizes the results and demonstrates that the two subunits, 35 kDa and 40 kDa of CLMF together showed the highest incorporation (58,615 cpm and 38,361 cpm incorporation for 1:20 and 1:100 dilution). As Gubler *et al.* discloses in column

1, page 4143: "we initiated a search for novel cytokines that would synergize with suboptimal concentrations of recombinant IL-2 to activate cytotoxic lymphocytes *in vitro* and thus might have synergistic immunoenhancing effects when administered together with recombinant IL-2 *in vivo*. This led to the identification of a factor, designated CLMF".

Therefore, while Gubler *et al.* did not use the same MLR assay as disclosed in the instant specification, they used a similar *in vitro* assay of T-cell proliferation, confirming Appellants' assertion that such *in vitro* systems are predictive of *in vivo* efficacy. Further, Appellants submit that the "body of work" performed by Gubler *et al.* was CLMF cDNA cloning, expression, and computer searches for homology, which are routine experiments done to characterize any novel protein and do not represent "a number of biological activities." The only other biological assay performed in this study was the "LAK cell induction assay" discussed above. The activation of lymphocytes in an *in vitro* T-cell proliferation assay similar to the MLR assay was sufficient for the authors to conclude that CLMF/IL-12 was an immunoenhancing agent that could be administered *in vivo*.

The Examiner asserts that there is allegedly "no evidence of record which correlates an activity of at least 180% of control as predictive of an activity of IL-12. It is not clear from what data this conclusion is derived. Therefore, the Declaration is not persuasive to overcome the holding of a lack of utility for the claimed invention based on the MLR assay" (Pages 3-4 of the Office Action mailed October 20, 2004).

The case law has clearly established that in considering affidavit evidence, the Examiner must consider all of the evidence of record anew.¹⁹ "After evidence or argument is submitted by the applicant in response, patentability is determined on the totality of the record, by a preponderance of the evidence with due consideration to persuasiveness of argument"²⁰ Furthermore, the Federal Court of Appeals held in *In re Alton*, "We are aware of no reason why

¹⁹ *In re Rinehart*, 531 F.2d 1084, 189 USPQ 143 (C.C.P.A. 1976); and *In re Piasecki*, 745 F.2d 1015, 226 USPQ 881 (Fed. Cir. 1985).

²⁰ *In re Alton*, 37 USPQ2d 1578, 1584 (Fed. Cir 1996) (quoting *In re Oetiker*, 977 F.2d 1443, 1445, 24 USPQ2d 1443, 1444 (Fed. Cir. 1992)).

opinion evidence relating to a fact issue should not be considered by an examiner"²¹. Applicants also respectfully draw the Examiner's attention to the Utility Examination Guidelines²² which state, "Office personnel must accept an opinion from a qualified expert that is based upon relevant facts whose accuracy is not being questioned; it is improper to disregard the opinion solely because of a disagreement over the significance or meaning of the facts offered." The statement in question from an expert in the field (the Fong Declaration) states that "(i)t is my considered scientific opinion that a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present invention with an activity of at least 180% of the control is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant." Therefore, barring evidence to the contrary regarding the above statement in the Fong Declaration, this rejection is improper under both the case law and the Utility guidelines.

In summary, Appellants respectfully submit that the Examiner has not shown that it is it is more likely than not that one of ordinary skill in the art would doubt the truth of Appellants' statement of utility. As discussed above, Appellants have provided a Declaration from an expert in the art which supports the statements in the specification as filed that molecules such as PRO1346, which test positive in the MLR assay, have therapeutic utility as immunostimulants. The art of record, such as Gubler *et al.*, confirms that *in vitro* assays such as the MLR assay can be successfully used to identify compounds having immunomodulatory activity *in vivo*. Further, the disclosed MLR assay is one which one of skill art would understand, based upon knowledge available at the time of filing, is useful to identify molecules capable of boosting the immune system to respond to viral or tumor antigens that may not have been immunologically active previously. The Patent Office has not cited any references or other evidence to demonstrate that one of ordinary skill in the art would find it more likely than not that molecules which test positive in the disclosed MLR assay would not have real-world therapeutic utility. Thus the

²¹ *In re Alton, supra.*

²² Part IIB, 66 Fed. Reg. 1098 (2001).

Patent Office has failed to meet its initial burden of proof that Appellants' claims of utility are not substantial or credible.

For the reasons given above, Appellants respectfully submit that the results of the MLR assay as shown in Example 151 of the present specification provide a specific, substantial and credible utility under 35 U.S.C. §101 for the claimed invention.

ISSUE II: Claims 119-121 and 123 satisfy the enablement requirement of 35 USC §112, first paragraph.

Claims 119-121 and 123 stand rejected under 35 U.S.C. §112, first paragraph, allegedly "since the claimed invention is not supported by a specific, substantial and credible asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention." (Page 6 of the Office Action mailed March 9, 2004).

In this regard, Appellants refer to the arguments and information presented above in response to the outstanding rejection under 35 U.S.C. § 101, wherein those arguments are incorporated by reference herein. Appellants submit that, as discussed above, the MLR assay demonstrates utility for the PRO1346 polypeptide for the treatment of conditions where the stimulation of lymphocyte proliferation would be desirable, including viral infections such as HIV and Epstein-Barr, and cancers such as melanoma. The claimed antibodies that bind PRO1346 would therefore have utility in the purification of PRO1346 to be used in the therapeutic applications discussed above. Antibodies that bind PRO1346 could also be used as antagonists, which would find practical utility when an inhibition of the immune response is desirable, such as in autoimmune disorders. Based on such a utility, one of skill in the art would know exactly how to use the claimed antibodies that bind PRO1346, without any undue experimentation.

Accordingly, Appellants respectfully request reconsideration and reversal of the enablement rejection of Claims 119-121 and 123 under 35 U.S.C. §112, first paragraph.

ISSUE III: Claims 119-121 and 123 are not anticipated under 35 U.S.C. §102(b) by Fernandez et al., WO 00/61754

Claims 119-121 and 123 stand rejected under 35 U.S.C. §102(b) as being anticipated by Fernandez *et al.*, WO 00/61754, published on October 19, 2000.

Appellants submit that, as discussed above in response to the outstanding rejections under 35 U.S.C. §101 and 35 U.S.C. §112, first paragraph, for alleged lack of utility and enablement (Issue I and Issue II), Appellants rely on the MLR assay results (Example 151) to establish a credible, substantial and specific asserted utility for the polypeptide PRO1346 and the claimed antibodies that bind it. These results were first disclosed in PCT/US00/05841, filed March 2, 2000. As discussed above, the disclosure of the instant application, which is similar to that of the earlier-filed application (PCT/US00/05841), provides the support required under 35 U.S.C. §112 for the subject matter of the instant claims. Accordingly, Applicants submit that the subject matter of the instant claims is disclosed in the manner provided by 35 U.S.C. §112 in PCT/US00/05841. Therefore, the effective filing date of this application is October 2, 2000, the filing date of PCT/US00/05841.

The PCT patent application by Fernandez *et al.*, WO 00/61754, was published on October 19, 2000, which is over seven months after the effective filing date of the instant application; hence Fernandez *et al.* is not prior art.

The Examiner has asserted that "Applicant asserts that PCT/US00/05841, filed March 2, 2000 discloses a MLR (mixed leukocyte reaction) assay and that the data generated in the MLR assay establish patentable utility ... However, a review of the instant application and this assay do not lead to a conclusion of utility based on this assay, and therefore, priority to this PCT ...application is not afforded for the reasons of record." (Page 2 of the Office Action mailed October 21, 2004).

In this regard, Appellants refer to the arguments and information presented above in response to the outstanding rejections under 35 U.S.C. §101 and 35 U.S.C. §112, first paragraph, for alleged lack of utility and enablement. These arguments are incorporated by reference herein. Appellants respectfully submit that as described above under Issue I, the presently claimed invention is supported by a specific, substantial and credible utility and, therefore, the present

specification teaches one of ordinary skill in the art “how to use” the claimed invention without undue experimentation, as described above.

Accordingly, Appellants respectfully request reconsideration and reversal of the rejection of Claims 119-121 and 123 under 35 U.S.C. §102(b) as being anticipated by Fernandez *et al.*

CONCLUSION

For the reasons given above, Appellants submit that the MLR assay disclosed in Example 151 of the specification provides at least one patentable utility for the antibodies of Claims 119-121 and 123, and that one of ordinary skill in the art would understand how to use the claimed antibodies, for example in the purification of PRO1346 to be used in therapeutic applications where enhancement of an immune response is beneficial, such as the treatment of viral infections or cancer. Based on such a utility, one of skill in the art would know exactly how to use the claimed antibodies that bind PRO1346, without any undue experimentation. Therefore, Claims 119-121 and 123 meet the requirements of 35 U.S.C. §101 and 35 U.S.C. §112, first paragraph. Further, this patentable utility for the claimed antibodies was first disclosed in PCT/US00/05841, filed on March 2, 2000, priority to which is claimed in the instant application. Accordingly, the instant application has an effective priority date of March 2, 2000, and therefore Fernandez *et al.*, WO 00/61754 published on October 19, 2000, is not prior art and does not anticipate the claims under 35 U.S.C. §102(b).

Accordingly, reversal of all the rejections of Claims 119-121 and 123 is respectfully requested.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39780-2730 P1C24).

Respectfully submitted,

Date: August 19, 2005

By: Barrie Greene
Barrie Greene (Reg. No. 46,740)

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

SV 2141685 v1
8/19/05 9:19 AM (39780.2730)

8. CLAIMS APPENDIX

Claims on Appeal

119. An isolated antibody, or fragment thereof, that specifically binds to the polypeptide of SEQ ID NO: 314.

120. The antibody of Claim 119 which is a monoclonal antibody.

121. The antibody of Claim 119 which is a humanized antibody.

123. The antibody of Claim 119 which is labeled.


9. EVIDENCE APPENDIX

Declaration of Sherman Fong, Ph.D. under 35 C.F.R 1.132, with attached Exhibits A-E:

- A. Current Protocols in Immunology, Vol. 1, Richard Coico, Series Ed., John Wiley & Sons, Inc., 1991, Unit 3.12
- B. Steinman, R.M., "The dendritic cell advantage: New focus for immune-based therapies," *Drug News Perspect.* 13:581-586 (2000).
- C. Gubler, U. et al., "Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor," *Proc. Natl. Acad. Sci. USA* 88:4143-4147 (1991).
- D. Peterson, A.C. et al., "Immunization with melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma," *J. Clin. Oncol.* 21:2342-2348 (2003).
- E. Thurner, B. et al., "Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma," *J. Exp. Med.* 190:1669-1678 (1999).

The Declaration of Dr. Sherman Fong and attached Exhibits A-E were submitted with Appellants' response filed September 9, 2004, and noted as entered into the record in the Office Action mailed October 21, 2004.

SV 2141685 v1
8/19/05 9:19 AM (39780.2730)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:
Serial No.:
Filing Date:
For:

Docket No.:
Group Art Unit:
Examiner:

DECLARATION OF SHERMAN FONG, Ph.D. UNDER 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Sherman Fong, Ph.D. declare and say as follows: -

1. I was awarded a Ph.D. in Microbiology by the University of California at Davis, CA in 1975.
2. After postdoctoral training and holding various research positions at Scripps Clinic and Research Foundation, La Jolla, CA, I joined Genentech, Inc., South San Francisco, CA in 1987. I am currently a Senior Scientist at the Department of Immunology/Discovery Research of Genentech, Inc.
3. My scientific Curriculum Vitae is attached to and forms part of this Declaration.
4. I am familiar with the Mixed Lymphocyte Reaction (MLR) assay, which has been used by me and others under my supervision, to test the immune stimulatory or immune inhibitory activity of novel polypeptides discovered in Genentech's Secreted Protein Discovery Initiative project.
5. The MLR assay is a well known and widely used proliferative assay of T-cell function, the basic protocols of which are described, for example, in Current Protocols in Immunology Vol. 1, Richard Coico, Series Ed., John Wiley & Sons, Inc., 1991, Unit 3.12. (Exhibit A). This publication is incorporated by reference in the description of the MLR protocol in the present application.

6. The T-lymphocytes or "T-cells" of our immune system can be induced to proliferate by a variety of agents. The MLR assay is designed to study a particularly important induction mechanism whereby responsive T-cells are cultured together (or "mixed"), with other lymphocytes that are "allogeneic", e.g. lymphocytes that are taken from different individuals of the same species. In the MLR protocol of the present application, a suspension of PBMCs that includes responder T-cells, is cultured with allogeneic PBMCs that predominantly contain dendritic cells. According to the protocol, the allogeneic "stimulator" PBMCs are irradiated at a dose of 3000 Rad. This irradiation is done in order to create a sample of cells that has mainly dendritic cells. It is known that the dendritic cell population among the PBMCs are differentially affected by irradiation. At low doses (500-1000 Rad), the proliferation of most cells, including the B cells in the PBMCs, is preserved, however, at doses above 2000 Rad, this function of B cells is abolished. Dendritic cells on the other hand, maintain their antigen presentation function even at a 3000 Rad dose of radiation. (See, e.g. Current Protocols in Immunology, *supra*, at 3.12.9). Accordingly, under the conditions of the MLR assay used to test the PRO polypeptides of the present invention, the stimulator PBMCs remaining after irradiation are essentially dendritic cells.
7. Dendritic cells are the most potent antigen-presenting cells, which are able to "prime" naive T cells *in vivo*. They carry on their surface high levels of major histocompatibility complex (MHC) products, the primary antigens for stimulating T-cell proliferation. Dendritic cells provide the T-cells with potent and needed accessory or costimulatory substances, in addition to giving them the T-cell maturing antigenic signal to begin proliferation and carry out their function. Once activated by dendritic cells, the T-cells are capable of interacting with other antigen presenting B cells and macrophages to produce additional immune responses from these cells. For further details about the properties and role of dendritic cells in immune-based therapies see, e.g. Steinman, Drug News Perspect. 13(10):581-586 (Exhibit B).
8. The MLR assay of the present application is designed to measure the ability of a test substance to "drive" the dendritic cells to induce the proliferation of T-cells that are activated, or co-stimulated in the MLR, and thus identifies immune stimulants that can boost the immune system to respond to a particular antigen that may not have been immunologically active previously.

9. Such immune stimulants find important clinical applications. For example, IL-12 is a known immune stimulant, which has been shown to stimulate T-cell proliferation in the MLR assay. IL-12 was first identified in just such an MLR [Gubler et al. PNAS 88, 4143 (1991) (Exhibit C)]. In a recent cancer vaccine trial, researchers from the University of Chicago and Genetics Institute (Cambridge, MA) have demonstrated the efficacy of the approach, relying on the immune stimulatory activity of IL-12, for the treatment of melanoma. [Peterson et al. Journal of Clinical Oncology 21 (12). 2342-48 (2003) (Exhibit D)] They extracted circulating white blood cells carrying one or more markers of melanoma cells, isolated the antigen, and returned them to the patients. Normally patients would not have an immune response to his or her own human antigens. The patients were then treated with different doses of IL-12, an immune stimulant capable of inducing the proliferation of T cells that have been co-stimulated by dendritic cells. Due to the immune stimulatory effect of IL-12, the treatment provided superior results in comparison to earlier work, where patients' own dendritic cells were prepared from peripheral blood mononuclear cells (PBMCs), treated with antigens, then cultured *in vitro* and returned to the patient to stimulate anti-cancer response. [Thurner et al. J. Exp. Med. 190 (11), 1669-78 (1999) (Exhibit E)].

10. It is my considered scientific opinion that a PRO polypeptide shown to stimulate T-cell proliferation in the MLR assay of the present invention with an activity at least 180% of the control, as specified in the present application, is expected to have the type of activity as that exhibited by IL-12, and would therefore find practical utility as an immune stimulant. Some PRO polypeptides do the reverse, and give inhibition of T-cell proliferation in the MLR assay. It is my considered scientific opinion that a PRO polypeptide shown to inhibit T-cell proliferation in the MLR assay where the activity is observed as 80% or less of the control, as specified in the present application, would be expected to find practical utility when an inhibition of the immune response is desired, such as in autoimmune diseases.

Dated: 6/16/04

By: Sherman Fong
Sherman Fong, Ph.D.



Sherman Fong, Ph.D.

Senior Scientist
Department of Immunology
Genentech Inc.
1 DNA Way.
South San Francisco, California 94080-4990

19 Basinside Way
Alameda, California 94502

Work Telephone: (650) 225-2783
Home Telephone: (510) 522-5411

FAX: (650) 225-8221

Education:

1978 - 1980 Postdoctoral Fellow in Immunology, Research Institute of Scripps Clinic,
Scripps Clinic and Research Foundation, La Jolla, California

1975 - 1978 Postdoctoral Fellow in Immunology, University of California at
San Francisco, San Francisco, California

1970 - 1975 Ph.D. in Microbiology, University of California at
Davis, California

1966 - 1970 B.A. in Biology/Microbiology, San Francisco State
University, San Francisco, California

Professional Positions:

Currently: Senior Scientist, Department of Immunology/Discovery Research, Genentech, Inc., South San Francisco, California

8/00-8/01 Acting Director, Department of Immunology, Genentech, Inc. South San Francisco, California

10/89 Senior Scientist in the Department of Immunology/Discovery Research, Genentech, Inc.
South San Francisco, California

3/89 - 10/89 Senior Scientist and Immunobiology Group Leader, Department of Pharmacological Sciences, Immunobiology Section/Medical Research and Development, Genentech, Inc., S. San Francisco, California

9/87 - 3/89 Scientist, Department of Pharmacological Sciences, Immunopharmacology Section/Medical Research and Development, Genentech, Inc., S. San Francisco, California

1/82 - 9/87 Assistant Member (eq. Assistant Professor level), Department of Basic and Clinical Research, Division of Clinical Immunology, Scripps Clinic and Research Foundation, La Jolla, California

6/80 - 12/81 Scientific Associate in the Department of Clinical Research, Division of Clinical Immunology, Scripps Clinic and Research Foundation, La Jolla, California

7/78 - 6/80 Postdoctoral training in the laboratory of Dr. J. H. Vaughan, Chairman, Department of Clinical Research, Division of Clinical Immunology, Scripps Clinic and Research Foundation, La Jolla, California

2/75 - 6/78 Postdoctoral training in the laboratory of Dr. J. W. Goodman, Department of Microbiology and Immunology, School of Medicine, University of California, San Francisco, California

7/71 - 12/74 Research Assistant and Graduate Student, Department of Medical Microbiology, School of Medicine, University of California, Davis, California, under Dr. E. Benjamini

Awards:

Recipient: National Institutes of Health Postdoctoral Fellowship Award (1975).

Recipient: Special Research Award, (New Investigator Award), National Institute of Health (1980).

Recipient: P.I., Research Grant Award, National Institute of Health (1984).

Recipient: Research Career Development Award (R01), National Institutes of Health (1985).

Recipient: P.I., Multi-Purpose Arthritis Center Research Grant, NIH (1985)

Recipient: P.I., Research Grant Award, (R01 Renewal), National Institute of Health (1987).

Scientific Associations:

Sigma Xi, University of California, Davis, California Chapter

Member, The American Association of Immunologists

Committee Service and Professional Activities:

Member of the Immunological Sciences Study Section, National Institutes of Health Research Grant Review Committee, (1988-1992).

Advisory Committee, Scientific Review Committee for Veteran's Administration High Priority Program on Aging, 1983.

Ad Hoc member of Immunological Sciences Study Section, National Institutes of Health, 1988.

Ad Hoc Reviewer: Journal of Clinical Investigations, Journal of Immunology, Arthritis and Rheumatism, International Immunology, Molecular Cell Biology, and Gastroenterology

Biotechnology Experience

Established at Genentech in 1987-1989 within the Immunobiology Laboratory, in the Department of Pharmacological Sciences, group to study the immunogenicity of recombinant hGH (Protropin®) in hGH transgenic mice.

Served as Immunologist on the Biochemical Subteam for Protropin® Project team.

Served as Immunologist on the Met-less hGH and Dnase project teams, two FDA approved biological drugs: second generation hGH Nutropin® and Pulmozyme® (DNase).

Served immunologist in 1989-1990 on the CD4-IgG project team carrying out in vitro immunopharmacological studies of the effects of CD4-IgG on the in vitro human immune responses to mitogens and antigens and on neutrophil responses in support of the filing of IND to FDA in 1990 for use of CD4-IgG in the prevention of HIV infection. Product was dropped.

In 1989-1991, initiated and carried research and development work on antibodies to CD11b and CD18 chains of the leukocyte $\beta 2$ integrins. Provided preclinical scientific data to Anti-CD18 project team

supporting the advancement of humanized anti-CD18 antibody as anti-inflammatory in the acute setting. IND filed in 1996 and currently under clinical evaluation.

1993-1997, **Research Project Team leader** for small molecule $\alpha 4\beta 1$ integrin antagonist project. Leader for collaborative multidisciplinary team (N=11) composed of immunologists, molecular/cell biologists, protein engineers, pathologists, medicinal chemists, pharmacologists, pharmaceutical chemists, and clinical scientists targeting immune-mediated chronic inflammatory diseases. Responsible for research project plans and execution of strategy to identify lead molecules, assessment of biological activities, preclinical evaluation in experimental animals, and identification of potential clinical targets. Responsible for identification, hiring, and working with outside scientific consultants for project. Helped establish and responsible for maintaining current research collaboration with Roche-Nutley. Project transferred to Roche-Nutley.

1998-present, worked with Business Development to identify and create joint development opportunity with LeukoSite (currently Millennium) for monoclonal antibody against $\alpha 4\beta 7$ integrin (LDP-02) for therapeutic treatment for inflammatory bowel disease (UC and Crohn's disease). Currently, working as scientific advisor to the core team for phase II clinical trials for LDP-02.

Currently, **Research Project Team Biology Leader** (1996-present) for small molecule antagonists for $\alpha 4\beta 7$ /MAdCAM-1 targeting the treatment of human inflammatory bowel diseases and diseases of the gastrointestinal tract. Responsible for leading collaborative team (N=12) from Departments of Immunology, Pathology, Analytical Technology, Antibody Technology, and Bio-Organic Chemistry to identify and evaluate lead drug candidates for the treatment of gastrointestinal inflammatory diseases.

Served for nearly fifteen years as Ad Hoc reviewer on Genentech Internal Research Review Committee, Product Development Review Committee, and Pharmacological Sciences Review Committee.

Worked as Scientific advisor with staff of the Business Development Office on numerous occasions at Genentech, Inc. to evaluate the science of potential in-licensing of novel technologies and products.

2000-2001 Served as Research Discovery representative on Genentech Therapeutic Area Teams (Immunology/Endocrine, Pulmonary/Respiratory Disease Task Force)

Invited Symposium Lectures:

Session Chairperson and speaker, American Aging Association 12th Annual National Meeting, San Francisco, California, 1982.

Invited Lecturer, International Symposium, Mediators of Immune Regulation and Immunotherapy, University of Western Ontario, London, Ontario, Canada, 1985.

Invited Lecturer, workshop on Human IgG Subclasses, Rheumatoid Factors, and Complement. American Association of Clinical Chemistry, San Francisco, California, 1987.

Plenary Lecturer, First International Waaler Conference on Rheumatoid Factors, Bergen, Norway, 1987.

Invited Lecturer, Course in Immunorheumatology at the Universite aux Marseilles, Marseilles, France, 1988.

Plenary Lecturer, 5th Mediterranean Congress of Rheumatology, Istanbul, Turkey, 1988.

Invited Lecturer, Second Annual meeting of the Society of Chinese Bioscientist of America, University of California, Berkeley, California, 1988.

Lecturer at the inaugural meeting of the Immunology by the Bay sponsored by The Bay Area Bioscience Center. The $\beta 2$ Integrins in Acute Inflammation, July 14, 1992.

Lecturer, "Research and Development – An Anatomy of a Biotechnology Company", University of California, Berkeley, Extension Course, given twice a year—March 9, 1995 to June 24, 1997.

Lecturer, "The Drug Development Process – Biologic Research - Genomics", University of California, Berkeley Extension, April 21, 1999, October, 1999, April 2000, October, 2000.

Lecturer, "The Drug Development Process – Future Trends/Impact of Pharmacogenomics", University of California Berkeley Extension, April 2001, October 2001, April 2002.

Invited Speaker, "Targeting of Lymphocyte Integrin $\alpha 4 \beta 7$ Attenuates Inflammatory Bowel Diseases", in Sympoium on "Nutrient effects on Gene Expression" at the Institute of Food Technology Symposium, June, 2002.

Patents:

Dennis A. Carson, Sherman Fong, Pojen P. Chen.

U.S. Patent Number 5,068,177: Anti-idiotypic Antibodies induced by Synthetic Polypeptides, Nov. 26, 1991

Sherman Fong, Caroline A. Hebert, Kyung Jin Kim and Steven R. Leong.

U.S. Patent Number 5,677,426: Anti-IL-8 Antibody Fragments, Oct. 14, 1997

Claire M. Doerschuk, Sherman Fong, Caroline A. Hebert, Kyung Jin Kim, Steven R. Leong. U.S. Patent Number 5,686,070: Methods for Treating Bacterial Pneumonia, Nov. 11, 1997

Claire M. Doerschuk, Sherman Fong, Caroline A. Hebert, Kyung Jin Kim, Steven R. Leong. U.S. Patent 5,702,946: Anti-IL-8 Monoclonal Antibodies for the Treatment of Inflammatory Disorders, Dec. 30, 1997

Sherman Fong, Caroline A. Hebert, Kyung Jin Kim, Steven R. Leong.

U.S. Patent Number 5,707,622: Methods for Treating Ulcerative Colitis, Jan. 13, 1998

Sherman Fong, Napoleone Ferrara, Audrey Goddard, Paul Godowski, Austin Gurney, Kenneth Hillan, and Mickey Williams. U.S. Patent Number 6,074,873: Nucleic acids encoding NL-3, June 13, 2000

Sherman Fong, Napoleone Ferrara, Audrey Goddard, Paul Godowski, Austin Gurney, Kenneth Hillan, and Mickey Williams. U.S. Patent Number 6,348,351 B1: The Receptor Tyrosine Kinase Ligand Homologues. February 19, 2002

Patent Applications:

Sherman Fong, Kenneth Hillan, Toni Klassen

U.S. Patent Application: "Diagnosis and Treatment of Hepatic Disorders"

Sherman Fong, Audrey Goddard, Austin Gurney, Daniel Tumas, William Wood

U.S. Patent Application: Compositions and Methods for the Treatment of Immune Related Diseases.

Sherman Fong, Mary Gerritsen, Audrey Goddard, Austin Gurney, Kenneth Hillan, Mickey Williams, William Wood. U.S. Patent Application: Promotion or Inhibition of Cardiovasculogenesis and Angiogenesis

Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin Gurney, Mary Napier, Daniel Tumas, William Wood. US Patent Application: Compounds, Compositions and Methods for the Treatment of Diseases Characterized by A33-Related Antigens

Chen, Filvaroff, Fong, Goddard, Godowski, Grimaldi, Gurney, Hillan, Tumas, Vandlen, Van Lookeren, Watanabe, Williams, Wood, Yansura

US Patent Application: IL-17 Homologous Polypeptides and Therapeutic Uses Thereof

Ashkenazi, Botstein, Desnoyers, Eaton, Ferrara, Filvaroff, Fong, Gao, Gerber, Gerritsen, Goddard, Godowski, Grimaldi, Gurney, Hillan, Kljavin, Mather, Pan, Paoni, Roy, Stewart, Tumas, Williams, Wood
US Patent Application: Secreted And Transmembrane Polypeptides And Nucleic Acids Encoding The Same

Publications:

1. Scibienski R, Fong S, Benjamini E: Cross tolerance between serologically non-cross reacting forms of egg white lysozyme. *J Exp Med* 136:1308-1312, 1972.
2. Scibienski R, Harris M, Fong S, Benjamini E: Active and inactive states of immunological unresponsiveness. *J Immunol* 113:45-50, 1974.
3. Fong S: Studies on the relationship between the immune response and tumor growth. Ph D Thesis, 1975.
4. Benjamini E, Theilen G, Torten M, Fong S, Crow S, Henness AM: Tumor vaccines for immunotherapy of canine lymphosarcoma. *Ann NY Acad Sci* 277:305, 1976.
5. Benjamini E, Fong S, Erickson C, Leung CY, Rennick D, Scibienski RJ: Immunity to lymphoid tumors induced in syngeneic mice by immunization with mitomycin C treated cells. *J Immunol* 118:685-693, 1977.
6. Goodman JW, Fong S, Lewis GK, Kamin R, Nitecki DE, Der Balian G: T lymphocyte activation by immunogenic determinants. *Adv Exp Biol Med* 98:143, 1978.
7. Goodman JW, Fong S, Lewis GK, Kamin R, Nitecki DE, Der Balian G: Antigen structure and lymphocyte activation. *Immunol Rev* 39:36, 1978.
8. Fong S, Nitecki DE, Cook RM, Goodman JW: Spatial requirements of haptenic and carrier determinants for T-dependent antibody responses. *J Exp Med* 148:817, 1978.
9. Fong S, Chen PP, Nitecki DE, Goodman JW: Macrophage-T cell interaction mediated by immunogenic and nonimmunogenic forms of a monofunctional antigen. *Mol Cell Biochem* 25:131, 1979.
10. Tsoukas CD, Carson DA, Fong S, Pasquali J-L, Vaughan JH: Cellular requirements for pokeweed mitogen induced autoantibody production in rheumatoid arthritis. *J Immunol* 125:1125-1129, 1980.
11. Pasquali J-L, Fong S, Tsoukas CD, Vaughan JH, Carson DA: Inheritance of IgM rheumatoid factor idiotypes. *J Clin Invest* 66:863-866, 1980.
12. Fong S, Pasquali J-L, Tsoukas CD, Vaughan JH, Carson DA: Age-related restriction of the light chain heterogeneity of anti-IgG antibodies induced by Epstein-Barr virus stimulation of human lymphocytes in vitro. *Clin Immunol Immunopathol* 18:344, 1981.
13. Fong S, Tsoukas CD, Frincke LA, Lawrance SK, Holbrook TL, Vaughan JH, Carson DA: Age-associated changes in Epstein-Barr virus induced human lymphocyte autoantibody responses. *J Immunol* 126:910-914, 1981.
14. Tsoukas CD, Fox RI, Slovin SF, Carson DA, Pellegrino M, Fong S, Pasquali J-L, Ferrone S, Kung P, Vaughan JH: T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells. *J Immunol* 126:1742-1746, 1981.
15. Fong S, Tsoukas CD, Pasquali J-L, Fox RI, Rose JE, Raiklen D, Carson DA, Vaughan JH: Fractionation of human lymphocyte subpopulations on immunoglobulin coated petri dishes. *J Immunol Methods* 44:171-182, 1981.
16. Pasquali J-L, Tsoukas CD, Fong S, Carson DA, Vaughan JH: Effect of Levamisole on pokeweed mitogen stimulation of immunoglobulin production in vitro. *Immunopharmacology* 3:289-298, 1981.

17. Pasquali J-L, Fong S, Tsoukas CD, Hench PK, Vaughan JH, Carson DA: Selective lymphocyte deficiency in seronegative rheumatoid arthritis. *Arthritis Rheum* 24:770-773, 1981.
18. Fong S, Fox RI, Rose JE, Liu J, Tsoukas CD, Carson DA, Vaughan JH: Solid-phase selection of human T lymphocyte subpopulations using monoclonal antibodies. *J Immunol Methods* 46:153-163, 1981.
19. Pasquali J-L, Fong S, Tsoukas CD, Slovin SF, Vaughan JH, Carson DA: Different populations of rheumatoid factor idiotypes induced by two polyclonal B cell activators, pokeweed mitogen and Epstein-Barr virus. *Clin Immunol Immunopathol* 21:184-189, 1981.
20. Carson DA, Pasquali J-L, Tsoukas CD, Fong S, Slovin SF, Lawrance SK, Slaughter L, Vaughan JH: Physiology and pathology of rheumatoid factors. *Springer Semin Immunopathol* 4:161-179, 1981.
21. Fox RI, Fong S, Sabharwal N, Carstens SA, Kung PC, Vaughan JH: Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. *J Immunol* 128:351-354, 1982.
22. Seybold M, Tsoukas CD, Lindstrom J, Fong S, Vaughan JH: Acetylcholine receptor antibody production during leukoplasmapheresis for Myasthenia Gravis. *Arch Neurol* 39:433-435, 1982.
23. Tsoukas CD, Fox RI, Carson DA, Fong S, Vaughan JH: Molecular interactions in human T-cell-mediated cytotoxicity to Epstein-Barr virus. I. Blocking of effector cell function by monoclonal antibody OKT3. *Cell Immunol* 69:113-121, 1982.
24. Sabharwal UK, Vaughan JH, Fong S, Bennett P, Carson DA, Curd JG: Activation of the classical pathway of complement by rheumatoid factors: Assessment by radioimmunoassay for C4. *Arthritis Rheum* 25:161-167, 1982.
25. Fox RI, Carstens SA, Fong S, Robinson CA, Howell F, Vaughan JH: Use of monoclonal antibodies to analyze peripheral blood and salivary gland lymphocyte subsets in Sjogren's Syndrome. *Arthritis Rheum* 25:419, 1982.
26. Fong S, Miller JJIII, Moore TL, Tsoukas CD, Vaughan JH, Carson DA: Frequencies of Epstein-Barr virus inducible IgM anti-IgG B lymphocytes in normal children and in children with Juvenile Rheumatoid Arthritis. *Arthritis Rheum* 25:959-965, 1982.
27. Goodman JW, Nitecki DE, Fong S, Kaymakcalan Z: Antigen bridging in the interaction of T helper cells and B cells. *Adv Exp Med Biol* 150:219-225, 1982.
28. Goodman JW, Nitecki DE, Fong S, Kaymakcalan Z: Antigen bridging in T cell-B cell interaction: Facts or fiction. In: *Protein Conformation as Immunologic Signal*. EMBO Workshop, Portonere, Italy, 1982.
29. Tsoukas CD, Carson DA, Fong S, Slovin SF, Fox RI, Vaughan JH: Lysis of autologous Epstein-Barr virus infected B cells by cytotoxic T lymphocytes of rheumatoid arthritis patients. *Clin Immunol Immunopathol* 24:8-14, 1982.
30. Fong S, Vaughan JH, Tsoukas CD, Carson DA: Selective induction of autoantibody secretion in human bone marrow by Epstein-Barr virus. *J Immunol* 129:1941-1945, 1982.
31. Sabharwal UK, Fong S, Hoch S, Cook RD, Vaughan JH, Curd JG: Complement activation by antibodies to Sm in systemic lupus erythematosus. *Clin Exp Immunol* 51:317-324, 1983.

32. Tsoukas CD, Carson DA, Fong S, Vaughan JH: Molecular interactions in human T cell mediated cytotoxicity to EBV. II. Monoclonal antibody OKT3 inhibits a post-killer-target recognition/adhesion step. *J Immunol* 129:1421-1425, 1982.
33. Welch MJ, Fong S, Vaughan JH, Carson DA: Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. *Clin Exp Immunol* 51:299-305, 1983.
34. Fong S, Vaughan JH, Carson DA: Two different rheumatoid-factor producing cell populations distinguished by the mouse erythrocyte receptor and responsiveness to polyclonal B cell activators. *J Immunol* 130:162-164, 1983.
35. Fox RI, Hueniken M, Fong S, Behar S, Royston I, Singhal SK, Thompson L: A novel cell surface antigen (T305) found in increased frequency on acute leukemia cells and in autoimmune disease states. *J Immunol* 131:762-767, 1983.
36. Fong S: Solid-phase panning for the fractionation of lymphoid cells. In: *Cell separation: methods and selected applications*. Pretlow TG, Pretlow TP (eds.) pp. 203-219. Academic Press, New York, 1983.
37. Carson DA, Fong S: A common idiotype on human rheumatoid factors identified by a hybridoma antibody. *Mol Immunol* 20:1081-1087, 1983.
38. Fong S, Gilbertson TA, Carson DA: The internal image of IgG in cross-reactive anti-idiotypic antibodies against human rheumatoid factors. *J Immunol* 131:719-724, 1983.
39. Fox RI, Adamson TC, Fong S, Young C, Howell FV: Characterization of the phenotype and function of lymphocytes infiltrating the salivary gland in patients with primary Sjogren syndrome. *Diagn Immunol* 1:233-239, 1983.
40. Fox RI, Adamson III TC, Fong S, Robinson CA, Morgan EL, Robb JA, Howell FV: Lymphocyte phenotype and function in pseudolymphoma associated with Sjogren's syndrome. *J Clin Invest* 72:52-62, 1983.
41. Fong S, Gilbertson TA, Chen PP, Vaughan JH, Carson DA: Modulation of human rheumatoid factor-specific lymphocyte responses with a cross-reactive anti-idiotypic bearing the internal image of antigen. *J Immunol* 132:1183-1189, 1984.
42. Chen PP, Houghten RA, Fong S, Rhodes GH, Gilbertson TA, Vaughan JH, Lerner RA, Carson DA: Anti-hypervariable region antibody induced by a defined peptide. A new approach for studying the structural correlates of idiotypes. *Proc Natl Acad Sci USA* 81:1784-1788, 1984.
43. Fox RI, Fong S, Tsoukas CD, Vaughan JH: Characterization of recirculating lymphocytes in rheumatoid arthritis patients: Selective deficiency of natural killer cells in thoracic duct lymph. *J Immunol* 132:2883-2887, 1984.
44. Chen PP, Fong S, Normansell D, Houghten RA, Karras JG, Vaughan JH, Carson DA: Delineation of a cross-reactive idiotype on human autoantibodies with antibody against a synthetic peptide. *J Exp Med* 159:1502-1511, 1984.
45. Fong S, Carson DA, Vaughan JH: Rheumatoid factor. In: *Immunology of Rheumatic Diseases*. Gupta S, Talal N (eds.): Chapter 6. pp. 167-196. Plenum Publishing Corp., New York, 1985.

46. Fong S: Immunochemistry. In: Immunology as applied to Otolaryngology. Ryan AF, Poliquis JF, Harris A (eds.): pp. 23-53. College Hill Press, San Diego, 1985.
47. Fong S, Chen PP, Vaughan JH, Carson DA: Origin and age-associated changes in the expression of a physiologic autoantibody. *Gerontology* 31:236-250, 1985.
48. Chen PP, Fong S, Houghten RA, Carson DA: Characterization of an epibody: An anti-idiotypic which reacts with both the idiotype of rheumatoid factors (RF) and the antigen recognized by RFs. *J Exp Med* 161:323, 1985.
49. Chen PP, Goni F, Fong S, Jirik F, Vaughan JH, Frangione B, Carson DA: The majority of human monoclonal IgM rheumatoid factors express a primary structure-dependent cross-reactive idiotype. *J Immunol* 134:3281-3285, 1985.
50. Lotz M, Tsoukas CD, Fong S, Carson DA, Vaughan JH: Regulation of Epstein-Barr virus infections by recombinant interferon. Selected sensitivity to interferon-gamma. *Eur J Immunol* 15:520-525, 1985.
51. Chen PP, Kabat EA, Wu TT, Fong S, Carson DA: Possible involvement of human D-minigenes in the first complementarity-determining region of kappa light chains. *Proc Natl Acad Sci USA* 82:2125-2127, 1985.
52. Goldfien RD, Chen PP, Fong S, Carson DA: Synthetic peptides corresponding to third hypervariable region of human monoclonal IgM rheumatoid factor heavy chains define an immunodominant idiotype. *J Exp Med* 162:756-761, 1985.
53. Fong S, Chen PP, Gilbertson TA, Fox RI, Vaughan JH, Carson DA: Structural similarities in the kappa light chains of human rheumatoid factor paraproteins and serum immunoglobulins bearing a cross-reactive idiotype. *J Immunol* 135:1955-1960, 1985.
54. Chen PP, Goni F, Houghten RA, Fong S, Goldfien RD, Vaughan JH, Frangione B, Carson DA: Characterization of human rheumatoid factors with seven anti-idiotypes induced by synthetic hypervariable-region peptides. *J Exp Med* 162:487-500, 1985.
55. Fong S, Gilbertson TA, Hueniken RJ, Singhal SK, Vaughan JH, Carson DA: IgM rheumatoid factor autoantibody and immunoglobulin producing precursor cells in the bone marrow of humans. *Cell Immunol* 95:157-172, 1985.
56. Fong S, Chen PP, Goldfien RD, Jirik F, Silverman G, Carson DA: Recurrent idiotypes of human anti-IgG autoantibodies: their potential use for immunotherapy. In: *Mediators of Immune Regulation and Immunotherapy*. Singhal SK, Delovitch TL (eds.): pp. 232-243. Elsevier Science Publishing Co., New York, 1986.
57. Fox RI, Chen PP, Carson DA, Fong S: Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjogren's syndrome. *J Immunol* 136:477-483, 1986.
58. Jirik FR, Sorge J, Fong S, Heitzmann JG, Curd JG, Chen PP, Goldfien R, Carson DA: Cloning and sequence determination of a human rheumatoid factor light-chain gene. *Proc Natl Acad Sci USA*, 83:2195-2199, 1986.
59. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, Vaughan JH: Release of lymphokines following Epstein-Barr virus infection in vitro. I. The sources and kinetics of production of interferons and interleukins in normal humans. *J Immunol*, 136:3636-3642, 1986.

60. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, Vaughan JH: Release of lymphokines following infection with Epstein-Barr virus in vitro. II. A monocyte dependent inhibitor of interleukin-1 downregulates the production of interleukin-2 and gamma interferon in rheumatoid arthritis. *J Immunol*, 136:3643-3648, 1986.
61. Fong S, Chen PP, Gilbertson TA, Weber JR, Fox RI, Carson DA: Expression of three cross reactive idiotypes on rheumatoid factor autoantibodies from patients with autoimmune diseases and seropositive adults. *J Immunol*, 137:122-128, 1986.
62. Fong S, Gilbertson TA, Chen PP, Karras JG, Vaughan JH, Carson DA: The common occurrence of internal image type anti-idiotypic antibodies in rabbits immunized with monoclonal and polyclonal human IgM rheumatoid factors. *Clin Exp Immunol*, 64:570-580, 1986.
63. Fox RI, Carson DA, Chen P, Fong S: Characterization of a cross reactive idioype in Sjogren's syndrome. *Scand J Rheum* S61:83-88, 1986.
64. Silverman GJ, Carson DA, Solomon A, Fong S: Human kappa light chain subgroup analysis with synthetic peptide-induced antisera. *J Immunol Methods* 95:249-257, 1987.
65. Goldfien R, Chen P, Kipps TJ, Starkebaum G, Heitzmann JG, Radoux V, Fong S, Carson DA: Genetic analysis of human B cell hybridomas expressing a rheumatoid factor-associated cross-reactive idioype. *J Immunol* 138:940- 944, 1987.
66. Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD, Silverman G, Radoux V, Fong S: Rheumatoid factors and immune networks. *Annu Rev Immunol* 5:109-126, 1987.
67. Kipps TJ, Fong S, Tomhave E, Chen PP, Goldfien RD, Carson DA: High frequency expression of a conserved kappa variable region gene in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 84:2916-2920, 1987
68. Fong S, Chen PP, Fox RI, Goldfien RD, Silverman GJ, Radoux V, Jirik F, Vaughan JH, Carson DA: Rheumatoid factors in human autoimmune disease: Their origin, development and function. *Path Immunopath Res* 5:407-449, 1987.
69. Goldfien RD, Fong S, Chen P, Carson DA: Structure and function of rheumatoid factor: Implications for its role in the pathogenesis of mixed cryoglobulinemia. In: *Antiglobulins, cryoglobulins and glomerulonephritis, Proceedings of 2nd International Milano Meeting of Nephrology*. Ponticelli C, Minetti L, D'Amico G (eds.) Martinus Nijhoff, Dordrecht pp. 17-27, 1986.
70. Silverman GJ, Carson DA, Patrick K, Vaughan JH, Fong S: Expression of a germline human kappa chain associated cross reactive idioype after in vitro and in vivo infection with Epstein-Barr virus. *Clin Immunol Immunopathol* 43:403-411, 1987.
71. Silverman GJ, Fong S, Chen PP, Carson DA: Clinical update: Cross reactive idioype and the genetic origin of rheumatoid factors. *J Clin Lab Anal*, 1:129-135, 1987.
72. Chen PP, Fong S, Carson DA: Molecular basis of reactivity of epibodies. In: *Elicitation and use of anti-idiotypic antibodies and their biological applications*. Bona C (ed.), CRC Press, Boca Raton, Fla, in press.
73. Fong S, Chen PP, Carson DA, Fox, RI: Rheumatoid factor in Sjogren's syndrome. In: *Sjogren's Syndrome: Clinical and Immunological Aspects*. Talal N, Moutsopoulos HM, Kassan SS (eds.), Springer-Verlag, New York, pp. 203-217, 1987.

74. Chen PP, Fong S, Carson DA: The use of defined peptides in characterizing idiotypes. *Int Rev Immunol* 2:419-432, 1987.
75. Chen PP, Fong S, Goni F, Houghten RA, Frangione B, Liu F, Carson DA: Analyses of human rheumatoid factors with anti-idiotypes induced by synthetic peptides. *Monogr Allergy* 22:12-23, 1987.
76. Carson DA, Chen PP, Radoux V, Jirik F, Goldfien RD, Silverman GJ, Fong S: Molecular basis for the cross-reactive idiotypes on human anti-IgG autoantibodies (rheumatoid factors) In: *Autoimmunity and Autoimmune Disease*. Ciba Foundation Symposium 129 pp. 123-130, 1987.
77. Radoux V, Fong S, Chen PP, Carson DA: Rheumatoid factors: current concepts. In: *Advances in Inflammation Research*. Lewis, A. (Ed), Raven Press, New York, pp.295-304, 1987.
78. Kipps TJ, Fong S, Chen PP, Miller WE, Piro LD, Carson DA: Immunoglobulin V gene utilization in CLL. In: *Chronic lymphocytic leukemia: recent progress and future direction*, Alan R Liss, Inc., New York, pp. 115-126, 1987.
79. Fong S, Chen PP, Fox RI, Goldfien RD, Radoux V, Silverman GJ, Crowley JJ, Roudier J, Carson DA: The diversity and idiotypic pattern of human rheumatoid factors in disease. *Concepts in Immunopath* 5: 168-191, 1988.
80. Fox RI, Fong S, Chen PP, Kipps TJ: Autoantibody production in Sjogren's syndrome: a hypothesis regarding defects in somatic diversification of germline encoded genes. *In Vivo* 2: 47-56, 1988.
81. Chen PP, Fong S, Goni F, Silverman GJ, Fox RI, Liu M-K, Frangione B, Carson DA: Cross-reacting idiotypes on cryoprecipitating rheumatoid factor. *Springer Seminar Series in Immunopath* 10: 35-55, 1988.
82. Chen PP, Fong S, Carson DA: Rheumatoid factor. *Rheumatic Diseases of North America* 13:545-568, 1987.
83. Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik FR, Goldfien RD, Fox RI, Silverman GJ, Fong S. Idiotypic and genetic studies of human rheumatoid factors. *Arthritis Rheum* 30: 1321-1325, 1987.
84. Fong S, Chen PP, Crowley JJ, Silverman GJ, Carson DA: Idiotypic characteristics of rheumatoid factors. *Scand J Rheumatol, Suppl.* 75: 58-65, 1988.
85. Crowley JJ, Goldfien RD, Schrohenloher RE, Spiegelberg HL, Silverman GJ, Mageed RA, Jefferis R, Koopman WJ, Carson DA, Fong S: Incidence of three cross reactive idiotypes on human rheumatoid factor paraproteins. *J Immunol* 140: 3411-3418, 1988.
86. Fong S, Chen PP, Crowley JJ, Silverman GJ, Carson DA: Idiotypes and the structural diversity of human rheumatoid factors. *Springer Seminar Series in Immunopath* 10: 189-201, 1988.
87. Silverman GJ, Goldfien, Chen PP, Mageed RA, Jefferis R, Goni F, Frangione B, Fong S, Carson DA. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors: implications for structural and genetic basis of autoantibodies in humans. *J Clin Invest* 82: 469-475, 1988.
88. Fox RI, Chan E, Benton L, Fong S, Friedlander M. Treatment of primary Sjogren' syndrome with hydroxychloroquine. *American Journal of Medicine* 85 (suppl 4A): 62-67, 1988.
89. Fong S. La Diversite Structurale Des Facteurs Rhumatoïdes Humains. In *Immunorhumatologie*. Roux H, Luxembourg A, Roudier J, (Eds.). Solal, editeurs, Marseille, pp 162-166, 1989.

90. Fu, Y., Arkin, S., Fuh, G., Cunningham, B.C., Wells, J.A., Fong, S., Cronin, M., Dantzer, R., Kelley, K. Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor. *J. Clin. Invest* 89: 451-457, 1992.
91. Weber, J.R., Nelson, C., Cunningham, B.C., Wells, J.A., Fong, S. Immunodominant structures of human growth hormone identified by homolog-scanning mutagenesis. *Mol. Immunol.* 29: 1081-1088, 1992.
92. Bushell, G., Nelson, C., Chiu, H., Grimley, C., Henzel, W., Burnier, J., Fong, S. The role of cathepsin B in the generation of T cell antigenic epitopes of human growth hormone. *Mol. Immunol.* 30:587-591, 1993.
93. Bednarczyk, J.L., Wygant, J.N., Szabo, M.C., Molinari-Storey, L., Renz, M., Fong, S., McIntyre, B.W. Homotypic leukocyte aggregation triggered by a monoclonal antibody specific for novel epitope expressed by the integrin $\beta 1$ subunit: Conversion of non-responsive cells by transferring human $\alpha 4$ subunit cDNA. *J. Cell. Biochem.* 51: 465-478, 1993.
94. Berman, P.W., Nakamura, G., Riddle, L., Chiu, H., Fisher, K., Champe, M., Gray, A., Ward, P., Fong, S. Biosynthesis and function of membrane bound and secreted forms of recombinant Mac-1. *J. Cell. Biochem.* 52:183-195, 1993.
95. Crowe, D.T., Chiu, H., Fong, S., Weissman, I.L. Regulation of the avidity of integrin $\alpha 4\beta 7$ by the $\beta 7$ cytoplasmic domain. *J. Biol. Chem.* 269:14411-14418, 1994.
96. Renz, M.E., Chiu, H.H., Jones, S., West, C., Fox, J., Kim, J.K., Presta, L.G., Fong, S. Structural requirements for adhesion of soluble recombinant murine VCAM-1 to $\alpha 4\beta 1$. *J. Cell Biol.* 125:1395-1406, 1994.
97. Chiu, H. H., Crowe, D. T., Renz, M. E., Presta, L. G., Jones, S., Weissman, I. L., and Fong, S. Similar but non-identical amino acid residues on vascular cell adhesion molecule-1 are involved in the interaction with $\alpha 4\beta 1$ and $\alpha 4\beta 7$ under different activity states. *J. Immunol.* 155:5257-5267, 1995.
98. Viney, J. L., Jones, S., Chiu, H., Lagrimas, B., Renz, M., Presta, L., Jackson, D., Hillan, K., Fong, S. Mucosal Addressin Cell Adhesion Molecule-1. A structural and functional analysis demarcates the integrin binding motif. *J. Immunol.* 157: 2488-2497, 1996.
99. Fong, S., Jones, S., Renz, M.E., Chiu, H.H., Ryan, A.M., Presta, L. G., and Jackson, D. Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1)—Its binding motif for $\alpha 4\beta 7$ and role in experimental colitis. *Immunologic Research* 16: 299-311, 1997.
100. Jackson, D.Y., Quan, C., Artis, D.R., Rawson, T., Blackburn, B., Struble, M., Fitzgerald, G., Chan K., Mullin, S., Burnier, J.P., Fairbrother, W.J., Clark, K., Beresini, M., Chiu, H., Renz, M., Jones, S., and Fong, S. Potent $\alpha 4\beta 1$ Peptide Antagonists as Potential Anti-Inflammatory Agents. *J. Med. Chem.* 40: 3359-3368, 1997.
101. Viney, J.L. and Fong, S. $\beta 7$ Integrins and Their Ligands in Lymphocyte Migration to the Gut. *Chemical Immunology: 'Mucosal T Cells'*. *Chemical Immunology* 71:64-76, 1998.
102. Bradley, L.M., Malo, M.E., Fong, S., Tonkonogy, S.L., and Watson, S.R. Blockade of both L-selectin and $\alpha 4$ Integrins Abrogate Naïve CD4 Cell Trafficking and Responses in Gut-Associated Lymphoid Organs. *International Immunology* 10, 961-968, 1998.

103. Quan, C., Skelton, N., Clark, K., Jackson, D.Y., Renz, M., Chiu, H.H., Keating, S.M., Beresini, M.H., Fong, S., and Artis D.R. Transfer of a Protein Binding Epitope to a Minimal Designed Peptide. *Biopolymers (Peptide Science)*;47,265-275, 1998.
104. Hillan, K.J., Hagler, K.E., MacSween, R.N.M., Ryan, A.M., Renz, M.E., Chiu, H.H., Ferrier, R.K., Bird, G.L., Dhillon, A.P., Ferrell, L.D., Fong, S. Expression of the Mucosal Vascular Addressin, MAdCAM-1, in Inflammatory Liver Disease. *Liver* 19, 509-518, 1999
105. Pender, S.L.F., Salmela, M.T., Monteleone, G., Schnapps, D., McKenzie, C., Spencer, J., Fong, S., Saarialho-Kere, U., and MacDonald, T.T. Ligation of alpha 4 beta 1 integrin on human intestinal mucosal mesenchymal cells selectively upregulates membrane type-1 matrix metalloproteinase and confers a migratory phenotype. *American Journal of Pathology* 157, 1955-1962, 2000.
106. Liang, T.W., DeMarco, R., Gurney, A., Hooley, J., Huang, A., Klassen, T., Mrsny, R., Tumas, D., Wright, B.D., and Fong, S. Characterization of Human Junctional Adhesion Molecule (huJAM): Evidence for involvement in cell-cell contact and tight junction regulation. *American Journal of Physiology; Cell Physiology* 279, C1733-C1743, 2000.
107. Liang, T.W., Chiu, H.H., Gurney, A., Sidle, A., Tumas, D.B., Schow, P., Foster, J., Klassen, T., Dennis, K., DeMarco, R.A., Pham T., Frantz, G., Fong, S. VE-JAM/JAM 2 interacts with T, NK, and dendritic cells through JAM 3. *J.Immunology* 168, 1618-1626, 2002.
107. Dupree, N., Artis, D.R., Castanedo, G., Marsters, J., Sutherlin, D., Caris, L., Clark, K., Keating, S., Beresini, M., Chiu, H., Fong, S., Lowman, H., Skeleton, N., and Jackson, D. Selective $\alpha 4\beta 7$ Antagonists and Their Potential as Anti-Inflammatory Agents. *J. Med. Chem.* 45, 3451-3457, 2002.
108. Castanedo, G.M., Sailes, F.C., Dubree, N., Nicholas, J., Caris, L., Keating, S., Chiu, H., Fong, S., Marsters, J., Jackson, D.Y., Sutherlin, D.P. The Solid Phase Synthesis of Dual $\alpha 4\beta 1/\alpha 4\beta 7$ Antagonists: Two Scaffolds with Overlapping Pharmacophores. *Bioorganic and Medicinal Chemistry Letters* 12, 2913-2917, 2002.

CURRENT PROTOCOLS IN IMMUNOLOGY

VOLUME 1

EDITORIAL BOARD

JOHN E. COLIGAN
National Institute of Allergy and Infectious Diseases

ADA M. KRUISBEEK
Netherlands Cancer Institute

DAVID H. MARGULIES
National Institute of Allergy and Infectious Diseases

ETHAN M. SHEVACH
National Institute of Allergy and Infectious Diseases

WARREN STROBER
National Institute of Allergy and Infectious Diseases

SERIES EDITOR

Richard Coico
City University of New York Medical School



John Wiley & Sons, Inc.

Copyright © 1991–1994 by Current Protocols
Copyright © 1994–2001 by John Wiley & Sons, Inc.
All rights reserved.

Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

While the authors, editors, and publisher believe that the specification and usage of reagents, equipment, and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they accept no legal responsibility for any errors or omissions, and make no warranty, express or implied, with respect to material contained herein. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. This is particularly important in regard to new or infrequently employed chemicals or experimental reagents.

Library of Congress Cataloging in Publication Data:

Current protocols in immunology / edited by John E. Coligan ... [et al.].
p. cm.

Kept up to date by quarterly supplements.

4 vols. Includes index.

ISBN 0-471-52276-7

1. Immunology—Laboratory manuals I. Coligan, John E.

[DLM: 1. Clinical Protocols. 2. Immunologic Techniques. QW 525 C976]

QR183.C87 1991

616.07'0'072—dc20

DNLM/DLC

for Library of Congress

Printed in the United States of America

10

90-15726
CIP

Proliferative Assays for T Cell Function

UNIT 3.12

A number of agents can specifically or nonspecifically induce T cell activation, resulting in cytokine production, cytokine receptor expression, and ultimately proliferation of the activated T cells. Although proliferation is not a specific effector function of T lymphocytes—in contrast to helper function for B lymphocytes (UNIT 3.10) or cytotoxicity (UNIT 3.11)—proliferation assays are reliable, simple, and easy to perform and have been widely used to assess the overall immunocompetence of an animal. In addition, the assays described in this unit form the basis for identifying the appropriate cellular population that might be used to obtain T cell clones (UNIT 3.13) or T cell hybridomas (UNIT 3.14).

The assays have been divided into two groups on the basis of whether they are used to stimulate primed or unprimed T lymphocytes. The first basic protocol describes the use of agents that are capable of activating unprimed T lymphocytes in culture either by pharmacologic means (calcium ionophore and phorbol ester stimulation), by direct cross-linking of the T cell receptor (TCR) on a large percentage of responder cells (anti-CD3, anti-TCR- $\gamma\delta$, or anti-TCR- $\alpha\beta$ monoclonal antibodies), by cross-linking the receptors on certain subpopulations of T cells with monoclonal antibodies specific for the V regions of β chains of the TCR (anti-V β) or with enterotoxins specific for certain V β -chain regions, or by indirectly cross-linking the TCR (lectins or monoclonal antibodies to non-TCR antigens). The first alternate protocol describes the use of plate-bound antibodies specific for the TCR to stimulate proliferation. The second alternate protocol describes the activation of unprimed T cells to cell-associated antigens in the mixed leukocyte reaction (MLR). The first support protocol describes the preparation and use of T cell-depleted accessory or stimulator cells and the second support protocol describes methods for blocking accessory cell proliferation. Finally, the second basic protocol describes the induction of a T cell proliferative response to soluble protein antigens or to cell-associated antigens against which the animal has been primed in vivo.

The assays in this unit employ murine T lymphocytes. Induction of proliferative responses of murine B lymphocytes is described in UNIT 3.10. Related assays for use with human peripheral blood lymphocytes are described in UNIT 7.9.

NOTE: All solutions and equipment coming into contact with cells must be sterile, and proper sterile technique should be used accordingly.

ACTIVATION OF UNPRIMED T CELLS

Unprimed T cells can be induced to proliferate by a variety of agents, including pharmacological agents, anti-CD3/TCR or anti-Thy-1 monoclonal antibodies, enterotoxins and lectins. The commentary briefly describes the specificities of these agents, while Table 3.12.1 lists sources and concentrations for use in this protocol. Although this procedure is intended to measure proliferation of T cells specifically, in many cases induction of T cell proliferation is dependent on the presence of non-T cells that function as accessory cells. The latter provide additional costimulatory signals for T cell proliferation as well as cross-link (via their Fc receptors) monoclonal antibodies bound to cell-surface antigens. The requirement for non-T accessory cells varies with the nature of the stimulatory ligand and can range from absolute dependence to accessory cell-independent T cell activation (see Table 3.12.1). The activation is calculated after determining the difference in incorporation of [3 H]thymidine between stimulated and control cells.

BASIC PROTOCOL

In Vitro Assays
for Mouse B and
T Cell Function

3.12.1

Table 3.12.1 Agents Used to Activate Unprimed T Cells in Proliferative Assays

Agent ^a	Source/ cat. no. ^b	Concentration	Accessory cells ^c	Mode of action, etc.
PMA	SIG P8139	1-10 ng/ml	No	Use with ionomycin or A23187; pharmacologic
Ionomycin	CAL 407950	200-500 ng/ml	No	Use with PMA; pharmacologic
A23187	CAL 100105	100-500 ng/ml	No	Use with PMA; pharmacologic
PHA	WD HA16	1-5 µg/ml	Yes	Indirect TCR cross-linking
Con A	PH 17-0450-01	1-10 µg/ml	Yes	Indirect TCR cross-linking
Anti-Thy-1	PG mAb-G7	1-50 µg/ml	Yes ^c	Indirect TCR cross-linking
Anti-CD3	PG HM-CD3	0.1-5 µg/ml	Yes ^c	Use plate-bound or soluble; direct TCR cross-linking
Anti-TCR-αβ	PG HM-AB-TCR	0.1-10 µg/ml	Yes ^c	Use plate-bound or soluble; direct TCR cross-linking
Anti-TCR-γδ	PG HM-GD-TCR-1; HM-GD-TCR-3	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Anti-Vβ-8.1, 8.2 ^c	PG MM-Vβ-TCR-1	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Anti-Vβ-6 ^c	PG RM-Vβ-TCR-2	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Anti-Vβ-11	PG RM-Vβ-TCR-3	0.1-100 µg/ml	No	Use plate-bound; direct TCR cross-linking
Staph tox A	TT AT101	1-10 µg/ml	Yes ^c	Vβ-1,3,10,11,17-receptor specificity
Staph tox B	TT BT202; SIG S4881	1-100 µg/ml	Yes ^c	Vβ-3,7,8,17-receptor specificity
Staph tox E	TT ET404	1-10 µg/ml	Yes ^c	Vβ-11,15,17-receptor specificity

^aAbbreviations: PMA, phorbol 12-myristate 13-acetate; PHA, phytohemagglutinin; Con A, concanavalin A; Staph tox A, B, & E, *Staphylococcus enterotoxins* A, B, & E.

^bSupplier addresses and phone numbers are provided in APPENDIX 5. Abbreviations: CAL, Calbiochem; PG, Pharmingen; PH, Pharmacia LKB; SIG, Sigma; TT, Toxin Technology; WD, Wellcome Diagnostics.

^cWhen using anti-CD3 and anti-TCR antibodies in soluble form (rather than plate-bound), accessory cells are required. When using Staph enterotoxins, accessory cells must express appropriate MHC class II molecules. Accessory cell dependence is not absolute with anti-Thy-1 antibodies.

Materials

Complete RPMI-5 and RPMI-10 media (APPENDIX 2)

Responder cells: lymphocytes from nonimmunized mouse thymus, spleen, or lymph nodes (UNIT 3.1)

Activating agent(s) (Table 3.12.1)

Phosphate-buffered saline (PBS; APPENDIX 2)

Accessory cells: unfractionated mouse spleen cell suspension, irradiated or treated with mitomycin C (second support protocol) or T cell-depleted (first support protocol)

[³H]thymidine (APPENDIX 3)

15- and 4-ml disposable, polystyrene conical tubes with screw caps

Low-speed centrifuge with Sorvall H-1000B rotor (or equivalent)

1-, 5-, and 10-ml disposable polystyrene pipets

96-well flat- or round-bottom microtiter plates with lids (Costar #3596 or #3799)

25- to 100- μ l single- and multichannel pipettors with disposable tips

Additional reagents and equipment for removing organs (UNIT 1.9), preparing single-cell suspensions (UNIT 3.1), and counting, labeling, and harvesting cells (APPENDIX 3)

1. Prepare responder leukocyte suspensions from thymus, spleen, or lymph node in complete RPMI-5 as described in UNIT 3.1.

The size of the intended experiment dictates the number of organs to be collected. See annotation to step 3 for an indication of cell number required, and UNIT 3.1 for number of cells per organ. Spleen, thymus, and lymph node can be used as responder cells, while only spleen is a source of accessory cells. Purified T cells or subpopulations of T cells (i.e., CD4⁺ or CD8⁺) cells may also be used. See UNITS 3.1-3.6 for enrichment/depletion methods.

2. Centrifuge single-cell suspensions in 15-ml conical tubes for 10 min in Sorvall H-1000B rotor at ~ 1000 rpm ($200 \times g$), room temperature, and discard supernatant.
3. Resuspend cell pellet in complete RPMI-5. Count responder cells and adjust to $\sim 10^6$ cells/ml with complete RPMI-10.

While this concentration (1×10^5 cells/ml or 2×10^5 cells/well) will give satisfactory responses with most cell populations, it is useful to compare 2, 4, and 8×10^5 cells per well in initial pilot experiments. If unfractionated spleen or lymph node cells are used as the responder population, sufficient accessory cells are present and there is no need to supplement the cultures with additional cells. However, if highly purified T cells or T cell subpopulations are used as responders, it will be necessary to add non-T accessory cells depending on the nature of the activating agent (see Table 3.12.1). This is most easily accomplished by adding increasing numbers (0.1 , 0.5 , and 1.0×10^5) of syngeneic spleen (accessory) cells in 0.1 ml to 2×10^5 T cells in 0.1 ml (see first support protocol). Also, a meaningful comparison of the responsiveness of different cell populations requires titrations of both the activating agents as well as the responding cell populations, and a kinetic experiment.

4. Prepare working solutions of activating agents in 4-ml conical tubes at room temperature as follows. For MAb, toxin, or lectin, make a series of four dilutions from 1 mg/ml stock solutions—e.g., 100, 30, 10, and 3 μ g/ml in PBS. For the pharmacological agent, make single dilutions of 100 ng/ml solution of PMA and 1 μ g/ml A23187 (or 4 μ g/ml ionomycin) in PBS.

If MAb in supernatant or ascites form are being used, at least four dilutions should also be used. Working solutions should be used immediately, since the various proteins, especially MAB, may bind to the plastic.

In Vitro Assays
for Mouse B and
T Cell Function

See Table 3.12.1 for V β specificities of staphylococcal enterotoxins. It is essential to verify that the mouse strain employed expresses the MHC class II surface molecules for which the enterotoxin has a specific binding affinity. See Marrack and Kappler (1989) for further discussion of various enterotoxins and their specificities.

5. Add 20 μ l of each dilution of activating reagent (MAb, enterotoxin or lectin) to each of three wells of a 96-well flat- or round-bottom microtiter plate. Include control wells with 20 μ l of PBS only. Add 20 μ l PMA or calcium ionophore at the single concentration indicated in step 4, as the dose-response curve for these agents is extremely narrow.

A series of four dilutions will form one row of each microtiter plate, allowing for efficient organization of the plates.

6. To the wells of the 96-well microtiter plate containing activating agent, add 2×10^5 cells in 0.2 ml.
7. Place microtiter plates in a humidified 37°C, 5% CO₂ incubator for 2 to 4 days.

Optimum culture periods for stimulating cells will vary depending on cell type and laboratory conditions and must be determined empirically (see critical parameters).

8. Add [³H]thymidine to each well. Return the plates to CO₂ incubator to pulse 18 to 24 hr. Harvest cells using a semiautomated sample harvester and measure cpm in β scintillation counter.
- 9a. Compute the data as the difference in cpm of stimulated (experimental) and control (no activating agent added) cultures. This is done by subtracting the arithmetic mean of cpm from triplicate control cultures from the arithmetic mean of cpm from corresponding stimulated cultures. The results are referred to as " Δ cpm."
- 9b. Alternatively, compute the data as the ratio of cpm of stimulated and control cultures. This is done by dividing the arithmetic mean of cpm from stimulated cultures by the arithmetic mean of cpm from control cultures. The results are referred to "SI" (stimulation index).

The second method (step 9b) has the disadvantage that small changes in background values will result in large changes in SI and should be interpreted with caution. In most publications, Δ cpm rather than SI values are preferred.

ALTERNATE PROTOCOL

ACTIVATION OF UNPRIMED T CELLS WITH PLATE-BOUND ANTIBODIES

Although it is possible to induce T cell activation with monoclonal antibodies to the CD3/TCR complex in solution during culture, such activation depends on cross-linking of the antibody by Fc receptor-bearing accessory cells. This protocol describes the use of monoclonal antibodies to the CD3/TCR complex by coupling them to the wells of the microtiter plates. The T cell proliferative response induced under these conditions does not require the presence of significant numbers of accessory cells, although the responses obtained may be suboptimal (Jenkins et al., 1990).

Use of this protocol is recommended for use with those antibodies to the CD3/TCR complex which bind poorly to the Fc receptor present on murine accessory cells and which do not induce T cell activation in soluble form. Although all monoclonal antibodies readily couple to plastic under these conditions, it is very difficult to induce a proliferative response with certain antibodies such as the G7, anti-Thy-1 monoclonal antibody. In such cases, the conditions described in the basic protocol should be followed.

Additional Materials

PBS (APPENDIX 2), room temperature and 4°C

1 mg/ml purified anti-CD3 or anti-TCR MAb in PBS (for nonspecific activation of T cells) or 1 mg/ml purified anti-V β or anti-TCR- $\gamma\delta$ MAb in PBS (for activation of T cells with specific receptors; see Table 3.12.1)

1. In 4-ml conical polystyrene tubes, prepare a series of four dilutions of MAb from sterile 1 mg/ml stock solutions—e.g., 100, 10, 1, and 0.1 μ g/ml—using room temperature PBS.

Sources and recommended concentrations of monoclonal antibodies can be found in Table 3.12.1; since MAb will bind to plastic, the working dilutions should be used immediately.

The ability of anti-TCR antibodies to cross-link receptor molecules varies depending on the purity of the MAb preparation and the affinity of the MAb for the TCR/CD3 complex. Optimum dilutions will have to be determined in dose-response experiments. Alternatively, preparations of ascites fluid from the MAb can be tested at different dilutions (e.g., 1:100, 1:200, 1:400, and 1:800), but use of purified antibody will allow for better standardization of the assay.

Because the efficacy of MAb-induced activation depends on the amount of antibody bound to the bottom of the wells, it is crucial to make the dilutions in a buffer without any additional source of proteins such as FCS or albumin; these would compete with the binding of the antibody, and therefore reduce the responsiveness. For this reason, it is also not recommended to perform the assay with culture supernatants of the appropriate hybridomas.

2. Add 30 μ l of each concentration of MAb solution to each of three wells of a 96-well round-bottom microtiter plate. Include control wells of 30 μ l PBS only.

A series of four dilutions will form one row of each plate, allowing for efficient organization of the plates. Consistently better responses are seen with round-bottom (compared with flat-bottom) plates in antibody-mediated experiments.

Most often, optimal responses are seen with 10 μ g/ml antibody. There is no point in adding more than the indicated amount of antibody, since the maximum amount that can bind to surface of the wells is ~2 to 3 μ g (A.M.K., unpub. observ.).

3. Cover the plate and gently tap its side to ensure complete covering of the bottom of the wells. Incubate plates 90 min at 37°C. During incubation, proceed to step 4.

During this incubation, the antibodies bind to the plastic in the wells for subsequent cross-linking of the T cell receptors on responding T cells. Plates can also be prepared the night before an experiment and kept in the refrigerator overnight, after the 37°C incubation.

4. Prepare responder cell suspensions as in steps 1 to 3 of the basic protocol.

Highly purified T cell populations can be used in these studies as the proliferative response induced is accessory cell-independent. However, the presence of non-T accessory cells does not interfere with the proliferative response.

5. Wash the wells of the incubated plates by adding 200 μ l cold PBS and inverting the plates with a flick of the hand on a stack of paper towels placed in a tissue culture hood. Repeat washing procedure two more times to remove excess antibody.

6. To the wells of the washed plates, add $\sim 2 \times 10^5$ cells in 0.2 ml.

If cells are not ready at this stage, plates may be kept in the refrigerator overnight after 100 μ l PBS has been added. Presumably, longer storage periods should be acceptable, but our experience is limited to ≤ 4 day periods. The PBS should be removed before the cells are added.

In Vitro Assays
for Mouse B and
T Cell Function

3.12.5

Most cell populations will give peak responsiveness at this cell dosage, but pilot experiments should be performed to establish optimal conditions.

7. Proceed as in steps 7 to 9 of the basic protocol, but incubate cultures for 2 to 3 days before adding [^3H]thymidine.

Kinetic assays should be performed to determine the optimum culture period.

ALTERNATE PROTOCOL

T CELL PROLIFERATION IN MIXED LYMPHOCYTE CULTURES

In the mixed lymphocyte culture (MLC) or reaction (MLR), suspensions of responder T cells are cultured with allogeneic stimulator lymphocytes. The activating stimulus is the foreign histocompatibility antigen (usually MHC class I or class II molecules) expressed on the allogeneic stimulator cells. Responder cells need not be primed because a sufficiently high number of T cells in the MLC will respond to the stimulator population. If the stimulator cell population contains T cells, their uptake of [^3H]thymidine must be prevented by irradiation or treatment with mitomycin C; alternatively the stimulator cell suspension can be depleted of T cells (see support protocols).

Additional Materials

Responder cells: lymphocytes from nonimmunized mouse thymus, spleen, or lymph nodes (UNITS 1.9 & 3.1) or purified T cells or T cell subpopulations (UNITS 3.1-3.6)

Stimulator cells: allogeneic mouse spleen cells that differ from the responder cells at H-2 or Mls loci, irradiated or treated with mitomycin C (second support protocol) or T cell-depleted (first support protocol)

1. Prepare responder cell populations as in steps 1 to 3 of the basic protocol. Although unfractionated cell populations can be used as responders in certain situations, it may be preferable to use purified T cells or T cell subsets.

To estimate the MLR of a cell population, it is necessary to perform a dose-response assay with different numbers of responder cells. Typically, three replicate wells are set up containing each of the following: 0.5×10^5 , 1×10^5 , and 4×10^5 cells (optimal responses are usually obtained with the latter two densities). The setup for these four cell densities will occupy one row (12 wells) of a microtiter plate.

For thymocytes, it may be necessary to use 8×10^5 cells per well because the frequency of responding T cells is lower; the lowest number of responder cells could then be 1×10^5 and the doses in between would be 2×10^5 and 4×10^5 . Using this range of higher numbers of responder cells may also be preferred when experimental manipulations are expected to reduce the frequency of responding T cells.

2. To a 96-well microtiter plate, add 5×10^4 to 4×10^5 responder cells in 0.1 ml to each well. For each experimental group, set up three replicate wells.

Stimulation of leukocytes for proliferation in 96-well microtiter plates can be run in parallel with cytotoxic T lymphocyte (CTL) generation (UNIT 3.11), which is performed in 24-well microtiter plates. For example, cells can be diluted to 4×10^6 cells/ml and added to 24-well plates in 1.0 ml/well for CTL generation and to 96-well plates in 0.1 ml/well for proliferation.

3. Prepare a single-cell suspension of irradiated or mitomycin C-treated stimulator cells. Alternatively, prepare a suspension of T-cell depleted stimulator cells. Add 0.1 ml to each well of the plates containing responder cells.

The optimum number of stimulator cells must be determined for each MLC and for different responder cells. For a range of responder cells from 0.5×10^5 to 4×10^5 , test stimulator cells at densities of 2, 4, and 8×10^6 /ml (i.e., 2, 4, and 8×10^5 /well). It should be noted that the stimulator cell suspension provides both the specific antigen to be recognized by the responder T cells as well as nonspecific accessory cells. If

highly purified T cells are used as the responder population, it is therefore not necessary to supplement the cultures with non-T accessory cells syngeneic to the responder T cells.

Separate wells with control cultures should be set up that include—for each dose of responder and stimulator cells—replicate wells of responder cells with irradiated or mitomycin C-treated syngeneic stimulator cells. Values obtained from these controls reflect “background” proliferation values (see step 9 of basic protocol). Other negative controls often included are wells with stimulator cells alone and wells with responder cells alone. These are not used for the calculation of the data, but are useful to compare with the background proliferation values; the latter should not be much higher (<2-fold) than those obtained with stimulator or responder cells alone. Higher background values indicate potential autoreactivity.

4. Follow steps 7 to 9 of the basic protocol, but incubate the cultures for 3 to 6 days.

Optimum culture periods for stimulating cells will vary depending on cell type and laboratory conditions, and must be determined empirically (see critical parameters).

DEPLETION OF T CELLS FROM ANTIGEN-PRESENTING/STIMULATOR CELL SUSPENSIONS

SUPPORT PROTOCOL

Although normal unfractionated spleen cell populations can be used as a source of accessory cells, in certain types of experiments it may be preferable to use spleen cell populations from which the T cells have been removed. This procedure ensures that none of the observed proliferative responses of the responder population result from T cell factors derived from the accessory cell population. For example, even T cells whose cell division has been blocked (second support protocol) can produce cytokines. In the following steps, T cell-depleted spleen cell suspensions are prepared using a lytic monoclonal antibody to the T cell antigen, Thy-1. Because almost all the antigen presentation or stimulator cell activity in spleen resides in the non-T cell fraction, this procedure also leads to enrichment of functional antigen-presenting cell function. Further enrichment of antigen-presenting cells (APC) by flotation of the T cell-depleted spleen cells on Percoll gradients is also described. Other procedures leading to enrichment of APC are described elsewhere; the method described in UNIT 3.7 does not deplete T cells and therefore is not recommended here; the method described in UNIT 3.15 leads to higher levels of enrichment that are not required in the protocols presented here.

Additional Materials

- Spleen cells from nonimmunized mice
- Hanks balanced salt solution (HBSS; APPENDIX 2)
- Low-Tox rabbit complement (Cedarlane #CL3051), reconstituted with ice-cold distilled water and filter-sterilized
- Anti-Thy-1.2 ascites (HO-13-4; ATCC #TIB 99) or anti-Thy-1.1 ascites (HO-22-1; ATCC #TIB 100; alternatively, see Table 3.4.1 for other anti-Thy-1 MAb and UNIT 2.6 for production of ascites)
- 70% Percoll solution (UNIT 3.8 and reagents and solutions)

1. Centrifuge the spleen cell suspension derived from single spleen down to a pellet.

The spleen cells should always be from nonprimed animals and should be syngeneic to the responder T cells unless they are to be used as stimulator cells in the MLC.

2. To the pellet, add 0.9 ml HBSS, 0.1 ml complement, and 25 μ l anti-Thy-1 ascites.

If cells from more than a single spleen are needed, the procedure should be scaled up accordingly.

In Vitro Assays
for Mouse B and
T Cell Function

3.12.7

The choice of anti-Thy-1 reagent to be used depends on the strain of animal from which the spleen was derived. The great majority of commonly available mouse strains (except AKR) express the Thy-1.2 allele.

3. Incubate the mixture at 45 min in a 37°C water bath.
4. Centrifuge 10 min in Sorvall H-1000B rotor at ~1000 rpm (200 × g), room temperature, and discard supernatant. Resuspend pellet in HBSS and wash two more times.
5. Count viable cells (APPENDIX 3) and resuspend in complete RPMI-10 or PBS for inactivation as in the second support protocol, or in HBSS to prepare low-density accessory cells (see below).

The T cell-depleted spleen cell population is comprised of B cells, macrophages, and dendritic cells. Further enrichment of cells with enhanced accessory cell function can be obtained by fractionation of this population on Percoll.

6. Dilute 70% Percoll solution to 55% by mixing 23.58 ml of the 70% Percoll with 6.42 ml HBSS. Resuspend T cell-depleted spleen cells from step 5 in HBSS at 20×10^6 cells/ml.
7. Layer 3 ml cell suspension over 3 ml of 55% Percoll solution in a 15-ml conical centrifuge tube.
8. Spin 13 min in H-1000B rotor at 3000 rpm (1900 × g), room temperature.
9. Remove cells that band at the Percoll/HBSS interface with a 5-in. Pasteur pipet and wash 3 times in HBSS as in step 4.
10. Count viable cells and resuspend in complete RPMI-10 for inactivation according to the second support protocol.

The population obtained from steps 6 to 10 is comprised of large cells including macrophages, dendritic cells, and activated B lymphocytes. This population of cells is enriched in accessory cell function. When used in either of the basic protocols with purified T responder cells, fewer of the Percoll-purified cells should be needed to provide accessory function.

SUPPORT PROTOCOL

BLOCKING CELLULAR DIVISION OF ACCESSORY/STIMULATOR CELLS

There are two situations in which inhibition of accessory or stimulator cell division should be blocked. When purified T cells rather than unfractionated lymphoid populations are used in the basic protocol, cultures are frequently supplemented with accessory cells syngeneic to the responder T cells. If accessory cell DNA synthesis is inhibited, one can then be certain that the resultant proliferative response is comprised entirely of responder T cells and does not contain a component of recruited B cell proliferation derived from the accessory cell populations. In the MLR, the stimulator cells are spleen cells from mice that differ from the responder cells in *H-2* and/or *Mls* gene expression (see APPENDIX 1, Tables A.1C.1 and A.1F.1) and they can also recognize alloantigens on the responder cells. This responsiveness of stimulator cells against responder cells in an MLR (so-called back-stimulation) must be prevented by blocking cellular division. This can be done by treatment of stimulator cells with mitomycin C (a DNA cross-linking reagent) or by g irradiation. Many investigators prefer mitomycin C treatment when antigenic differences encoded for by *Mls* genes are to be measured, or when an irradiation source is not available. For more information on the loci encoding *Mls* genes, see Tables A.1F.2 and A.1F.3.

Mitomycin C Treatment

Additional Materials

Mitomycin C (Sigma #M-0503; store in dark)

Proliferative
Assays for T Cell
Function

3.12.8

1. In a 15-ml aluminum foil-wrapped tube, prepare a solution of mitomycin C in PBS at 0.5 mg/ml and filter sterilize.

Since mitomycin C is very light-sensitive, it is necessary to prepare a fresh stock solution each day for each experiment.

2. Prepare spleen cell suspension as described in steps 1 and 2 of the basic protocol at a concentration of 5×10^7 cells/ml in PBS.
3. Add mitomycin C to a final concentration of 50 μ g/ml (100 μ l/ml of cell suspension) and wrap the tube in aluminum foil. Incubate 20 min at 37°C.
4. Add an excess of complete RPMI-5 (i.e., fill tube with ~12 ml) and centrifuge 10 min in Sorvall H-1000B rotor at 1200 rpm (300 \times g). Discard supernatant and repeat washing procedure two more times.

Three washes are crucial, because any traces of mitomycin C left among the cells will reduce proliferative responses when the cells are added to an MLC.

5. Resuspend pellet in complete RPMI-10. Count cells with hemacytometer. Adjust to desired concentration as described in the annotation to step 6 of the basic protocol.

Irradiation Treatment

Prepare a spleen cell suspension as described in steps 1 to 3 of the basic protocol, at a final concentration of $5-10 \times 10^6$ cells/ml in complete RPMI-10. Using a source of ionizing irradiation (^{60}Co or ^{137}Cs γ -irradiator; e.g., Gammacell 1000, Nordion), deliver 1000 to 2000 rad of irradiation to the cells.

This dose range of irradiation is suitable for most immunologic applications employing spleen cell suspensions. However, antigen presentation by different spleen cells is differentially affected by irradiation (Ashwell et al., 1984): at low doses (500 to 1000 rad), antigen-presenting function of B cells is preserved; after doses of 1100 to 2000 rad, a substantial decline is observed; and doses >2000 rad abolish the participation of B cells as APC. Macrophages and dendritic cells, on the other hand, maintain antigen presentation through doses of 3000 rad. To ensure that B cells do not participate in the responses measured, some investigators prefer to use doses of 2000 rad. However, responsiveness to *MLs* antigens can best be measured with stimulator cells that received doses of <1000 rad, since B cells present *MLs* more effectively. Alternatively, *MLs* responsiveness can be measured after mitomycin C treatment of stimulator cells, since it also preserves the antigen-presentation function of B cells.

When transformed cell lines are used as antigen-presenting or accessory cells, higher doses must be used to ensure blockage of cell division. The appropriate dose will have to be determined empirically for each cell line, but is likely to be at least 5000 rad; some transformed cell lines require as much as 10,000 to 12,000 rad, and may be more sensitive to mitomycin C treatment.

ACTIVATION OF PRIMED T CELLS

Proliferative responses to viruses, protein antigens, minor transplantation antigens, and the male H-Y antigen require in vivo immunization followed by in vitro stimulation. Furthermore, enhanced proliferative responses to those antigens that will generate primary in vitro responses (i.e., MHC antigens) can be obtained by in vivo priming. Multiple immunizations usually elevate in vitro responses.

To immunize animals for in vitro secondary responses to soluble protein antigens or peptides, dissolve antigens and emulsify in complete Freund's adjuvant (UNIT 2.5). For strong responses by draining lymph node cells, immunize animals in a hind footpad. For

BASIC PROTOCOL

In Vitro Assays
for Mouse B and
T Cell Function

3.12.9

strong responses by spleen cells, immunize intraperitoneally. Tail-base immunization also can be used as an efficient route of immunization; follow procedure for intradermal injection. To prime animals against cellular antigens, inject intraperitoneally with $1-5 \times 10^7$ cells that express the antigen. Immunization protocols are described in UNIT 1.6.

Within 2 to 3 weeks after in vivo priming, in vitro responsiveness of primed T cells can usually be measured. This assay is often used as a preparation for subsequent in vitro cloning procedures (UNIT 3.14) and T cell hybridoma preparation (UNIT 3.13).

Materials

Complete RPMI-10 medium (APPENDIX 2)

Responder cells: Purified T cells isolated from lymph nodes (UNITS 3.1-3.6) of in vivo primed mice

Antigen: 1 mg/ml sterile protein antigen(s) (UNIT 3.13), in PBS or suspension of irradiated or mitomycin C-treated stimulator cells expressing alloantigens at 8×10^6 cells/ml (UNIT 3.11, support protocol) in complete RPMI-10 medium (APPENDIX 2)

Accessory cells: suspension of irradiated or mitomycin C-treated (or T cell-depleted) spleen cells syngeneic to the responding T cells at 5×10^6 cells/ml in complete RPMI-10 medium

4-ml conical tubes

96-well flat-bottom microtiter plates with lids

1. Follow steps 1 to 3 of the first basic protocol for preparation of responder cells.
2. Prepare 4-fold dilution series of the antigens in 4-ml conical tubes, using complete RPMI-10.

The following dilutions are recommended: 100, 10, 1, and 0.1 μ g/ml protein antigens and 8, 4, 2, and 1×10^5 cells/ml of stimulator cells in complete medium.

3. Add antigens to 96-well flat-bottom microtiter plates, at 30 μ l/well for protein antigens or 100 μ l/well for cellular antigens. For each experimental group, set up three replicate wells and include control wells with medium only (no antigen).

By using four concentrations of antigens and three replicate wells for each dose, one row of a microtiter plate will cover the entire tested range.

4. Add responder T cells in 0.1 ml to each well.

Purified T cells are recommended; otherwise extremely high background values may be obtained. This appears to be due in part to proliferation of recruited cells (T and non-T) that are not antigen-specific. If unfractionated lymph node cells from recently primed mice are used, add $1-2 \times 10^5$ cells per well and proceed to step 6.

5. If purified lymph node T cells specific for protein antigens are used, add 0.1 ml of accessory spleen cells syngeneic to the donor of the responder T cells at 5×10^5 cells per well.

Purified T cells require an exogenous source of accessory non-T cells. Accessory cells function both as antigen-presenting cells and as a source of undefined "second signals." They are not required for cell preparations primed against cellular antigens, because accessory cell function is provided by the stimulator cells.

6. Proceed as in steps 7 to 9 of the basic protocol.

Culture periods before labeling can vary widely and kinetic assays should be performed. In general, for T cells from primed mice, it is likely that the response will peak at day 4 or 5.

REAGENTS AND SOLUTIONS

Percoll solution

Diluent:

45 ml 10× PBS, pH 7.4 (APPENDIX 2)

3 ml 0.6 M HCl

132 ml H₂O

Filter sterilize

70% Percoll solution:

63 ml Percoll (Pharmacia LKB #170891-01)

37 ml sterile diluent (above)

Final osmolarity should be 310 to 320 osM

COMMENTARY

Background Information

Proliferative assays for measuring T cell function have certain advantages and disadvantages compared to the cytotoxic T lymphocyte (CTL) assay described in UNIT 3.11 or the lymphokine production assays in UNITS 3.15 & 6.3. Advantages are that proliferative assays are less time-consuming, less labor-intensive, less cell-consuming, and less expensive than "true" effector T cell function assays. A disadvantage is that antigen specificity is not as easily demonstrated in proliferative assays as in CTL assays, unless antigen-specific clones of proliferating cells are used. Furthermore, the proliferative assay only detects dividing cells instead of measuring true effector T cell function.

It is not clear which T cell function is measured in proliferative assays; the proliferative response should therefore be used solely as general indicators of T cell reactivity. Data obtained in proliferative assays might variously reflect proliferation of CTL, lymphokine-producing T cells, or nonactivated "bystander" cells, and will be severely affected by the function of non-T cells such as accessory cells (see below). Since the majority of T cells respond to and produce IL-2 upon activation, differences in responsiveness in a proliferative assay in part reflect differences in IL-2 production by the responding T cells. Proliferative assays therefore become more meaningful when combined with the lymphokine detection assays presented in UNITS 3.15 & 6.3. Since responsiveness to IL-2 is also determined by the levels and functionality of IL-2 receptors, further information will be added by including measurements of IL-2 receptors (UNIT 6.1) or by flow cytometry (UNIT 5.4). Yet, as a first approximation of cellular activation, proliferative assays are valuable.

Critical Parameters and Troubleshooting

Parameters affecting the magnitude of T cell proliferative responses include cell concentration, type of medium, source of serum, incubator conditions (CO₂ level and humidity), type and concentration of activating agent, type of responding T cells, type of accessory/ stimulator cells, mouse strain, and culture time. Optimal conditions for individual laboratories and experiments must be derived empirically with respect to these variables, but general guidelines are provided below.

A number of agents can be employed in the first basic protocol to induce T cell proliferation (Table 3.12.1). T cells may be activated by pharmacologic means by producing an elevation of intracellular free calcium with a calcium ionophore combined with activation of protein kinase C with a phorbol ester. The most direct means of inducing T cell activation involves stimulation with monoclonal antibodies that interact with the CD3/TCR complex—i.e., anti-CD3, anti-TCR- $\alpha\beta$ or - $\gamma\delta$, as well as anti-V β antibodies that are capable of interacting with a subset of cells bearing a specific TCR. A vigorous T cell proliferative response of defined subsets can also be induced with certain bacterial toxins known as staphylococcal enterotoxins. These toxins are often referred to as "superantigens" (Marrack and Kappler, 1989) because they stimulate T cells via the variable (V) gene segment of the TCR. Different toxins have affinities for different V β chains and these specificities make them valuable reagents for activating T cells. The activating capacity of toxins is also dependent on their ability to bind to MHC class II molecules (i.e., responding T cells react with the toxin/class II complex); thus, responsiveness varies with the

In Vitro Assays
for Mouse B and
T Cell Function

3.12.11

mouse strain used. Lectins such as phytohemagglutinin (PHA) and concanavalin A (Con A) have been widely used for many years to activate T cells. Although the precise mechanism of action of these agents is unknown, it is likely that lectins activate T cells by indirectly cross-linking the TCR because TCR-negative cells will not respond to these agents. Lastly, it is also possible to induce T cell activation with monoclonal antibodies to cell-surface antigens other than the TCR; this protocol employs the G7 monoclonal antibody, one of the most effective of the anti-Thy-1 activators (Gunter et al., 1984).

When comparing the reactivity of different cell populations, it is essential to perform dose-response assays for responder T cells and activating agents and for both responder and stimulator T cells (in MLR), since each population may yield optimal responses at different cell numbers. This may reflect differences in frequency of responding cells, and hence may indicate a need to perform limiting dilution assays (UNIT 3.15). Since peak responsiveness of different populations of T cells may occur at different times, it is also essential to perform kinetic experiments—i.e., compare responsiveness at days 2, 3, 4, and 5.

Differences in responsiveness need not necessarily be due to differences in the frequency of responding T cells, but may also indicate differences in the efficacy with which co-stimulatory activity or “second signals” are delivered by the accessory cells present in different cell populations. The type of interactions pertinent to the generation of primary responses by T cells is explained in the commentaries of UNITS 3.8, 3.11, & 3.13. Specific requirements for inducing activation with immobilized antibodies have been described (Staerz and Bevan, 1986; Hathcock et al., 1989; Jenkins et al., 1990). A responding cell population completely devoid of accessory cells (such as purified populations of splenic or lymph node T cells or cloned T cells) will yield fine responsiveness in an MLC, since accessory cell function is provided by the stimulator cells; however, the same population will generally not yield responses when mitogens, antigens, or enterotoxins are used. In such a setting, accessory cells may also function as antigen-presenting cells (APC). Addition of irradiated or mitomycin C-treated syngeneic sources of accessory cells (either whole spleen cells or purified APC; see first support protocol) can be used to restore responsiveness in purified T cells. The need for accessory cells can sometimes be

bypassed when anti-TCR monoclonal antibodies are coupled to plastic, or when certain anti-Thy-1 monoclonal antibodies are used; however, these conditions do not necessarily result in optimal responsiveness (Jenkins et al., 1990).

The level of [3 H]thymidine incorporation should not be regarded only as a reflection of cellular proliferation: some nondividing cells will synthesize DNA and “cold” thymidine released by disintegrating cells will compete with incorporation of labeled thymidine. Therefore, measurements of DNA synthesis should be accompanied by counting viable cells over the length of the culture period if a true estimate of cellular proliferation is to be obtained. Of course, cell death of nonactivated cells will also interfere with the accuracy of this last parameter.

The sensitivity of proliferation assays is such that small errors in cell numbers will result in large differences in [3 H]thymidine incorporation values. When values obtained in triplicate cultures correspond poorly (e.g., >5% difference in cpm values >1000), technical problems such as cell clumping, dilution, and pipetting should be considered. Excessively high values may be obtained from contaminated wells, as [3 H]thymidine will be incorporated into replicating bacteria; therefore, it is good practice to check the wells from microtiter plates under an inverted microscope for contamination. Contamination may also interfere with proliferation of the activated lymphocytes.

It is also useful to check for blast formation by microscopic examination of the cultures: activated lymphocytes will tend to enlarge, and detection of blasts will give a general indication of successful activation.

The main problem that may occur with proliferative response assays is high levels of background [3 H]thymidine incorporation in control cultures without antigens. This problem is frequently due to the fetal calf serum (FCS) used to supplement the cultures, which may be mitogenic for B cells. Different lots of FCS should be screened to select those that are nonstimulatory or only weakly stimulatory in the absence of other stimuli, and that support strong proliferative responses upon antigenic stimulation of T cells.

If flat-bottom microtiter plates are used in the procedure and weak responses occur, it may be useful to switch to round-bottom plates. Our laboratory has found consistently better responses in round-bottom plates when

thymocytes are used as responder cells or with slight alloantigenic differences between responding and stimulating cells. In addition, antibody-mediated experiments yield better results with round-bottom plates. Presumably, this reflects better cell contact obtained in such plates; optimal responses will almost certainly occur at different cell numbers than in flat-bottom plates and densities will have to be adjusted accordingly.

Although satisfactory responses to most alloantigens can be obtained with complete RPMI-10 medium, it may be necessary to compare different media. This need arises when the proliferative responses are weak (i.e., when [^3H]thymidine values for activated cultures are <10-fold higher than those for control cultures) and may occur under various circumstances: weak alloantigenic differences between responder and stimulator cells, weak T cell proliferative function in the responder cells or diminished APC function in the stimulator cells due to experimental manipulations, or a low precursor frequency of responding T cells. Thymocytes in particular do not contain a high level of responding T cells. Frequently, proliferation can be improved when complete Clicks or Dulbeccos media are used (with additives as described in APPENDIX 2), presumably because these media contain additional nutrients and have an osmolality more compatible with mouse serum than RPMI.

When RPMI is used as medium, 5% CO_2 will be sufficient, but for other media, a 7.5% CO_2 concentration in the incubator will be more satisfactory. Generally, the buffering capacity of DMEM is insufficient at 5%, but fine at 7.5%. Much will also depend on the proliferative activity of the responding population of T cells (e.g., vigorous proliferation will reduce the pH in the cultures); it is therefore recommended to compare responsiveness in initial pilot experiments in incubators set at different CO_2 concentrations.

The culture period required for stimulation—after which the cells are to be labeled—varies for different laboratories, media, and types of responding and stimulator cells. Conditions eliciting weak responses, such as those obtained with thymocytes or a weak alloantigenic difference, will require a longer culture period (5 to 6 days) than those which elicit a higher frequency of responding T cells (3 to 4 days). Because laboratory conditions vary, it will be necessary to run a kinetic assay to determine the optimal time for T cell prolifer-

ation. Addition of [^3H] thymidine on days 2, 3, 4, 5, and 6 will provide a useful test; further extension of the culture period will not yield any improvements, due to exhaustion of nutrients in the medium.

Anticipated Results

For proliferative assays described in the basic protocol, which activate the majority of the responding T cells, responses of 100,000 cpm should be obtained; in the MLR or following activation with monoclonal antibodies to subpopulations of T cells (anti-V β), responses up to 100,000 cpm may be observed; however, measurements of 20,000 cpm (with tight standard errors) can be quite satisfactory. Background values of <1000 cpm should be expected. Reported results (as described in step 9a) should be mean cpm of experimental wells minus background cpm (Δ cpm).

Time Considerations

The time required to set up proliferative assays is not more than a day, with the number of hours depending on the number of different groups of responder cells that must be prepared. The time required for incubation of cells ranges from 2 to 6 days, as noted above in critical parameters. Following an additional 18- to 24-hr incubation period for pulsing, harvesting the cells and measuring cpm will require several hours depending on the number of plates (~15 min for harvesting each plate and ~100 min for counting each plate at 1 min/sample).

Literature Cited

- Ashwell, J.D., DeFranco, A.L., Paul, W.E., and Schwartz, R.H. 1984. Antigen presentation by resting B cells: Radiosensitivity of the antigen-presentation function and two distinct pathways of T cell activation *J. Exp. Med.* 159:861-869.
- Gunter, K.C., Malek, T.R., and Shevach, E.M. 1984. T cell activating properties of an anti-Thy-1 monoclonal antibody: Possible analogy to OKT3/Leu-4. *J. Exp. Med.* 159:716-730.
- Hathcock, K.S., Segal, D.M., and Hoder, R.J. 1989. Activation of $\text{Lyt}2^+$ ($\text{CD}8^+$) and $\text{Lyt}2^-$ ($\text{CD}4^+$) T cell subsets by anti-receptor antibody. *J. Immunol.* 142:2181-2186.
- Jenkins, M.K., Chen, C., Jung, G., Mueller, D.L., and Schwartz, R.H. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. *J. Immunol.* 144:16-22.
- Marrack, P. and Kappler, J. 1989. The staphylococcal enterotoxins and their relatives. *Science* 248:705-711.

Staerz, U.D. and Bevan, M.J. 1986. Activation of resting T lymphocytes by a monoclonal antibody directed against an allotypic determinant on the T cell receptor. *Eur. J. Immunol.* 16:263-268.

Key References

Corradin, G., Edlinger, H.M., and Chiller, M. 1977. Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell dependent proliferative response with lymph node cells from primed mice. *J. Immunol.* 119:1048-1055.

Rosenwasser, L.J. and Rosenthal, A.S. 1978. Adherent cell function in murine T lymphocyte antigen recognition. I. A macrophage-dependent T cell proliferation assay in the mouse. *J. Immunol.* 120:1991-1998.

Both of the above describe how specific proliferation of antigen-primed T cells can be measured.

Strong, D.M., Ahmed, A.A., Thurman, G.B., and Sell, K.W. 1973. In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester. *J. Immunol. Methods* 2:279-287.

Details the MLC proliferation assay.

Contributed by Ada M. Kruisbeek
Netherlands Cancer Institute
Amsterdam, The Netherlands

Ethan Shevach
National Institute of Allergy and
Infectious Diseases
Bethesda, Maryland

Dendritic cells are allowing scientists to overcome a longstanding obstacle to research in immunology by extending the playing field beyond antigens to immunogens and beyond models to pathogens that cause disease.

The Dendritic Cell Advantage: New Focus For Immune-Based Therapies

by Ralph M. Steinman

The focus of immune therapeutics has been on lymphocytes, the cellular mediators of immunity, and the suppression of lymphocyte function. The drug ciclosporin (cyclosporine) is an excellent and successful example. However, medicine needs therapies that enhance immunity or resistance to infections and tumors. Medicine also needs strategies, whether suppressive or enhancing, that are specific to the disease-causing stimulus or antigen. In contrast to lymphocytes, dendritic cells (DCs) provide a much earlier and antigen-specific means for manipulating the immune response. DCs capture antigens and then initiate and control the activities of lymphocytes, including the development of resistance to infections and tumors (reviewed in references 1-3).

Summary

Dendritic cells (DCs) provide a much earlier and antigen-specific means for manipulating the immune response. The best-studied function of DCs is to convert antigens into immunogens for T cells. The "DC advantage" entails a myriad of functions. DCs are more than antigen-presenting cells; they are accessories or adjuvants or catalysts for triggering and controlling immunity. Another special feature of DCs is their location and movement in the body; DCs are stationed at surfaces where antigens gain access to the body. The events that make up the life history of DCs are now being unraveled in molecular terms. As research on DCs expands, more potential functions and more sites for their manipulation are becoming apparent. © 2000 Prous Science. All rights reserved.

The controlling role of DCs is best known for thymus-dependent lymphocytes or T cells which are important in many diseases, the most poignant being the AIDS epidemic (Table 1). DCs were identified in a few laboratories that were focusing on the induction of immunity from resting T cells. It was noted that immune tissues (spleen, lymph nodes, lymph. blood) had a small fraction of cells with unusual

"tree-like" or "dendritic" processes. These distinctive cells had not been recognized previously and they proved to have distinct functions. Most importantly, DCs were potent inducers of immunity even in animals, not just the test tube, and now even in patients (reviewed in references 1-3).

The DC field was held back by the fact that there were so few cells relative

TABLE 1: HUMAN DISEASES THAT INVOLVE T CELLS

- Rejection of organ transplants and graft-vs.-host disease in bone marrow transplantation
- Resistance to many infections including vaccine design
- Vaccines against tumors and immune therapies for existing tumors
- Allergy
- AIDS
- Autoimmune diseases like insulin-dependent (juvenile) diabetes, multiple sclerosis, rheumatoid arthritis and psoriasis




Fig. 1. A key function of dendritic cells. Antigens within tumors, transplants and infectious agents need to be presented by DCs to become immunogens, i.e., to make T cells begin to grow and exhibit their helper and killer functions.

to other players in the immune system such as B cells, T cells and macrophages. In reality, DCs are quite abundant for the job they have to do, namely, to initiate immune responses from antigen-specific T cells. In immune system organs like lymph nodes, DCs form an extensive network throughout the T cell-rich regions and physically outnumber any given antigen-reactive T cell by at least 100 to 1. The DC field was also held back because many thought that the cells were no different from macrophages, thus keeping investigators from working on the active DCs. In reality, DCs were identified on the basis of profound differences from macrophages, and their many distinct properties and functions were only uncovered by separating DCs from macrophages.

The best-studied function of DCs is to convert antigens into immunogens for T cells. The antigen receptors on T cells do not focus on intact proteins in microbes and tumors, but instead recognize fragmented or processed proteins, that is, peptides. The processing of protein antigens into peptides occurs within cells, and then the peptides are

displayed or presented at the cell surface affixed to products of the major histocompatibility complex (MHC). The ensuing interaction between a T-cell receptor (TCR) and its specific MHC-peptide complex allows a T cell to detect peptides formed within cells in transplants, tumors, sites of infection and self tissues attacked during autoimmune disease (Table 1). "Antigens" refers to specific substances recognized by the immune system, while "immunogens" refers to antigens that effectively induce responses either by themselves or together with enhancing materials called "adjuvants." For T cells in particular, antigens and immunogens are not one and the same (Fig. 1). Even preprocessed peptides and MHC-peptide complexes are weak immunogens. This was evident early on in the work of Peter Medawar, the great scientist who discovered the immune basis of transplantation. He spent many years trying to purify functioning transplantation antigens. These efforts were to little avail.

What was not known in Medawar's time is that transplantation antigens

(later shown to be MHC-peptide complexes) become immunogenic when presented by DCs.⁴ In other words, transplantation antigens when presented on many cell types are weak immunogens, but on DCs they become powerful inducers of immunity.⁴ The same is true of peptides that become much more immunogenic when presented on DCs. DCs activate T cells by getting them to divide and express their helper and killer functions. Then the activated T cells interact with other antigen-presenting cells to eliminate the antigen in question. DCs are also called "nature's adjuvant," because prior adjuvants were artificial substances used to enhance immunity. The DC advantage entails a myriad of functions, some of which will be considered below.

Potency of dendritic cells in initiating immunity in tissue culture

What are some specific features of DCs that warrant attention? The first is their potency. Very small numbers of DCs are sufficient to trigger strong T-cell responses in test tubes. Immune assays are generally carried out with impure antigen-presenting cells, applied at a dose of one presenting cell for every T cell, the latter often preactivated. In contrast, roughly one DC per 30-100 T cells is more than sufficient to induce optimal responses, including responses by resting T cells. A single DC can simultaneously activate 10-20 T cells nestled within its sheet-like processes. Therefore, DCs are more than antigen-presenting cells; they are accessories or adjuvants or catalysts for triggering and controlling immunity.

It has always been clear that the accessory function of DCs did not depend exclusively on their capacity to process antigens to form MHC-peptide complexes. This is because the stimuli that were used to define the potency and immune-activating role of DCs did not require that the DCs process an applied antigen. Such stimuli included major transplantation antigens, mitogens, contact allergens, anti-

T-cell antibodies and superantigens. Furthermore, once resting T cells were activated by DCs, the T cells responded vigorously to antigens presented by other cell types, showing that the latter were not deficient in forming ligands for the antigen receptor on T cells, but instead lacked accessory properties.

The word "accessory" has since been replaced by the terms "professional" and "co-stimulatory," but the basic concept is unchanged by shifting terminology. T cells need stimuli other than their specific trigger or ligand (MHC-peptide complexes) to begin to grow and function, for example, to produce the interleukins and killer molecules mentioned above. DCs are potent in providing the needed accessory or co-stimulatory functions. For example, DCs produce an adhesion molecule called DC-SIGN that binds to a target on resting T cells called ICAM-3,⁵ and DCs express very high levels of a stimulatory molecule called CD86 that binds to CD28 on resting T cells.⁶ These are but two examples of the specialized activities of DCs. These cells do not operate as a single magic bullet.

Position of dendritic cells *in vivo*

Another special feature of DCs is their location and movement in the body. As criteria were developed to identify DCs, it became feasible to go back into the animal and patient to look for the corresponding cells in different tissues. DCs are stationed at surfaces where antigens gain access to the body (Fig. 2, left). The skin and the airway have been the best studied. DCs are found in afferent lymphatic vessels, special channels that allow cells to move from peripheral tissues to lymphoid organs, primarily the T-cell areas (Fig. 2, middle and right). This migration is most readily observed in models of skin transplantation and contact allergy, which are the two most powerful immune responses known.

DC migration is likely to be very important. The body's pool of T cells primarily traffics through the T-cell areas of lymph nodes, rather than




Fig. 2. Distribution of dendritic cells *in situ*. DCs at body surfaces and in solid organs can pick up antigens, move to the lymphoid tissues to find antigen-specific T cells and initiate immunity. Molecular mechanisms are being uncovered that govern the mobilization, maturation, migration and mortality of these DCs. In the lymph node, T lymphocytes are selected for expansion and differentiation into helper and killer T cells. The activated T cells then leave the lymph node to return to the body surface or peripheral organ to eliminate the antigen.

through tissues where antigens are usually deposited. So when DCs capture antigens in the skin, airway or another peripheral tissue, their migration to the T-cell areas gives them a chance to select the corresponding rare specific T cells from the assembled repertoire (Fig. 2). The selected T cells then increase in numbers (clonal expansion) and function, enabling the specific immune response to begin. The initial frequency of T cells that recognize an antigen is very small. Only one in 10,000–100,000 of T cells in the repertoire responds to a specific MHC-peptide complex. Therefore, it is so precise and efficient for DCs to be able to pick up an antigen in the periphery and then initiate the immune response from rare T-cell clones in lymphoid organs.

The events that make up the life history of DCs (Figs. 2 and 3) are now being unraveled in molecular terms. For example, scientists are figuring out how to expand antigen-capturing precursors to DCs using IL13 ligand and granulocyte colony-stimulating factor (G-CSF). Key players for the mobilization of DCs from the periphery to lymph nodes are the multidrug resistance receptors, usually studied for their capacity to mediate resistance to chemotherapeutic agents rather than

movement of DCs. Migration of DCs is controlled by chemokines produced in the lymphatic vessels and lymphoid organs (Fig. 2). These act on DC chemokine receptors to orchestrate their movement to the T-cell areas. Then within the lymphoid tissue, several members of the tumor necrosis factor (TNF) and TNF-receptor families, such as TRANCE and CD40 ligand, trigger DC production of cytokines like interleukin-12. The TNF family also maintains DC viability. Otherwise the cells die within a day or two. Each of these components of DC function provides targets for manipulating immunity.

Priming of T-cell immunity via dendritic cells

Animal studies

During the early research on DCs, several labs administered antigens to experimental animals and then tried to identify the cells that had captured the antigens in a form that was immunogenic. Regardless of the route of antigen administration (blood, muscle, skin, intestine and airway), DCs were the major reservoir of immunogen.




Fig. 3. The life history of dendritic cells. DCs arise from proliferating progenitors, primarily in the bone marrow, and this can be driven by cytokines like flt-3 ligand and G-CSF. Precursors are formed, such as the monocytes in blood, which then give rise to immature DCs. The immature DCs are capable of producing large amounts of antigen-presenting MHC products and capturing antigens. Multidrug resistance receptors are newly recognized players in the mobilization of immature DCs. DCs mature in response to various stimuli such as infection and inflammation, and migrate under the influence of chemokines to the lymphoid tissues. There the DCs die within a day unless their lifespan is prolonged by TNF-family molecules expressed by the activated T cells.

Next, DCs were used as nature's adjuvant to immunize animals. The DCs were taken from mice or rats, exposed to antigens *ex vivo* and injected back into immunologically naive recipients. The animals became immunized to the antigens that had been captured by the DCs, and the immunization took place in the lymph nodes draining the site of DC injection. Genetic proof was provided that the DCs were priming the animal directly and not simply handing off their antigen to other cells.^{7,8}

DC-based immunization is really very different from all prior attempts at cell therapy. Immunology has had extensive experience with "passive immunization," whereby a recipient is given large numbers of cells that are activated prior to injection. It is hard to produce such large numbers of cells, and their lifespan, diversity and efficacy are all finite. In contrast, when relatively small numbers of antigen-charged DCs are used to induce immunity, this produces "active immunization." Now the animals (and patients, see below) can make their own diverse and longer lasting immune response to the antigen-bearing DCs.

Human studies

The above experiments made it clear that DCs, pulsed *ex vivo* with antigens, actively immunized animals and raised the exciting possibility that scientists would be able to induce resis-




Fig. 4. The use of dendritic cells as adjuvants for enhancing immunity to tumors and infectious agents in humans. This new form of immune therapy begins with the isolation of DC precursors from the patient, usually from blood. The precursors develop *ex vivo* (in relatively simple tissue culture systems) into large numbers of more mature DCs. During this time, the DCs are charged with antigens from the tumor or infection. Then the DCs are reinfused to elicit immunity and thereby resistance to the disease.

tance to tumors, infections and transplants in patients. For example, could one expose patients' DCs *ex vivo* to antigens in their tumors and then reinfuse the antigen-bearing DCs to elicit tumor-specific immunity (Fig. 4)? This approach is actually not terribly complicated, but one first had to overcome a major obstacle and learn to generate large numbers of DCs. These techniques became available in the 1990s. They have energized the field and, accordingly, clinical trials for the immunization of humans against cancer have begun on most continents.

It is evident that DCs can serve as adjuvants for humans, converting antigens into immunogens.^{9,10} Even in advanced cancer, immune responses already have been observed that are similar to or better than immune responses obtained with other approaches. However, this approach is still in its preliminary stages, since a good deal of science remains to be developed. On the one hand, there are critical unknowns in terms of overall DC biology. Many of the clinical studies to date, for example, have overlooked key features that could improve DC function, such as the need for DCs

to be sufficiently mature (see below) to be effective *in vivo*. Also, DC biology has to be placed in the context of specific tumors and pathogens and patients for DC-based therapies to be optimized.

To summarize and further illustrate the role of DCs in the context of human disease (Table I), consider the need to harness T cells to resist tumors and chronic infections. Protein antigens often are known for a tumor-like melanoma, or for a virus like HIV-1 whose genetic sequence has been available for more than 15 years. However, this knowledge about antigens from melanoma and HIV-1 antigens remains to be converted into methods that provide better immunogens either for immune therapy of melanoma or for the design of HIV-1 vaccines. This is because some important facts of immunological life are being overlooked. When antigens are injected, they also need to gain access to the right DCs to become immunogens (Fig. 1).

Delivering antigens to dendritic cells

Broadly speaking, a central goal is to learn how to deliver or "target" antigens to DCs and simultaneously to differentiate or "mature" the cells to their most potent state. These two challenges, antigen targeting and DC maturation, prove to be intertwined.

Targeting means that the antigen should be in a form that the DCs can recognize. Without such recognition, the uptake and subsequent processing of antigen to form MHC-peptide complexes is suboptimal. DCs have a number of special mechanisms for capturing antigens and converting these into MHC-peptide complexes (Table II). For example, DCs have a receptor called DEC-205 whose binding partners or ligands are still unknown. Nonetheless, it is clear that DEC-205 greatly increases the capacity of DCs to form MHC-peptide complexes.¹¹ DCs also carry out a fascinating process called "cross-presentation." DCs can take up dying cells and effi-

TABLE II: DENDRITIC CELL SPECIALIZATION TO INCREASE MHC-PEPTIDE COMPLEX FORMATION

- Receptors for antigen uptake, e.g., DEC-205
- Processing of dying cells, nonreplicating microbes and immune complexes onto MHC class I ("cross-presentation")
- Regulation of antigen processing by maturation stimuli
- Clustering of T-cell receptor ligands with co-stimulators like CD86

ciently extract peptides from them, so antigens "cross" from the dying cell to the DC. The discoverers of this phenomenon called it "resurrecting the dead."¹² Cross-presentation allows DCs to efficiently form MHC-peptide complexes from dead cells in tumors, transplants and tissues under autoimmune attack.

Special uptake and processing mechanisms allow DCs to tailor a protein antigen, as well as the proteins in a complex microbe or tumor cell, into peptides that bind to an individual's MHC products. The latter are exceptionally polymorphic, differing genetically from one individual to another. As a result, the relevant immunizing peptides differ from one individual to another. One reason why peptides are not ideal immunogens is that they must be individualized. DCs, in contrast, can capture antigens with high efficiency and likewise extract peptides that are relevant for any individual.

A second DC advantage is that these cells have the many required accessory or co-stimulatory properties for converting the selected peptides ("antigens") into effective immunogens. A third DC advantage is that these cells position themselves in a way that leads to the identification of rare antigen-reactive T lymphocytes *in vivo* (Fig. 2). DCs thus overcome many of the difficult obstacles in initiating immunity.

In order for an antigen to be a strong immunogen, one needs to provide a stimulus for the final differentiation or maturation of the DCs (Fig. 3). Most DCs in the body are in an immature state and lack many features that lead to a strong T-cell response.

Immature DCs, for example, lack the CD86 and CD40 molecules that greatly boost the DC-T cell interaction. Immature DCs also lack a chemokine receptor called CCR7 that seems very important for proper migration and homing to lymph nodes to start immunity. For cancer immunology, it is unlikely that tumors provide maturation stimuli. Tumors may even block DC maturation induced by other stimuli. Therefore it is important to learn how to deliver tumor cells to DCs and bypass the normal obstacles to effective antitumor immunity.

Surprising recent evidence actually links DC maturation to the efficient formation of MHC-peptide complexes or TCR ligands (Table II). Immature DCs take up antigens, but they do not make abundant MHC-peptide complexes until they receive a maturation stimulus.^{13,14} Maturation also up-regulates CD86 co-stimulators, but the CD86 actually travels together with the TCR ligands to the surface of the DCs. At the DC surface, the MHC molecules and CD86 remain clustered with each other, keeping the machinery for T-cell activation juxtaposed. This phenomenon will help explain the potency of DCs, because TCR ligands and co-stimulators are displayed together on the cell surface and in high levels.

Control points beyond antigen targeting and maturation of DCs

Research on DCs is moving more vigorously, because the cells are more readily available and because their role in the immune system is considered essential. Nonetheless, researchers in this field are just beginning to find ways to manipulate DCs *in situ*. Putting together an antigen that targets

to DCs with a stimulus for DC maturation will be a major step in improving the conversion of antigens into immunogens, as in immune-based therapies against tumors and infectious agents.

Additional challenges and questions are evident:

- How can DC numbers be increased *in situ* and how can active DCs be mobilized to a cancer or site of chronic infection?
- Can DCs induce strong immune memory to make vaccination long lasting and effective (we have only been reviewing the role of DCs in the initiation of immunity)?
- Can DCs change the quality of the immune response? "Quality" refers to recent evidence for different types of DCs, especially a subset that induces Th1-type T cells for resistance to infectious agents and strong memory.
- Is it possible to move beyond DC-based immunization experiments and use DCs to either regulate or tolerize the immune system, as frequently required in transplantation and autoimmune diseases?
- Can DCs influence elements of the immune system other than T cells; for example, B cells and the innate defenses provided by natural killer (NK) and NK-T cells?

The answer to all these questions is a preliminary "yes." As research on DCs expands, more potential functions and more sites for their manipulation are becoming apparent.

Dendritic cells and better control of disease

DCs provide important avenues for the investigation of human disease. Many labs are exploiting DCs to identify antigens relevant for immunity against human pathogens. In these experiments, one introduces complex but clinically important antigens to DCs and then identifies which components are best presented to the immune system. We have recently used this approach to identify previously un-

known immune responses to the Epstein-Barr virus,¹⁵ a virus we all carry that has the potential to cause cancer like Hodgkin's lymphoma. Other laboratories have been using DCs to identify new antigens in other infectious agents, in transplants and in cancers like melanoma.

Investigators are also manipulating DCs *ex vivo* and then reinfusing the cells to identify conditions leading to strong immunity in patients (Fig. 4). In particular, DC-mediated active immunization against cancer is being vigorously pursued, as mentioned above. Instead of manipulating DCs *ex vivo*, a more desirable goal would be able to alter DCs directly *in situ*. Some approaches are under way. An example is the injection of cytokines like flt3 ligand and G-CSF to mobilize various precursor populations of DCs. One should also develop methods to control DC mobilization, migration and maturation. In sum, DCs are allowing scientists to overcome a longstanding obstacle to research in immunology by extending the playing field beyond antigens to immunogens and beyond models to pathogens that cause disease.

References

1. Hart, D.N.J. Dendritic cells: Unique leukocyte populations which control the primary immune response. *Blood* 1997, 90: 3245-87.
2. Banchereau, J. and Steinman, R.M. Dendritic cells and the control of immunity. *Nature* 1998, 392: 245-52.
3. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B. and Palucka, K. Immunobiology of dendritic cells. *Annu Rev Immunol* 2000, 18: 767-811.
4. Steinman, R.M. and Witmer, M.D. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. *Proc Natl Acad Sci USA* 1978, 75: 5132-6.
5. Geijtenbeek, T.B.H., Torensma, R., van Vliet, S.J., van Duijnhoven, G.C.F., Adema, G.J., van Kooyk, Y. and Figdor, C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. *Cell* 2000, 100: 575-85.
6. Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K.S., Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P.S., Ikchura, S., Muramatsu, S., Hodes, R.J. and Steinman, R.M. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells *in situ* and during maturation *in vitro*. *J Exp Med* 1994, 180: 1849-60.
7. Inaba, K., Metlay, J.P., Crowley, M.T. and Steinman, R.M. Dendritic cells pulsed with protein antigens *in vitro* can prime antigen-specific, MHC-restricted T cells *in situ*. *J Exp Med* 1990, 172: 631-40.
8. Liu, T.M. and MacPherson, G.G. Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and can prime naive T cells *in vivo*. *J Exp Med* 1993, 177: 1299-307.
9. Dhodapkar, M., Steinman, R.M., Sapp, M., Desai, H., Foxsella, C., Krasovsky, J., Donahoe, S.M., Dunbar, P.R., Cerundolo, V., Nixon, D.F. and Bhardwaj, N. Rapid generation of broad T-cell immunity in humans after single injection of mature dendritic cells. *J Clin Invest* 1999, 104: 173-80.
10. Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Brückner, F.B., Steinman, R.M., Fink, A., Kämpgen, F. and Schuler, G. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 1999, 190: 1669-78.
11. Mahnke, K., Guo, M., Lee, S., Sepulveda, H., Swain, S., Nussenzweig, M. and Steinman, R.M. The dendritic cell receptor for endotoxin, DEC-205, can recycle and enhance antigen presentation in major histocompatibility complex class II-positive lysosomal compartments. *J Cell Biol* 2000, 151: 673-84.
12. Albert, M.L. and Bhardwaj, N. Resurrecting the dead: DCs cross-present antigen derived from apoptotic cells on MHC I. *Immunologist* 1998, 6: 194-8.
13. Inaba, K., Turley, S., Iyoda, T., Yamakita, F., Shimoyama, S., Reis e Sousa, C., Gorman, R.N., Mellman, I. and Steinman, R.M. The formation of immunogenic MHC class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. *J Exp Med* 2000, 191: 927-36.
14. Turley, S.J., Inaba, K., Garrett, W.S., Ebersold, M., Untermaier, J., Steinman, R.M. and Mellman, I. Transport of peptide-MHC class II complexes in developing dendritic cells. *Science* 2000, 288: 522-7.
15. Munz, C., Bickham, K.L., Subklewe, M., Tsang, M.J., Chahroudi, A., Kurilla, M.G., Zhang, D., O'Donnell, M. and Steinman, R.M. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. *J Exp Med* 2000, 191: 1649-60.

Ralph M. Steinman, M.D., is Henry G. Kunkel Professor and Senior Physician, Laboratory of Cellular Physiology and Immunology, The Rockefeller University, 1230 York Ave., New York, New York 10021-6399, U.S.A.

Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor

(heterodimeric lymphokine/T-cell growth factor/lymphokine-activated killer cells/coordinate gene regulation/interleukin-12)

UELI GUBLER*†, ANNE O. CHUA*, DAVID S. SCHOENHAUT*, CYNTHIA M. DWYER†, WARREN MCCOMAS*, RICHARD MOTYKA*, NASRIN NABAVI§, AIMEE G. WOLITZKY§, PHYLLIS M. QUINN§, PHILIP C. FAMILLETTI‡, AND MAURICE K. GATELY§

Departments of *Molecular Genetics, †Bioprocess Development, and ‡Immunopharmacology, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ 07110

Communicated by John J. Burns, February 4, 1991

ABSTRACT Cytotoxic lymphocyte maturation factor (CLMF) is a disulfide-bonded heterodimeric lymphokine that (i) acts as a growth factor for activated T cells independent of interleukin 2 and (ii) synergizes with suboptimal concentrations of interleukin 2 to induce lymphokine-activated killer cells. We now report the cloning and expression of both human CLMF subunit cDNAs from a lymphoblastoid B-cell line, NC-37. The two subunits represent two distinct and unrelated gene products whose mRNAs are coordinately induced upon activation of NC-37 cells. Coexpression of the two subunit cDNAs in COS cells is necessary for the secretion of biologically active CLMF; COS cells transfected with either subunit cDNA alone do not secrete bioactive CLMF. Recombinant CLMF expressed in mammalian cells displays biologic activities essentially identical to natural CLMF, and its activities can be neutralized by monoclonal antibodies prepared against natural CLMF. Since this heterodimeric protein displays the properties of an interleukin, we propose that CLMF be given the designation interleukin 12.

The molecular cloning and expression of recombinant cytokines has made possible both significant advances in our understanding of the molecular basis of immune responses and the development of new approaches to the treatment of disease states. As an example, recombinant interleukin 2 (recombinant IL-2) has been shown to be capable of causing regression of established tumors in both experimental animals (1) and in man (2); however, its clinical use has been associated with significant toxicity (2). One potential approach to improving the therapeutic utility of recombinant cytokines is to use them in combination (3, 4). With this concept in mind, we initiated a search for novel cytokines that would synergize with suboptimal concentrations of recombinant IL-2 to activate cytotoxic lymphocytes *in vitro* and thus might have synergistic immunoenhancing effects when administered together with recombinant IL-2 *in vivo*. This led to the identification of a factor, designated cytotoxic lymphocyte maturation factor (CLMF), that synergized with recombinant IL-2 to facilitate the generation of both cytolytic T lymphocytes (CTLs) and lymphokine-activated killer (LAK) cells *in vitro* (5, 6). CLMF was subsequently purified to homogeneity from a human lymphoblastoid B-cell line (NC-37) and was shown to be a 75-kDa disulfide-bonded heterodimer composed of two subunits with molecular masses of 40 kDa and 35 kDa (7).[†] We now report the molecular cloning and expression of CLMF.

MATERIALS AND METHODS

cDNA Cloning. A subline of NC-37 cells selected for its ability to produce high levels of CLMF (7), NC-37.98, was induced with phorbol 12-myristate 13-acetate (PMA) and calcium ionophore A23187 for 16 hr. Poly(A)⁺ RNA was isolated, and random hexamer-primed cDNA libraries were established in phage λ gt10 by standard procedures. Mixed-primer polymerase chain reaction (PCR) using controlled ramp times (8) was performed as follows. PCR primers contained all possible codons and were 14 or 15 nucleotides long (Fig. 1) with a 5' extension of 9 nucleotides containing an *Eco*RI site for subcloning. Degeneracies varied from 1 in 32 to 1 in 4096; 0.5–4 pmol per permutation of forward and reverse primer was used in a 50- to 100- μ l PCR mixture with 40 ng of cDNA made from NC-37.98 cells that had been activated by culture with 10 ng of PMA and 25 ng of calcium ionophore A23187 per ml for 16 hr (40-kDa subunit) or with 3 μ g of human genomic DNA (35-kDa subunit). PCR cycling parameters were as follows. Initial denaturation was at 95°C for 7 min. Low-stringency annealing was performed by cooling to 37°C over 2 min, incubating 2 min at 37°C, heating to 72°C over 2.5 min, extending at 72°C for 1.5 min, heating to 95°C over 1 min, and denaturing at 95°C for 1 min. This cycle was repeated once. Thirty standard cycles (40-kDa subunit) or 40 standard cycles (35-kDa subunit) were performed as follows: 95°C for 1 min, 55°C for 2 min, and 72°C for 2 min. Final extension was at 72°C for 10 min. "Amplicons" of the expected size were gel-purified, subcloned, and sequenced. The 40-kDa subunit cDNAs were isolated by hybridizing the 54-mer amplicon in 5 \times SSC (1 \times SSC = 0.15 M NaCl/0.015 M sodium citrate, pH 7) containing 20% formamide at 37°C overnight. Filters were washed in 2 \times SSC at 42°C for 30 min and exposed to x-ray film. The 35-kDa subunit cDNAs were isolated by hybridizing the 51-mer amplicon in 5 \times SSC/20% formamide at 37°C overnight. The filters were washed in 2 \times SSC at 40°C for 30 min and exposed to x-ray film. Positive clones were plaque-purified, their inserts were subcloned into the pBluescript plasmid, and their sequences were determined by using Sequenase.

Expression. cDNAs were separately engineered for expression in vectors containing the simian virus 40 early promoter essentially as described (9). COS cells were transfected with both CLMF subunit expression plasmids mixed together or

Abbreviations: CLMF, cytotoxic lymphocyte maturation factor; rCLMF and nCLMF, recombinant and natural CLMFs; CTL, cytolytic T lymphocyte; IL, interleukin; LAK, lymphokine-activated killer; PHA, phytohemagglutinin; PMA, phorbol 12-myristate 13-acetate; n, natural; PCR, polymerase chain reaction.

[†]To whom reprint requests should be addressed.

[‡]The cDNA sequences reported in this paper have been deposited in the Genbank data base [accession nos. M38443 (35-kDa CLMF subunit) and M38444 (40-kDa CLMF subunit)].

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

```

1  MCFPARSLLLV ATLVLDDHLS LARNLPVATP DPGMFPC^LHH SQNLLRAVSN
51  MIQKARQTLF FYPCTSEEID HEDITKDKTS TVEAC^LPLEL TKNESCLNSR
101 ETSFITNGSC LASRKTSFMM ALCLSSIIYD LKMYQVEFKT MNAKLLMDPK
151 RQIFLDQNM L AVIDELMQAL NFNSETVPQK SSLEEDFYK TKIKLC^ILLH
201 AFRIRAVTID RVTSYLNAS

1  MCHQQLVISW FSLVFLASPL VAIWELKKDV YVVELDWYPD APGEMVVLTC
51  DTPEEDGITW TLDQSSEVLG SGKTLTIQVK EFGDAGQYTC HKGGEVLSHS
101 LLLHKKEDG IWSTDILKQD KEPKNKTFLR CEAKNYSGRF TCW^LTTIST
151 DLTF^SVKSSR GSSDPQGVTC GAATLSAERV RGDNKEYEYS VECQEDSACP
201 AAESLPIEV MVD^AVHKLKY ENYTSSFFIR DIKPDPPKN LQLKPLKNSR
251 QVEVSWEYPD TWSTPHSYFS LTFCVQVQ^GK SKREKKDRVF TDKTSATVIC
301 RKNASISVRA QDRYYSSWS EWASVPC^S

```

FIG. 1. Amino acid sequences of the 35-kDa (Upper) and 40-kDa (Lower) CLMF subunits as deduced from the respective cDNAs and shown in single-letter code. Signal peptides are overlined, cysteine residues are marked by a caret, and N-linked glycosylation sites (NXS, NXT, where X is another amino acid) are underlined. The peptide sequences used to generate PCR probes are overlined with arrows indicating the direction of amplification.

with each one separately by the DEAE-dextran method. Twenty-four hours after transfection, the serum-containing medium was replaced with medium containing 1% Nutridoma-SP (Boehringer Mannheim), and supernatant fluids were collected from the cultures after 40 hr. These fluids were stored at 4°C until tested in the bioassays.

General Methods. Standard molecular biological procedures were used as described (10). CLMF bioassays were performed as detailed (7).

Computer Searches. The National Biomedical Research Foundation protein data base (Release 26.0) as well as the Genbank and European Molecular Biology Laboratory databases (Releases 65.0 and 24.0, respectively) were searched for sequences homologous to CLMF cDNAs. The two subunit sequences were compared to each other using the ALIGN program (mutation data matrix, break penalty of 6; see ref. 11).

RESULTS

Partial N-terminal amino acid sequences of the two CLMF subunits (7) were used to generate completely defined 51- to 54-base-pair (bp)-long oligonucleotide probes by means of mixed primer PCR. These probes were used to screen cDNA libraries made from RNA from activated NC-37.98 cells, and cDNAs encoding the two subunits were isolated and characterized. Both cDNAs encode secreted proteins with a classical hydrophobic N-terminal signal peptide immediately followed by the N terminus of the mature protein as determined by protein sequencing (7). Two independent cDNA clones for the 40-kDa subunit were shown to be identical. Both encode the mature 40-kDa subunit that is composed of 306 amino acids (calculated $M_r = 34,699$) and contains 10 cysteine residues and four potential N-linked glycosylation sites (Fig. 1). Two of these sites are within isolated tryptic peptides derived from the purified 40-kDa CLMF subunit protein. Amino acid sequence analysis has shown that Asn-

222 is glycosylated, whereas Asn-125 is not (Fig. 1; F. Podlaski, personal communication). The mature 35-kDa subunit is composed of 197 amino acids (calculated $M_r = 22,513$), with 7 cysteine residues and three potential N-linked glycosylation sites (Fig. 1). When purified CLMF is reduced with 2-mercaptoethanol and analyzed by SDS/PAGE, the 35-kDa subunit appears to be heterogeneous, suggesting that it may be heavily glycosylated (7). Two variants of 35-kDa subunit-encoding cDNAs were isolated. The first type had the sequence shown in Fig. 1. Additional isolates contained what is probably an allelic variation, replacing Thr-213 with a methionine residue.

Computer searches of sequence databases showed that the amino acid sequences of the two subunits are not related to any known protein. The subunit sequences are also not related to each other, since a comparison using the ALIGN program (11) gave a score of 1.27; only scores >3 are considered to indicate significant evolutionary relationship (12). The genes encoding the subunits appear to be unique, since low- and high-stringency hybridizations of genomic blots revealed identical banding patterns (data not shown). RNA blots showed the size of the 40-kDa subunit mRNA to be 2.4 kb, whereas the 35-kDa subunit was encoded by a 1.4-kb transcript (Fig. 2). Expression of the two mRNAs encoding the subunits was coordinately regulated upon induction (Fig. 2). When NC-37.98 cells were activated with PMA and calcium ionophore for 72 hr, mRNA encoding each of the CLMF subunits was minimally detectable at 6 hr after the beginning of induction but was readily detected at 24 hr and continued to accumulate until maximal levels were reached at 72 hr (normalized to GAPDH mRNA levels; see the legend to Fig. 2). In contrast, the mRNA for IL-2 in activated NC-37.98 cells was already at high levels at 6 hr and subsequently decreased, whereas the mRNAs for the low-affinity IL-2 receptor (p55) followed the induction pattern seen for the CLMF subunits. Scanning of RNA blots also revealed that steady-state mRNA levels for the 40-kDa




FIG. 2. RNA blots showing the coordinate induction of the 35-kDa (A) and 40-kDa (B) CLMF subunit mRNAs and IL-2 mRNA (C) and its p55 receptor mRNA (D). Poly(A)⁺ RNA (5 μ g) from NC-37.98 cells activated with 10 ng of PMA and 25 ng of calcium ionophore A23187 per ml were loaded in each lane. Lanes from left to right in each panel show RNAs isolated 6, 24, 30, 48, and 72 hr after induction, respectively. (Upper) Four-day exposures. (Lower) Two-hour exposure of the same blots after stripping and rehybridization with a GAPDH probe. Marker sizes are in kb (BRL RNA ladder).

CLMF subunit were severalfold higher than those for the 35-kDa subunit expressed by the same cells. This finding parallels the observation that activated NC-37 cells secrete excess free 40-kDa subunit protein (7). The 3' untranslated sequences of both CLMF subunit mRNAs contain several copies of the octamer motif TTATTTAT (data not shown). This sequence is present in other transiently expressed mRNAs and is involved in regulating mRNA stability (13).

Coexpression of the 40-kDa and 35-kDa CLMF subunit cDNAs in COS cells was required to generate secreted biologically active CLMF (Table 1 and Fig. 3). COS cells transfected with cDNA encoding either the 40-kDa subunit alone or the 35-kDa subunit alone did not secrete biologically active CLMF (Table 1). Mixing media conditioned by COS

cells that had been separately transfected with one or the other of the two CLMF subunit cDNAs also did not give rise to bioactive CLMF (Table 1).

Two types of assays were used to compare rCLMF and nCLMF. The first assay measures the proliferation of phytohemagglutinin (PHA)-activated human peripheral blood lymphocytes, whereas the second assay evaluates the synergy between CLMF and suboptimal concentrations of IL-2 in the generation of LAK cells in hydrocortisone-containing cultures (7). The data in Fig. 3 show that rCLMF as expressed in COS cells and nCLMF as purified from NC-37 cells are essentially identical. Dose-response curves for rCLMF and nCLMF were superimposable in each of the two assays, and rCLMF was neutralized by a monoclonal antibody raised against nCLMF. Conditioned media from cultures of mock-transfected COS cells displayed no activity in these assays (Table 1 and data not shown).

DISCUSSION

In a previous report (7), we described the purification of a heterodimeric cytokine, CLMF, that synergized with low amounts of IL-2 to cause the generation of LAK cells in the presence of hydrocortisone and stimulated the proliferation of activated T cells independent of IL-2. In the present report, we have used the N-terminal amino acid sequence information previously obtained to clone the two subunit cDNAs of CLMF. Protein purification of NC-37 cell line-derived CLMF had shown that the protein was composed of two disulfide-bonded subunits with different N-terminal amino acid sequences (7). However, it was not clear from our previous results whether the two subunits were processed from one common gene product and whether proteolytic posttranslational processing other than signal peptide cleavage was occurring. The molecular cloning and sequencing of

Table 1. Coexpression of both CLMF subunit cDNAs is required for secretion of biologically active CLMF by COS cells

Addition	Conc., units/ml	Dilution	³ HThymidine incorporated by PHA-activated lymphoblasts, mean cpm \pm 1 SEM
Cytokine*	—		11,744 \pm 514
None	200		68,848 \pm 878
nCLMF	40		48,827 \pm 605
nCLMF	8		26,828 \pm 594
nCLMF	1.6		17,941 \pm 196
Culture fluid from COS cells transfected with			
A. 35-kDa CLMF subunit cDNA		1:20	11,912 \pm 660
		1:100	10,876 \pm 232
B. 40-kDa CLMF subunit cDNA		1:20	11,699 \pm 931
		1:100	11,666 \pm 469
C. 35-kDa + 40-kDa CLMF subunit cDNAs		1:20	58,615 \pm 587
		1:100	38,361 \pm 828
1:1 mix of culture fluids A and B		1:10 [†]	11,544 \pm 483
		1:50	10,503 \pm 259
CM from mock-transfected control [‡]		1:20	11,503 \pm 286
		1:100	10,751 \pm 303

PHA-activated lymphoblasts were prepared from human peripheral blood mononuclear cells as described (7). Lymphoblast proliferation was measured in a 48-hr assay (7) in which 2×10^4 lymphoblasts were incubated in 100- μ l cultures containing the indicated amounts of natural CLMF (nCLMF) or COS cell culture fluids. ³HThymidine was added to each culture 18 hr prior to harvest. Conc., concentration.

*nCLMF is purified NC-37-derived CLMF.

[†]1:10 dilution of the 1:1 mixture of culture fluids A and B was equivalent to a 1:20 final dilution of each of the individual culture fluids.

[‡]Conditioned medium (CM) from cultures of mock transfected COS cells.




FIG. 3. Comparison of biologic activities of nCLMF (circles) and recombinant CLMF (rCLMF, squares). nCLMF was purified from NC-37 cell-conditioned media; rCLMF was purified from conditioned media from cultures of COS cells transfected with cDNAs encoding the 40-kDa and 35-kDa human CLMF subunits. (Upper) T-cell growth factor assay. The ability of CLMF to stimulate the proliferation of human PHA-activated lymphoblasts in 48-hr cultures was assayed as described (7). CLMF preparations were mixed with neutralizing rat monoclonal anti-human CLMF antibody 4A1 (ref. 7; open symbols) or with normal rat IgG (Sigma; rlg, closed symbols) at a final concentration of 20 μ g/ml and were incubated for 30 min at 37°C prior to addition of PHA blasts. All values are means of triplicate determinations. (Lower) LAK cell induction assay. The ability of CLMF, alone or in combination with recombinant IL-2, to induce the generation of LAK cells in 4-day cultures was assessed as described (7). Low-density peripheral blood lymphocytes were incubated in the presence of various amounts of nCLMF or rCLMF with (closed symbols) or without (open symbols) recombinant IL-2 at 7.5 units/ml. Units of CLMF activity were based on previous titrations in the T-cell growth factor assay. Hydrocortisone sodium succinate (Sigma) was included at a concentration of 0.1 mM to minimize triggering of endogenous cytokine cascades. Lysis of ⁵¹Cr-labeled Daudi cells was assessed at an effector/target ratio of 5:1. The data shown represent the means of quadruplicate determinations. The spontaneous ⁵¹Cr release was 20%.

the corresponding cDNAs now has demonstrated that there is no common precursor for the two CLMF subunits; rather, they are encoded by completely different genes. The predicted and actual amino acid composition for the two subunits are strikingly similar; differences in predicted versus actual molecular weights are accounted for by glycosylation (F. Podlaski, personal communication). Thus, the only major posttranslational proteolytic event that appears to take place in the maturation of the CLMF subunits is signal peptide cleavage.

The kinetics of expression of the individual CLMF subunit mRNAs were examined and compared to the expression of mRNAs for IL-2 and the IL-2 receptor p55. Previously it had been observed that NC-37 cells, like certain murine (14) and marmoset (15) B-cell lines, secreted IL-2 when activated (M.K.G., unpublished results). RNA blots demonstrated that upon activation of NC-37 cells, both CLMF subunit mRNAs were coordinately induced with kinetics similar to the IL-2 receptor (p55) mRNAs. On the other hand, IL-2 mRNA levels peaked much earlier. Similar differences in induction kinetics were also seen at the level of IL-2 and CLMF bioactivity secreted from NC-37 cells (M.K.G., unpublished data). These kinetic differences are consistent with our previous observation that in a cytolytic lymphocyte response, IL-2 appears to act earlier than CLMF (5).

Transfection studies with COS cells established that only coexpression of both subunit cDNAs gives rise to secreted bioactive CLMF. Thus, it appears that the two proteins have to interact within the endoplasmic reticulum to assemble properly into bioactive secreted CLMF. By comparing the activity of rCLMF to that of nCLMF in the T-cell growth factor and LAK cell induction assays (Fig. 3) and assuming that the specific activity of rCLMF is similar to that of nCLMF [8×10^7 units/mg (7)], we estimate that the amount of rCLMF heterodimer produced in these experiments was 5–50 ng/ml. The finding that COS cells, which are fibroblast-like cells, are able to assemble correctly the two CLMF subunits to form bioactive CLMF indicates that this secretion and processing pattern is not limited to cells of the lymphoid lineage.

Western blot analysis using an anti-CLMF antibody specific for the 40-kDa subunit has allowed confirmation that (i) COS cells transfected with both CLMF subunit cDNAs secrete CLMF with the expected heterodimeric structure and (ii) COS cells transfected with the 40-kDa subunit cDNA alone secrete that subunit (F. Podlaski, personal communication). Since no bioactivity was detected in media conditioned by COS cells transfected with only the 40-kDa subunit, that subunit by itself appears either to have a much reduced specific activity compared with heterodimeric CLMF or to be completely inactive.

Because of the lack of a high-affinity antibody specific for the 35-kDa subunit, we have not yet been able to determine definitively whether COS cells transfected with only the 35-kDa subunit cDNA secrete that subunit. Since no bioactivity was detected in the media, secretion of a bioactive 35-kDa subunit by itself could be very inefficient; alternatively, similar to the 40-kDa subunit, the protein could be much less active or inactive altogether. Intracellular 35-kDa protein in the absence of the other subunit could be inherently unstable; there is precedence for this phenomenon, since it has been reported that 90% of the β chains of lutropin (LH), when expressed in the absence of α chains, are retained in the endoplasmic reticulum and are slowly degraded (16). Simple mixing of media conditioned by COS cells transfected separately with either one of the two CLMF subunit cDNAs did not yield bioactive CLMF. One possible explanation would be that the cells do not secrete the 35-kDa CLMF subunit by itself. More likely, our experimental conditions did not allow proper heterodimer formation. One would expect that only

carefully controlled renaturation and oxidation conditions would allow the disulfide bond formation required for generation of bioactive CLMF.

Normal human peripheral blood lymphocytes under the appropriate induction conditions produce both CLMF subunit mRNAs and secrete the active protein (N.N. and M.K.G., unpublished data). There is some evidence suggesting that CLMF is produced predominantly by B cells. In preliminary experiments, B-cell mitogens have appeared to be more effective than T-cell mitogens in eliciting CLMF production from peripheral blood lymphocytes (M.K.G., unpublished results). When screening human cell lines for their ability to produce CLMF activity (7), we observed that four of eight B-cell lines tested produced CLMF after activation with PMA and calcium ionophore, whereas none of five T-cell lines produced CLMF. Nevertheless, three of these T-cell lines secreted large amounts of IL-2 and tumor necrosis factor activity after activation (M.K.G., unpublished results). Likewise, natural killer cell stimulatory factor (NKSF), a heterodimeric cytokine similar or identical to CLMF, was isolated from RPMI 8866 lymphoblastoid B cells (17). A recent report (18) has indicated that B lymphocytes can secrete a cytokine(s) distinct from IL-2 that facilitates virus-specific cytolytic T-lymphocyte responses. It is possible that CLMF may have been the cytokine active in those studies. Thus, although B lymphocytes have not traditionally been viewed as cytokine-producing helper cells, it is conceivable that CLMF production constitutes a novel mechanism whereby B lymphocytes contribute to the amplification of T-lymphocyte responses. In addition to the biologic activities described in this report, CLMF by itself has been shown (i) to activate NK cells in an 18–22 hr assay, (ii) to facilitate the generation of specific allogeneic CTL responses, and (iii) to stimulate the secretion of γ interferon by resting peripheral blood lymphocytes (M.K.G., unpublished results). It can also synergize with low concentrations of recombinant IL-2 in the latter two assays and in causing the proliferation of resting peripheral blood lymphocytes. In view of its production by peripheral blood lymphocytes and its diverse actions on lymphoid cells, it appears that CLMF constitutes a new interleukin. We propose that CLMF be

given the provisional designation IL-12. The availability of recombinant CLMF will now make possible a broader and more detailed characterization of its biology.

1. Rosenberg, S. A., Mule, J. J., Speiss, P. J., Reichert, C. M. & Schwartz, S. L. (1985) *J. Exp. Med.* 161, 1169–1188.
2. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C. & Reichert, C. M. (1985) *N. Engl. J. Med.* 313, 1485–1492.
3. Iigo, M., Sakurai, S., Tamura, T., Saijo, N. & Hoshi, A. (1988) *Cancer Res.* 48, 260–264.
4. Winkchake, J. L., Stampf, S. & Zimmerman, R. J. (1987) *Cancer Res.* 47, 3948–3953.
5. Gately, M. K., Wilson, D. E. & Wong, H. L. (1986) *J. Immunol.* 136, 1274–1282.
6. Wong, H. L., Wilson, D. E., Jenson, J. C., Familletti, P. C., Stremlo, D. L. & Gately, M. K. (1988) *Cell Immunol.* 111, 39–54.
7. Stern, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y.-C. E., Quinn, P. M., Wolitzky, A. G., Familletti, P. C., Stremlo, D. L., Truitt, T., Chizzonite, R. & Gately, M. K. (1990) *Proc. Natl. Acad. Sci. USA* 87, 6808–6812.
8. Compton, T. (1990) in *PCR Protocols*, eds. Innis, M. A., Gelfand, D. H., Sninsky, J. J. & White, T. J. (Academic, New York), pp. 39–45.
9. Cullen, B. (1987) *Methods Enzymol.* 152, 684–703.
10. Maniatis, T., Fritsch, E. F. & Sambrook, J. (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
11. Dayhoff, M. O., Barker, W. C. & Hunt, L. T. (1983) *Methods Enzymol.* 91, 524–543.
12. Williams, A. F. (1987) *Immunol. Today* 8, 298–303.
13. Shaw, G. & Kamen, R. (1986) *Cell* 46, 659–667.
14. Taira, S., Matsui, M., Hayakawa, K., Yokoyama, T. & Naruchi, H. (1987) *J. Immunol.* 139, 2957–2964.
15. Brent, L. H., Miyawaki, T., Everson, M. P. & Butler, J. L. (1990) *Eur. J. Immunol.* 20, 1125–1129.
16. Corless, C. L., Matzuk, M. M., Ramabhadran, T. P., Krichevsky, A. & Boime, I. (1987) *J. Cell Biol.* 104, 1173–1181.
17. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B. & Trinchieri, G. (1989) *J. Exp. Med.* 170, 827–845.
18. Liu, Y. & Mullbacher, A. (1989) *Proc. Natl. Acad. Sci. USA* 86, 4629–4633.

Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma

By Amy C. Peterson, Helena Harlin, and Thomas F. Gajewski

Purpose: Preclinical studies showed that immunization with peripheral blood mononuclear cells (PBMC) loaded with tumor antigen peptides plus interleukin-12 (IL-12) induced CD8⁺ T-cell responses and tumor rejection. We recently determined that recombinant human (rh) IL-12 at 30 to 100 ng/kg is effective as a vaccine adjuvant in patients. A phase II study of immunization with Melan-A peptide-pulsed PBMC + rhIL-12 was conducted in 20 patients with advanced melanoma.

Patients and Methods: Patients were HLA-A2-positive and had documented Melan-A expression. Immunization was performed every 3 weeks with clinical re-evaluation every three cycles. Immune responses were measured by ELISpot assay before and after treatment and through the first three cycles, and were correlated with clinical outcome.

Results: Most patients had received prior therapy and had visceral metastases. Nonetheless, two patients achieved a

complete response, five patients achieved a minor or mixed response, and four patients had stable disease. The median survival was 12.25 months for all patients and was not yet reached for those with a normal lactate dehydrogenase. There were no grade 3 or 4 toxicities. Measurement of specific CD8⁺ T-cell responses by direct ex vivo ELISpot revealed a significant increase in interferon gamma-producing T cells against Melan-A ($P = .015$) after vaccination, but not against an Epstein-Barr virus control peptide ($P = .86$). There was a correlation between the magnitude of the increase in Melan-A-specific cells and clinical response ($P = .046$).

Conclusion: This immunization approach may be more straightforward than dendritic cell strategies and seems to have clinical activity that can be correlated to a biologic end point.

J Clin Oncol 21:2342-2348. © 2003 by American Society of Clinical Oncology.

MOST MELANOMA tumors express antigens that can be recognized by CD8⁺ T cells.^{1,2} Nonetheless, tumors frequently escape immune destruction, either from a failure to generate an optimal tumor antigen-specific T-cell response or from development of resistance to the T-cell response induced. One strategy to overcome the former hurdle is through active immunization, the opportunity for which has been facilitated by the molecular definition of melanoma antigens.³ Specific CD8⁺ T cells that are properly activated can home to tumor sites and kill tumor cells, to the extent to which they can overcome negative immunoregulatory pathways and tumor resistance.⁴

The optimal immunization strategy for inducing tumor antigen-specific CD8⁺ effector T cells in humans remains undefined. However, antigen-presenting cell-based strategies have shown promise. Both monocyte-derived^{5,6} and bone marrow-derived⁷ dendritic cells (DCs) have been loaded with

melanoma tumor antigens and administered in the advanced-disease setting, with evidence for immunization and tumor regression in subsets of patients. However, DCs are cumbersome to generate and alternative approaches that are more straightforward yet equally as effective would be useful. One cofactor produced by DCs that contributes to their efficacy is interleukin-12 (IL-12), which facilitates the induction of interferon gamma (IFN- γ)-producing cytolytic effector cells.⁸⁻¹⁰ Endogenous IL-12 seems necessary for optimal rejection of immunogenic murine tumors^{11,12} and provision of exogenous IL-12, either alone¹³ or combined with tumor antigen-based vaccines,¹⁴⁻¹⁹ can induce rejection of pre-established tumors in murine models. We previously have shown that coadministration of IL-12 with peripheral blood mononuclear cells (PBMCs) loaded with tumor antigen peptides induced specific cytolytic T-lymphocyte responses and tumor protection in mice, circumventing the need to generate dendritic cells.²⁰ The ease by which PBMC can be isolated from patients has made this an attractive approach for clinical translation. We recently conducted a phase I clinical study to determine the dose of recombinant human (rh) IL-12 necessary to induce T-cell responses in combination with antigen-loaded PBMCs, and found that doses from 30 to 100 ng/kg administered subcutaneously (sc) at the vaccine site were optimal and well tolerated.²¹ The effective range of doses indicated that a straight dose of 4 μ g might be used.

In this article, we describe results of a phase II clinical study of immunization with Melan-A/MART-1³ peptide-pulsed autologous PBMCs + rhIL-12 in HLA-A2-positive patients with

From the University of Chicago, Departments of Pathology and Medicine, Section of Hematology/Oncology, and the Ben May Institute for Cancer Research, Chicago, IL.

Submitted December 26, 2002; accepted March 26, 2003.

Supported by the Burroughs Wellcome Fund, Research Triangle Park, NC, and the Cancer Research Institute, New York, NY.

A.P. and H.H. contributed equally to this work.

Address reprint requests to Thomas F. Gajewski, MD, PhD, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL 60637; email: tgajewski@medicine.bsd.uchicago.edu.

© 2003 by American Society of Clinical Oncology.

0732-183X/03/2112-2342/\$20.00

advanced melanoma. Immune responses were analyzed using a direct ex vivo ELISpot assay. We show that this vaccine approach had clinical activity and that the magnitude of increased T-cell response correlated with clinical outcome.

PATIENTS AND METHODS

Patient Enrollment and Eligibility

This was an open-label, nonrandomized, single-institution study of Melan-A peptide-pulsed autologous PBMCs + rhIL-12.⁴ The protocol was approved by the University of Chicago Institutional Review Board and all patients signed written informed consent. Patients who were both HLA-A2-positive and showed Melan-A tumor expression by reverse transcriptase polymerase chain reaction (RT-PCR) were considered for inclusion. Additional inclusion criteria were life expectancy more than 12 weeks, Karnofsky performance status ≥ 70 , and adequate hematopoietic, renal, and hepatic function. Delayed-type hypersensitivity (DTH) skin testing was performed against mumps, *Candida*, and *Trichophyton*, not for eligibility but to correlate subsequently with clinical outcome and immunization potential. Patients were excluded if they had severe cardiovascular disease or arrhythmia, were pregnant or nursing, had biologic therapy received within 4 weeks, tested positive for hepatitis B surface antigen or human immunodeficiency virus (HIV), had clinically significant autoimmune disease or any illness requiring immunosuppressive therapy, had a psychiatric illness that would interfere with patient compliance and informed consent, had active gastrointestinal bleeding or uncontrolled peptic ulcer disease, or had uncontrolled brain metastases. Patients with treated brain metastases who were clinically and radiographically stable and did not require corticosteroids were allowed to enter onto the trial.

Patient Characteristics

Twenty patients with metastatic melanoma were enrolled after giving written informed consent. Patient characteristics are outlined in Table 1. All patients had advanced disease; the majority had at least three sites of metastasis, 60% of which were visceral (ie, noncutaneous and nonpulmonary metastases). Approximately two thirds of the patients had received prior therapy, and 10 patients had an elevated lactate dehydrogenase (LDH) level, which is an important negative prognostic factor.²² Only 45% were positive for at least one recall antigen (mumps, *Candida*, or *Trichophyton*) by DTH skin testing.

RT-PCR Analysis

RNA was isolated from fresh tumor cells using guanidine and cesium chloride. cDNA was synthesized and PCR was performed for Melan-A and beta-actin using the primer pairs and reaction conditions described previously.²¹ Control reactions without reverse transcriptase were performed to rule out a contribution of genomic DNA. PCR products were visualized using a 1.5% ethidium bromide-stained agarose gel. No formal quantitation was performed.

Vaccine Preparation

Therapy consisted initially of three 21-day cycles. Vaccinations were given on the first day of each cycle and rhIL-12 was administered subcutaneously on days 1, 3, and 5. Approximately 100 to 150 mL of peripheral blood from patients was collected on day 1 of each cycle into heparinized 60-mL syringes using sterile technique. PBMCs were isolated over a Lymphoprep gradient (Lymphoprep; Axis-Shield PoC, Oslo, Norway), counted, washed, and resuspended in Dulbecco's phosphate-buffered saline (DPBS) at 40×10^6 cells/mL. At least 10×10^6 cells from each sample were cryopreserved to prepare CD8⁺ and CD8⁻ fractions for subsequent correlative immunologic studies. The Melan-A₂₇₋₃₅ peptide (AAGIGILTV) was produced according to good manufacturing practice standards by Multiple Peptide Systems (San Diego, CA) and provided in lyophilized vials. Aliquots of peptide were prepared at 5 mmol/L in dimethyl sulfoxide and stored at

Table 1. Patient Characteristics

Patient Characteristic	Patients (n = 20)	
	No.	%
Age, years		
Median		58
Range		35-79
Sex		
Male	9	45
Female	11	55
Karnofsky performance status (ECOG)		
90%-100% (0)	10	50
70%-80% (1)	9	45
60%-70% (2)	1	5
No. of metastatic sites		
1	2	10
2		None
≥ 3	18	90
Location of metastases		
Visceral	13	65
Brain (treated)	4	20
Prior therapy		
None	6	30
Chemotherapy or immunotherapy	7	35
As only prior therapy	5	25
Chemotherapy	1	5
As only prior therapy	1	5
Immunotherapy	4	20
As only prior therapy	1	5
Other*	2	10
As only prior therapy		None
Adjuvant IFN- α	5	25
As only prior therapy	3	15
Elevated LDH	10	50
DTH recall positive	9	45

Abbreviations: ECOG, Eastern Cooperative Oncology Group; IFN- α , interferon α -2b; LDH, lactate dehydrogenase; DTH, delayed-type hypersensitivity.

*Experimental therapy other than a melanoma vaccine, immunomodulatory cytokine, or chemotherapy.

-80°C for up to 3 months. Peptide preparations were quality controlled for HLA-A2 binding, sterility, and identity by high-performance liquid chromatography and mass spectrometry. An aliquot of peptide was diluted to 20 μ mol/L in DPBS and mixed with an equal volume of patient PBMCs (final peptide concentration, 10 μ mol/L; target number of PBMCs, 10^6) followed by incubation at 37°C for 1 hour in 10 mL DPBS. The cells were then irradiated (20 Gy), washed in DPBS, and resuspended in 1 mL DPBS. The suspension of peptide-loaded PBMCs was injected sc using a 1-mL syringe and a 21-gauge needle, divided evenly into two sites. Preferred sites were those near draining lymph node basins but not near a tumor mass. The actual number of PBMCs administered per vaccine ranged from 78 to 100×10^6 .

rhIL-12 was provided by Genetics Institute (Cambridge, MA) as a lyophilized powder of 10 μ g under vacuum. Each vial was intended for single use only and was stored as a powder in our research pharmacy at 2 to 8°C until reconstituted with sterile water for injection. Once reconstituted, rhIL-12 was loaded into 3-mL syringes and used within 4 hours. rhIL-12 (4 μ g) was administered sc with a 25-gauge needle just after pulsed PBMC inoculation and immediately adjacent to one of the two immunization sites on days 1, 3, and 5. The same approximate location was used for each injection of peptide-pulsed PBMCs and rhIL-12 for each cycle.

Toxicity Assessment and Criteria for Clinical Response

Toxicities were determined using the National Cancer Institute common toxicity criteria scale version 2.0. A complete response (CR) was assigned if there was disappearance of all lesions without the appearance of any new

lesions; a partial response (PR) was defined as $\geq 50\%$ reduction in total tumor volume; a minor response (MR) was defined as less than 50% reduction in total tumor volume; progressive disease (PD) was assigned if new lesions appeared, any tumor reappeared, or if a 25% increase in tumor area was observed; a mixed response was assigned if at least one tumor decreased in size with other or new tumors growing; stable disease (SD) was anything that did not fit the aforementioned criteria. When possible, cutaneous lesions were photographed.

CD8⁺ T-Cell Preparation

CD8⁺ and CD8⁻ fractions from PBMC were isolated at the time of preparation of each vaccine and cryopreserved until analysis in batch fashion. CD8⁺ T lymphocytes were isolated by positive selection using CD8 microbeads and magnetic columns (MACS system; Miltenyi Biotech, Auburn, CA). The unbound CD8⁻ fraction was cryopreserved for use as antigen-presenting cells for in vitro expansion of specific CD8⁺ T cells. Although the primary ELISpot analysis was performed directly with thawed cells, a secondary assay was carried out after in vitro expansion. For in vitro expansion, CD8⁻ cells were thawed from each time point and pooled, pulsed with 50 $\mu\text{mol/L}$ Melan-A peptide in serum-free Iscove's modified Dulbecco's medium (IMDM) with beta₂-microglobulin, irradiated (3,000 rad), washed, and plated at 2×10^6 cells/well in 24-well plates. CD8⁺ T cells were thawed and cultured with the irradiated CD8⁻ cells at 4×10^5 cells/well in IMDM medium containing 10% human AB serum. After 5 days, the cells were collected and plated with a new batch of Melan-A-pulsed irradiated CD8⁻ cells. After an additional 5 days the cells were collected and tested.

ELISpot Assays

Briefly, 96-well membrane bottomed plates (MAHA S4510; Millipore, Bedford, MA) were coated with 15 $\mu\text{g/mL}$ of antihuman IFN- γ antibody (Mabtech, Cincinnati, OH) in PBS. The plates were washed and CD8⁺ T cells, either freshly thawed at 5×10^4 cells/well or after in vitro expansion at 5×10^3 cells/well, were plated in triplicate in IMDM medium with 10% human AB serum. T2 cells (transporter associated with antigen processing-deficient cell line, American Type Culture Collection no. CRI 1992) were pulsed for 1 hour at 37°C with 50 $\mu\text{mol/L}$ peptide (either derived from HIV [ILKEPVHGV], Epstein-Barr virus [EBV; GLCTLVAML], or Melan-A [AAGIGLTV]), washed, and plated at a 5-to-1 ratio to the T cells. A replicate of CD8⁺ T cells was stimulated with PMA (phorbol 12-myristate 13-acetate) (50 ng/mL) + ionomycin (0.5 $\mu\text{g/mL}$) as a positive control. After 24 hours, the cells were removed by washing with PBS + 0.05% Tween (wash buffer), and biotinylated antihuman IFN- γ antibody was added in PBS + 0.5% fetal calf serum. The plates were incubated for 2 to 4 hours at room temperature, washed, and streptavidin-alkaline phosphatase was added for 1 hour at room temperature. The plates were then washed, BCIP-NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro-blue tetrazolium) was added, and the plates were finally washed with water and allowed to air dry. Plates were scanned with an ELISpot reader (CTL Technologies, Cleveland, OH) and the number of spots per well was enumerated after the background was set on the basis of wells that had been incubated with medium alone; spot separation was adjusted using Immunospot software (CTL Technologies). For each sample, the number of T cells producing IFN- γ in response to EBV or Melan-A peptides was determined by subtracting the number of spots seen in response to HIV peptide. The mean and SD were determined for each triplicate sample. After immunization, the time point at which peak frequencies among the first three cycles were observed was used for data analysis.

Statistical Analysis

Comparisons between pre- and post-ELISpot frequencies were performed using a paired *t* test, and comparisons of augmented ELISpot frequencies between responders and nonresponders were made using an unpaired two-sided *t* test. Correlations between various dichotomous variables and clinical outcome were made using Fisher's exact test (two-sided). Survival data were determined using the Kaplan-Meier method, with differences among subgroups assessed by the log-rank test. All analyses were performed using SPSS software (version 8.0; SPSS Inc, Chicago, IL).

Table 2. Adverse Events

Adverse Event	Grade 1	Grade 2	Grade 3
Fatigue	16	0	0
Anorexia	6	0	0
Fever	7	0	0
Rash	3	0	0
Headache	3	0	0
Nausea	2	0	0
Injection site reaction	5	0	0
Neutropenia	1	2	0
Thrombocytopenia	2	0	0
Hepatic	5	2	0
Creatinine	1	0	0

NOTE. Adverse events were determined using the National Cancer Institute common toxicity criteria scale version 2.0.

RESULTS

Immunization Treatment and Toxicities

Each 3-week cycle consisted of immunization on day 1 and sc rhIL-12 administration on days 1, 3, and 5, as described in Methods. Three cycles constituted one course of therapy and patients were evaluated for response after each course. Patients were observed as inpatients in our General Clinical Research Center for the first 24 hours of each cycle.

Adverse reactions are listed in Table 2. All but one patient completed at least three cycles of therapy. There were no grade 3 to 4 toxicities; two patients had grade 2 neutropenia and two patients had grade 2 ALT or AST elevations, which were reversible. The most common adverse reactions were fatigue and fever.

Clinical Outcome

Clinical response outcomes are listed in Table 3. Two patients had a CR, for an overall response rate of 10%. In addition, four patients (20%) had a mixed response, one patient (5%) had an MR, four patients (20%) had SD, and the remaining nine patients (45%) had PD. The sites of tumor response were diverse. The two patients who experienced a CR both had numerous metastases of 2 cm or less and a normal LDH. One patient was female, had multiple cutaneous lesions, and no prior therapy; the other patient was male, had multiple lung lesions, and had experienced prior treatment failure from chemoinmunotherapy. Neither patient experienced a recurrence with a mean follow-up time of 28 months at the time of data analysis. Of the five other patients who showed a decrease in size of at least one tumor mass, three had responses in skin, one had a response in bone, and one had a response in an adrenal lesion. Three of the four patients with SD had visceral metastases.

Table 3. Clinical Outcome

Best Response	No. of Patients	%
Complete response	2	10
Partial response	0	0
Minor response	1	5
Mixed response	4	20
Stable disease	4	20
Progressive disease	9	45




Fig 1. Interferon gamma ELISpot frequencies by CD8⁺ T cells against Melan-A and (A) Epstein-Barr virus (EBV) (B) pre- and postimmunization. Control values with HIV peptide were subtracted out. Post- and pretreatment values were compared using a paired *t* test.

Peptide-Specific T-Cell Responses by ELISpot

A carefully controlled IFN-γ ELISpot assay was used to monitor the immune response to immunization. Cryopreserved CD8⁺ T cells were thawed in batch fashion and stimulated in triplicate directly *ex vivo* with T2 cells loaded with peptides derived from either HIV, EBV, or Melan-A. The HIV values were subtracted from those obtained with either Melan-A or EBV as an internal control at each time point. Seventeen of the enrolled patients had adequate cryopreserved material with which to perform immunologic assessments.

As shown in Fig 1, some patients displayed a high frequency of Melan-A-specific CD8⁺ T cells before vaccination, with as high as 1% of CD8⁺ cells responding to this peptide. These T cells were functional because they produced IFN-γ. The majority of patients showed an increase in the frequency of Melan-A-specific cells after immunization ($P = .015$). In contrast, the frequencies of specific CD8⁺ T cells responding to the EBV peptide did not vary significantly overall ($P = .86$). Although the changes in T-cell frequency were modest, these results demonstrate an antigen-specific response after immunization with Melan-A peptide-pulsed PBMC + rhIL-12.

The changes in Melan-A-specific ELISpot frequencies were compared among patients who had a mixed response or better and those who had no clinical response. As shown in Fig 2, the mean increase in Melan-A-specific T cells for the clinical responders was 112 ± 45 and for nonresponders was 26 ± 16 , indicating that a greater absolute increase in Melan-A-specific T cells was associated with tumor regression ($P = .046$).

Survival and Associations Between Immunologic Parameters and Clinical Outcome

The overall median survival was 12.25 months and is shown in Fig 3A. Seven patients remained alive at the time of data analysis, with all patients followed beyond 12 months. Because the presence of elevated levels of serum LDH is a known




Fig 2. Comparison of increased Melan-A ELISpot frequencies after immunization between clinical responders and nonresponders. The absolute difference between Melan-A-specific ELISpot frequencies post- and pretreatment was compared between responders and nonresponders using a two-sided, unpaired *t* test.

negative prognostic factor,²³ survival was also compared in response to this vaccine on the basis of LDH level (Fig 3B). The median survival for patients with an elevated LDH level was 9.25 months, whereas the median had not yet been reached for those with a normal LDH ($P = .005$). In addition, the median survival for patients who experienced a significant increase in Melan-A-specific T cells was not yet reached, compared with 8.5 months for patients without a significant increase in Melan-A-specific cells (Fig 3C; $P = .120$).

Additional immunologic parameters that had been measured were also analyzed for associations with either clinical response or survival and are summarized in Table 4. Neither a positive recall DTH to standard antigens nor a relatively high number of EBV- or Melan-A-specific CD8⁺ T cells before immunization correlated with either outcome. The median pretreatment Melan-A-specific T cell frequency was 23 in clinical nonresponders and -26 in responders. To increase the sensitivity of the assay to detect Melan-A-specific T cells, an *in vitro* expansion was performed on the preimmunization samples and analyzed by ELISpot as described in Methods. Ten patients showed high Melan-A-specific T cell frequencies after *in vitro* expansion. However, this also failed to correlate with clinical outcome. Finally, although a normal LDH level was associated with survival, it did not correlate with clinical response and also did not correlate with immune response. Collectively, these results reinforce the specificity of the result showing a significant association between an increased number of Melan-A-specific T cells and clinical outcome.

Expression of Melan-A in Resected Tumors After Immunization

It was conceivable that some patients developed PD despite immunization because of outgrowth of Melan-A-negative tumor cells. Posttreatment tumor samples were obtained from progressing tumors from three patients and analyzed by RT-PCR. Although the new metastasis that developed in patient 1 was negative for




Fig 3. Overall survival for all patients (A), on the basis of serum lactate dehydrogenase greater than 200 U/l (B), and on the basis of increased Melan-A-specific interferon gamma-producing CD8⁺ T cells (C) was determined using the Kaplan-Meier method. Differences between groups were compared using the log-rank test.

Melan-A expression, those samples from patients 4 and 6 retained detectable expression of Melan-A mRNA (Fig 1). These results indicate that, although outgrowth of antigen-negative tumors can occur, other mechanisms of resistance to immune destruction likely explain the lack of clinical response in other patients.

DISCUSSION

In this study we used Melan-A peptide-pulsed autologous PBMC + rhIL-12 as a vaccine to treat HLA-A2-positive patients with advanced melanoma. We observed a significant increase in Melan-A-specific IFN- γ -producing CD8⁺ T cells after immunization, and found a statistical association between clinical response and the magnitude of the specific T-cell increase. Although it is difficult to compare across individual, small phase II studies, these results are similar to those that have been reported using antigen-loaded dendritic cells, but with a strategy that may be more straightforward to execute.

Preparation of the peptide-loaded PBMCs typically took 5 hours from phlebotomy to injection, and quality control of the cell product was facilitated by the lack of an extended *in vitro* culture period and absence of exposure to culture medium or serum proteins that is required for dendritic cell preparations. Conversely, dendritic cell vaccines have been prepared in batches and cryopreserved in individual doses in some studies, which obviates the need to prepare a fresh vaccine at each time point. Cryopreservation of vaccines has not yet been examined with our current approach. A comparative trial between PBMC/rhIL-12 and dendritic cell-based vaccination may, therefore, be of interest as the technologies continue to develop. Our results

support the notion developed in preclinical models that IL-12 can contribute to effective antitumor immunity, and are consistent with the results of a recent adjuvant vaccine study using rhIL-12 in melanoma.²⁴

We used a direct *ex vivo* ELISpot assay to assess antigen-specific T-cell responses in this study. Control experiments testing EBV reactivity from normal donors revealed that ELISpot analysis could be performed accurately on cryopreserved CD8⁺ T cell samples immediately after thawing (H. Harlin and T. Gajewski, unpublished data). We found that background reactivity against the control HIV peptide varied among patients and to some extent among time points for an individual patient. The magnitude of increase in apparent Melan-A-reactive T cells would have been greater in some patients had the values obtained with the HIV control peptide not been subtracted. We believe that this experimental detail is critical because it normalizes the samples for background differences and provides an internal control for minor variation between individual vials of cryopreserved T cells. We also compared the Melan-A frequencies to those against an EBV control peptide, to determine whether the treatment was altering ELISpot results. We performed our analyses on purified CD8⁺ T cells to control for variable numbers between patients and across time points. It is possible that we excluded subpopulations of CD8⁺ T cells, CD4⁺ T cells, and natural killer T cells that could have produced IFN- γ in response to Melan-A. Nonetheless, our results revealed a measurable and significant increase in Melan-A-specific T cells posttreatment. Our currently employed ELISpot assay is distinct from the assay used in our phase I trial of peptide-pulsed

Table 4. Statistical Correlates With Response or Survival

Parameter	Correlation With Response (P)	Correlation With Survival (P)
Positive DTH recall	.642	.130
Strong EBV pre-Rx*	.131	.491
Increased EBV post versus pre†	.290	.644
Strong Melan-A pre-Rx†	.644	.481
Increased Melan-A post versus pre†	.046	.120
Strong in vitro expansion of Melan-A§	.304	.565
LDH levels < 200	.99	.005

NOTE. Associations with response were determined using Fisher's exact test (two sided), except the differences between pre- and posttreatment, which were determined using an unpaired *t* test. Associations with survival were determined using the Kaplan-Meier method and log-rank test. Significant values are indicated in boldface.

Abbreviations: DTH, delayed-type hypersensitivity; EBV, Epstein-Barr virus; Rx, immunization; LDH, lactate dehydrogenase; HIV, human immunodeficiency virus; IL-2, interleukin-2.

*At least 90 spots per 10^5 CD8⁺ T cells after subtraction of background against a control HIV peptide.

†Changes between post- and prevaccination samples were calculated as the difference between the absolute number of specific spots and compared using an unpaired *t* test between clinical responders and nonresponders.

‡At least 40 spots per 10^5 CD8⁺ T cells after subtraction of background against a control HIV peptide.

§At least 90 spots per 10^5 CD8⁺ T cells after subtraction of background against a control HIV peptide, after a 10-day in vitro expansion with Melan-A peptide-pulsed autologous CD8⁺ cells and IL-2.

PBMC + rhIL-12 and in other trials^{21,25} in which in vitro expansion had been performed before assessment of IFN- γ production. Analysis of T-cell responses with minimal in vitro manipulation should most accurately reflect the status of those cells in vivo.

High frequencies of Melan-A-specific, IFN- γ -producing CD8⁺ T cells were observed in some patients at study entry when they clearly had progressively growing melanoma. This observation indicates that the absolute frequency of functional T cells against a tumor antigen does not correlate with the behavior of the tumor. We also found no statistical association between this high frequency and clinical outcome; in fact, the two patients who experienced a CR had undetectable Melan-A-specific T cells before therapy. Although high frequencies of T cells reacting with a Melan-A tetramer have been detected in some normal donors,²⁶ those cells had a naïve surface phenotype and did not produce high levels of IFN- γ . What did correlate with clinical response in our current study is a meaningful increase in Melan-A-specific T cells posttreatment. These increases were modest (a net gain of 112 spots per 10^5 CD8⁺ T cells on average), indicating either that a subtle alteration in the steady-state between the immune response and a growing tumor in favor of increased T-cell frequencies is sufficient to translate into tumor regression, or that another immune function that we are not measuring is contributing to the final event of tumor shrinkage. Tumor regressions without detectable increases in




Fig 4. Melan-A expression in tumors that persisted after immunization. Three patients underwent surgical resection of lesions (after discontinuing the study), which were analyzed for Melan-A expression by qualitative reverse transcriptase polymerase chain reaction. Controls were analyzed without reverse transcriptase or with beta-actin primers.

T-cell frequencies using standard assays have been observed in other studies.²⁷

The median overall survival in our study was 12.25 months from treatment initiation, which is greater than the expected 6 to 9 months for this patient population. Although it was a relatively small study and subject to selection bias, most patients were pretreated and had visceral disease, one half of the patients had elevated serum LDH levels, and four patients had treated brain metastases. As has been seen in melanoma patients treated with standard therapies, we found that an elevated serum LDH level was a negative prognostic factor for survival. Whether this is reflective of tumor burden or the metabolic state of the tumor cells that have adapted to an anaerobic environment is unclear.

Some patients developed increases in Melan-A-specific T cells and developed progressive tumor growth despite retained expression of the antigen on posttreatment biopsies. This observation is similar to that seen in murine studies²⁸ and indicates mechanisms of tumor resistance downstream from initial T-cell priming, presumably within the tumor microenvironment. Potential explanations include poor T-cell trafficking to tumor sites, presence of negative regulatory cells, T-cell anergy or death, expression of inhibitory molecules by tumor cells, or downregulation of class I major histocompatibility complex or antigen-processing molecules.^{29,30} Future studies should investigate definable mechanisms of tumor escape that allow tumor cells to resist elimination by antigen-specific T cells in vivo.

ACKNOWLEDGMENT

We thank Genetics Institute/Wyeth for rhIL-12, and T. Karrison, M. Sherman, S. Swiger, and M. Posner for important contributions.

REFERENCES

- Boon T, Cerottini JC, Van den Eynde B, et al: Tumor antigens recognized by T lymphocytes. *Annu Rev Immunol* 12:337-365, 1994
- Kawakami Y, Robbins PF, Wang RF, et al: Identification of tumor-regression antigens in melanoma. *Import Adv Oncol* 3-21, 1996

3. Coulie PG, Brichard V, Van Pel A, et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 180:35-42, 1994
4. Gajewski TF, Fallarino F: Rational development of tumor antigen-specific immunization in melanoma. *Ther Immunol* 2:211-225, 1995
5. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 4:328-332, 1998
6. Thurner B, Haendle I, Roder C, et al: Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 190:1669-1678, 1999
7. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. *Cancer Res* 61:6451-6458, 2001
8. Gajewski TF, Renauld JC, Van Pel A, et al: Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. *J Immunol* 154:5637-5648, 1995
9. Mehrotra PT, Wu D, Crim JA, et al: Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. *J Immunol* 151:2444-2452, 1993
10. Trinchieri G: Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annu Rev Immunol* 13:251-276, 1995
11. Fallarino F, Uyttenhove C, Boon T, et al: Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. *J Immunol* 156:1095-1100, 1996
12. Fallarino F, Gajewski TF: Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of Stat1. *J Immunol* 163:4109-4113, 1999
13. Brunda MJ, Luistro L, Warrior RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. *J Exp Med* 178:1223-1230, 1993
14. Hallez S, Detremmerie O, Giannouli C, et al: Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. *Int J Cancer* 81:428-437, 1999
15. Fallarino F, Ashikari A, Boon T, et al: Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12-but not B7-1-transfected tumor cells. *Int Immunol* 9:1259-1269, 1997
16. Vagliani M, Rodolfo M, Cavallo F, et al: Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. *Cancer Res* 56:467-470, 1996
17. Cavallo F, Signorelli P, Giovarelli M, et al: Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. *J Natl Cancer Inst* 89:1049-1058, 1997
18. Rao JB, Chamberlain RS, Bronte V, et al: IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression. *J Immunol* 156:3357-3365, 1996
19. Sumimoto H, Tani K, Nakazaki Y, et al: Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice. *Cancer Gene Ther* 5:29-37, 1998
20. Fallarino F, Uyttenhove C, Boon T, et al: Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. *Int J Cancer* 80:324-333, 1999
21. Gajewski TF, Fallarino F, Ashikari A, et al: Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. *Clin Cancer Res* 7:895a-901a, 2001
22. Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. *Cancer* 88:1484-1491, 2000
23. Eton O, Legha SS, Moon TE, et al: Prognostic factors for survival of patients treated systemically for disseminated melanoma. *J Clin Oncol* 16:1103-1111, 1998
24. Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-12 on the immune response to a multi-peptide vaccine for resected metastatic melanoma. *J Clin Oncol* 19:3836-3847, 2001
25. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 4:321-327, 1998
26. Pittet MJ, Valmori D, Dumbar PR, et al: High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. *J Exp Med* 190:705-715, 1999
27. Marchand M, van Baren N, Weynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 80:219-230, 1999
28. Wick M, Dubey P, Koeppen H, et al: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. *J Exp Med* 186:229-238, 1997
29. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. *Immunol Today* 16:487-494, 1995
30. Marincola FM, Jaffee EM, Hicklin DJ, et al: Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. *Adv Immunol* 74:181-273, 2000

Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

By Beatrice Thurner,* Ina Haendle,* Claudia Röder,*
Detlef Dieckmann,* Petra Keikavoussi,† Helmut Jonuleit,§
Armin Bender,* Christian Maczek,* Doris Schreiner,*
Peter von den Driesch,* Eva B. Bröcker,‡ Ralph M. Steinman,||
Alexander Enk,§ Eckhart Kämpgen,‡ and Gerold Schuler*

From the *Department of Dermatology, University of Erlangen-Nuremberg, D-91052 Erlangen, Germany; the †Department of Dermatology, University of Würzburg, D-97080 Würzburg, Germany; the §Department of Dermatology, University of Mainz, D-55131 Mainz, Germany; and the ||Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021

Summary

Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tetanus toxoid or tuberculin. 11 far advanced stage IV melanoma patients, who were progressive despite standard chemotherapy, received five DC vaccinations at 14-d intervals. The first three vaccinations were administered into the skin, 3×10^6 DCs each subcutaneously and intradermally, followed by two intravenous injections of 6×10^6 and 12×10^6 DCs, respectively. Only minor (less than or equal to grade II) side effects were observed. Immunity to the recall antigen was boosted. Significant expansions of Mage-3A1-specific CD8⁺ cytotoxic T lymphocyte (CTL) precursors were induced in 8/11 patients. Curiously, these immune responses often declined after the intravenous vaccinations. Regressions of individual metastases (skin, lymph node, lung, and liver) were evident in 6/11 patients. Resolution of skin metastases in two of the patients was accompanied by erythema and CD8⁺ T cell infiltration, whereas nonregressing lesions lacked CD8⁺ T cells as well as Mage-3 mRNA expression. This study proves the principle that DC "vaccines" can frequently expand tumor-specific CTLs and elicit regressions even in advanced cancer and, in addition, provides evidence for an active CD8⁺ CTL-tumor cell interaction in situ as well as escape by lack of tumor antigen expression.

Key words: dendritic cells • vaccination • active immunotherapy • melanoma • cytotoxic T lymphocytes

It is now established that the immune system has cells, particularly CD8⁺ CTLs, that can recognize tumor antigens and kill tumors (1, 2). Nevertheless, a major problem is that these T cells are either not induced or only weakly induced, i.e., the T cells are not evident in the systemic circulation. One possibility is that there is inadequate tumor antigen presentation by dendritic cells (DCs),¹ "nature's adjuvant" for eliciting T cell immunity (3). Another is that

tumor-reactive T cells are tolerized by the tumors (1, 4). Melanoma provides a compelling setting in which to pursue a current goal of cancer immunotherapy, the generation of stronger tumor-specific T cell immunity, particularly with CTLs (4). The majority of tumor antigens identified so far are expressed by melanomas (2). Limited antimelanoma CTL responses have been detected (5), and infusions of IL-2 expanded killer cells can lead to rejection of melanoma (6).

Conventional adjuvants promote antibody rather than CTL responses. Therefore, several novel strategies are being explored to induce tumor-specific T cell immunity. DC vaccination is one of these (3). Immature DCs capture

¹Abbreviations used in this paper: CNS, central nervous system; DCs, dendritic cells; DTH, delayed-type hypersensitivity; MCM, monocyte-conditioned medium; RT, reverse transcriptase; TT, tetanus toxoid.

antigens but lack full T cell-stimulatory activity (7). In the presence of appropriate stimuli, such as inflammatory cytokines, the DCs mature. DCs upregulate T cell adhesion and costimulatory molecules as well as select chemokine receptors that guide DC migration into lymphoid organs for priming of antigen-specific T cells. The use of DCs as adjuvants is supported by many animal experiments with primarily mature DCs (3, 8). These studies have shown that the injection of tumor antigen-loaded DCs reliably induces tumor-specific CTL responses, tumor resistance, and in some cases, regression of metastases (3, 8). In the few pilot trials reported so far for humans, immature DCs have been employed (9-11). Scattered tumor responses are reported, but evidence for the induction of tumor-specific CTLs by DC vaccination has not been shown.

We have developed a technique to generate large numbers of homogenous populations of mature and stable DCs from monocytes in the absence of nonhuman proteins (12, 13). We are now exploring the use of these DCs as vaccine adjuvants in humans. Here we provide the proof of the principle by demonstrating that three intracutaneous injections of Mage-3A1 peptide-pulsed mature DCs reliably enhance Mage-3A1-specific CD8⁺ and recall CD4⁺ T cell immunity in heavily pretreated, progressive stage IV melanoma patients with large tumor loads. Expansions of Mage-3A1-specific CTL responses have not been previously detected after Mage-3A1 peptide vaccination in less advanced melanoma patients (14), underscoring the potent adjuvant properties of DCs. As regressions of metastases also occurred upon DC-mediated immunization and were accompanied by CD8⁺ T cell infiltration, we propose that the induced Mage-3A1-specific CTLs are active *in vivo*.

Materials and Methods

Patient Eligibility Criteria

Patients were eligible if they suffered from stage IV (i.e., distant metastases) cutaneous malignant melanoma (1988 American Joint Committee on Cancer/Union Internationale Contre Cancer pTNM staging system) that was not curable by resection and was progressive despite chemo(immuno)therapy. Further inclusion criteria were an expected survival ≥ 4 mo, Karnofsky Index $\geq 60\%$, age ≥ 18 yr, measurable disease, HLA-A1 positivity, expression of Mage-3 gene shown by reverse transcriptase (RT)-PCR in at least one excised metastasis, and no systemic chemo-, radio-, or immunotherapy within 4 wk (6 wk in the case of nitrosurea drugs) preceding the first DC vaccination. A positive skin test to recall antigens was not required. Important exclusion criteria were active central nervous system (CNS) metastasis, any significant psychiatric abnormality, severely impaired organ function (hematological, renal, liver), active autoimmune disease (except vitiligo), previous splenectomy or radiation therapy to the spleen, organ allografts, evidence for another active malignant neoplasm, pregnancy, lactation, or participation (or intent to participate) in any other clinical trial. Concomitant treatment (chemo- or immunotherapy, corticosteroids, investigational drugs, paramedical substances) was prohibited. Palliative radiation or surgical therapy of selected metastases and certain medications (acetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs, opiates) to control symptoms were allowed.

Clinical Protocol and Study Design

The study was performed at the Departments of Dermatology in Erlangen, Würzburg, and Mainz, Germany according to standards of Good Clinical Practice for Trials on Medicinal Products in the European Community. The protocol was approved by the Protocol Review Committee of the Ludwig Institute for Cancer Research (New York, NY) and performed under supervision of its Office of Clinical Trials Management as study LUD #97-001. The protocol was also approved by the ethics committees of the involved study centers.

The study design is shown in Table II. All patients gave written informed consent before undergoing a screening evaluation to determine their eligibility. Extensive clinical and laboratory assessments were conducted at visits 1, 5, and 8 (Table II) and consisted of a complete physical examination, staging procedures, and standard laboratory values as well as special ones (pregnancy test, free testosterone in males, autoantibody profile, and antibodies to HIV-1/2, human T cell lymphotropic virus type I, hepatitis B virus, and hepatitis C virus). Patients were hospitalized and examined the day before each vaccination and were monitored for 48 h after the DC injections. Adverse events and changes in laboratory values were graded on a scale derived from the Common Toxicity Criteria of the National Cancer Institute, National Institutes of Health, Bethesda, MD.

Production of the DC Vaccine

During prestudy screening, we tested a small amount of fresh blood to verify that appropriate numbers of mature DCs could be generated from the patient's monocytes (12). Sufficient DC numbers could be successfully generated in all patients, but in some patients the test generation revealed that TNF- α had to be added to assure full maturation. To avoid repetitive blood drawings, we performed a single leukapheresis during visit 2 to generate DCs as described (13). In short, PBMCs from the leukapheresis ($\geq 10^{10}$ nucleated cells) were isolated on LymphoprepTM (Nycomed Pharma) and divided into three fractions. The first fraction of 10^9 PBMCs was cultured on bacteriological petri dishes (Cat. #1005; Falcon Labware) coated with human Ig (100 $\mu\text{g}/\text{ml}$; SandoglobulinTM; Sandoz GmbH) in complete RPMI 1640 medium (BioWhittaker) supplemented with 20 $\mu\text{g}/\text{ml}$ gentamicin (Refobacin 10; Merck), 2 mM glutamine (BioWhittaker), and 1% heat-inactivated human plasma for 24 h to generate monocyte-conditioned medium (MCM) for later use as the DC maturation stimulus. The second fraction of 3×10^8 PBMCs was used for the generation of DCs for vaccination 1 and delayed-type hypersensitivity (DTH) test I. Adherent monocytes were cultured in 1,000 U/ml GM-CSF (10×10^7 U/mg; LeukomaxTM; Novartis) and 800 U/ml IL-4 (purity $>98\%$; 4.1×10^7 U/mg in a bioassay using proliferation of human IL-4R⁺ CTL; CellGenix; expressed in *Escherichia coli* and produced under good laboratory practice conditions but verified for good manufacturing practice [GMP] safety and purity criteria by us) for 6 d, and then MCM was added to mature the DCs. MCM was supplemented in patients 04, 06, 09, 11, and 12 with 10 ng/ml GMP-rhu TNF- α (purity $>99\%$; 5×10^7 U/mg in a bioassay using murine L-M cells; a gift of Dr. G.R. Adolf, Boehringer Ingelheim Austria, Vienna, Austria) to assure full maturation of DCs. Mature DCs were harvested on day 7. The third fraction of PBMCs was frozen in aliquots and stored in the gas phase of liquid nitrogen to generate DCs for later vaccinations and DTH tests.

DCs for vaccinations were pulsed with the Mage-3A1 peptide (15) (EVDPIGHLY, synthesized at GMP quality by Clinalfa) as tumor antigen, and as a recall antigen and positive control, tetanus toxoid (TT) or tuberculin (if at visit 1 the DTH to TT in the

Multitest Merieux was >10 mm; both purchased from the Bacterial Vaccines Department of the Statens Serum Institute, Copenhagen, Denmark). The recall antigen was added at $10 \mu\text{g/ml}$ for the last 24 h, and the Mage-3A1 peptide was added at $10 \mu\text{M}$ directly to the cultures for the last 8 h (if immunity to recall antigens was strongly boosted, the dose of recall antigen was reduced to 1.0 or $0.1 \mu\text{g/ml}$ or was omitted for the intravenous DC injections to avoid a cytokine release syndrome). On day 7, mature DCs were harvested, resuspended in complete medium, washed, and pulsed once more with Mage-3A1 peptide (now at $30 \mu\text{M}$) for 60 min at 37°C . DCs were finally washed and resuspended in PBS (GMP quality PBS; BioWhittaker) for injection. DCs to be used for Mage-3A1 DTH tests were pulsed with Mage-3A1 (but no recall antigen); DCs that served as negative control in the DTH tests were not pulsed at all. An aliquot of the DCs to be used for vaccinations was analyzed as described (13) to assure that functionally active and mature DCs were generated. The features of the DCs are described in Results. Release criteria were typical morphology ($>95\%$ nonadherent veiled cells) and phenotype ($>95\%$ HLA-DR $^{+++}$ CD86 $^{+++}$ CD40 $^{+}$ CD25 $^{+}$ CD14 $^{-}$ and $>65\%$ homogeneously CD83 $^{++}$).

Immunization Schedule

A total of five vaccinations (three into the skin followed by two intravenously) with antigen-pulsed DCs were given at 14-d intervals (Table II). This design was chosen to explore the toxicity and efficacy of various routes in this trial. For vaccinations 1–3, 3×10^6 DCs were given subcutaneously at two sites (1.5×10^6 DCs in $500 \mu\text{l}$ PBS per site) and 3×10^6 intradermally at 10 sites (3×10^5 DCs in $100 \mu\text{l}$ PBS per site). The injection sites were the ventromedial regions of the upper arms and the thighs close to the regional lymph nodes and were rotated clockwise. Limbs where draining lymph nodes had been removed and/or irradiated were excluded. For intravenous vaccinations 4 and 5, a total of 6 and 12×10^6 antigen-pulsed DCs (resuspended in 25 or 50 ml PBS plus 1% autologous plasma) was administered over 5 and 10 min, respectively. Premedication with an antipyretic (500 mg acetaminophen/paracetamol p.o.) and an antihistamine (2.68 mg clemastinhydrogenfumarat i.v.) was given 30 min before intravenous DC vaccination.

Evaluation of Immune Status

Recall Antigen-specific Proliferation and Cytokine Production. PBMCs were cultured in triplicate at two dose levels (3×10^4 and 1×10^5 PBMCs/well) plus or minus TT or tuberculin (at 0.1, 1, and $10 \mu\text{g/ml}$) and pulsed on day 5 with [^3H]thymidine for 12 h. In all cases, the highest cpm were obtained with the highest doses of PBMCs and antigen and are shown in Fig. 2. IL-4 and IFN- γ levels were measured in culture media by ELISA (Endogen, Inc.). In a separate plate, staphylococcal enterotoxin (SEA; Serva) was added at 0.5, 1, and 5 ng/ml, and proliferation was assessed after 3 d to provide a positive control for helper T cell viability and responsiveness.

Enzyme-linked Immunospot Assay for IFN- γ Release from Single Antigen-specific T Cells. To quantitate antigen-specific, IFN- γ -releasing, Mage-3A1-specific effector T cells, an enzyme-linked immunospot (ELISPOT) assay was used as described (16). PBMCs (10^5 and 5×10^5 /well) or in some cases CD8 $^{+}$ or CD4 $^{+}$ T cells (isolated by MACS $^{\text{TM}}$ according to the manufacturer, Miltenyi Biotec) were added in triplicate to nitrocellulose-bottomed 96-well plates (MAHA S4510; Millipore Corp.) precoated with the primary anti-IFN- γ mAb (1-D1K; Mabtech) in $50 \mu\text{l}$ ELISPOT

medium (RPMI 1640 and 5% heat-inactivated human serum) per well. For the detection of Mage-3A1-reactive T cells, the APCs were irradiated T2A1 cells (provided by P. van der Bruggen, Ludwig Institute of Cancer Research, Brussels, Belgium) pulsed with MHC class I-restricted peptides (Mage-3A1 peptide and the HIV-1 p17-derived negative control peptide GSEELRSLY) added at 7.5×10^4 /well (final volume $100 \mu\text{l}$ /well). After incubation for 20 h, wells were washed six times, incubated with biotinylated second mAb to IFN- γ (7-B6-1; Mabtech) for 2 h, washed, and stained with Vectastain Elite kit (Vector Labs.). For detection of TT-reactive T cells, TT was added at $10 \mu\text{g/ml}$ directly to the PBMCs (1 or 5×10^5 PBMCs/flat-bottomed 96-well plate). Assays were performed on fresh PBMCs. Spots were evaluated and counted using a special computer-assisted video imaging analysis system (Carl Zeiss Vision) as described (16).

Semiquantitative Assessment of CTL Precursors. The multiple microculture method developed by Romero et al. (17) was used to obtain a semiquantitative assessment of CTLp (precursors) specific for Mage-3A1 peptide. Aliquots of frozen PBMCs were thawed and assayed together. CD8 $^{+}$ T cells were isolated with magnetic microbeads (MACS $^{\text{TM}}$ separation columns; Miltenyi Biotec) and seeded at 10^4 /well in 96-well round-bottomed plates in RPMI 1640 with 10% heat-inactivated human serum. The CD8 $^{+}$ PBMCs were pulsed with peptide Mage-3A1 or the influenza PB1 control peptide VSDGGPNLY ($10 \mu\text{g/ml}$; 30 min at room temperature), irradiated (30 Gy from a cesium source), and added as an APC population at 10^3 /well together with IL-2 (10 IU/ml final) and IL-7 (10 ng/ml final) in a total volume of $200 \mu\text{l}$ /well. On day 7, $100 \mu\text{l}$ fresh medium was substituted, and peptide Mage-3A1 or PB1 ($1 \mu\text{g/ml}$ final) and IL-2 (10 U/ml) was added. On day 12, each microwell was divided into three equal samples to test cytolytic activity in a standard 4-h ^{51}Cr -release assay on peptide-pulsed ($10 \mu\text{g/ml}$ for 1 h at 37°C) T2A1 cells, nonpulsed T2A1 cells, and K562 target cells, respectively. All of the assays were performed with an 80-fold excess of nonlabeled K562 to block NK activity. Microwells were scored positive if lysis of T2A1 targets with peptide minus lysis without peptide was $\geq 12\%$ and this specific lysis was greater than or equal to twice the lysis of T2A1 targets without peptide plus six as described (18). We aimed at testing 30 microwells of 10^4 CD8 $^{+}$ T cells. Therefore, 1/30 positive wells equals at least one CTLp in 3×10^5 (i.e., 30 wells at 10^4 CTLp per well) CD8 $^{+}$ T cells (corresponding to $\sim 3 \times 10^6$ PBMCs).

DTH. DTH to Mage-3A1 peptide was assessed by intradermal injection at two sites of each 3×10^5 Mage-3A1 peptide-loaded DC in 0.1 ml PBS. Negative controls were nonpulsed autologous DCs in 0.1 ml PBS and 0.1 ml PBS. DTH to seven common recall antigens (Multitest Merieux) including TT and tuberculin was performed on visits 1, 5, and 8 (Table II).

Assessment and Analysis of Tumor Tissue

For recruitment into the study, Mage-3 gene expression in at least one metastatic deposit had to be demonstrated by RT-PCR as described (14). Accessible superficial skin metastases were removed whenever possible after the vaccinations and subjected to Mage-3 RT-PCR as well as routine histology and immunohistochemistry (to characterize cellular infiltrates).

Statistical Analysis

For analysis of the immune response, pre- and postimmunization values were compared by paired *t* test after logarithmic transformation of the data. Significance was set at $P < 0.05$.

Results

Patient Characteristics

All 13 patients were HLA-A1⁺, had proven Mage-3 mRNA expression in at least one excised metastasis, and suffered from advanced stage IV melanoma, i.e., distant metastases that were progressive despite chemotherapy and, in some cases, chemoimmunotherapy (Table I). We offered DCs to all patients who fulfilled the inclusion and exclusion criteria, i.e., we did not select for subsets of patients. Two patients (numbers 01 and 03) succumbed to melanoma after two and three vaccinations, respectively. 11 patients received all five planned DC vaccinations in 14-d intervals (Table II) and were thus fully evaluable.

Quality of the Vaccine

All vaccine preparations were highly enriched in mature DCs. More than 95% of the cells were large and veiled in

appearance, expressed a characteristic phenotype by flow cytometry (HLA-DR⁺⁺⁺CD86⁺⁺⁺CD40⁺CD25⁺CD14⁻), and acted as strong stimulators of an MLR at DC/T cell ratios of $\leq 1:300$ (13). Most (mean 80%) expressed the CD83 mature DC marker (19). These features were stable upon removal of cytokines and culture for one to two more days (13). The DCs were pulsed with Mage-3A1 peptide as a tumor antigen and TT or tuberculin as a recall antigen. The latter were internal controls for immunization and possibly provided help for CTL responses (20).

Toxicity

No major (above grade II) toxicity or severe side effects were observed in any patient, including the two patients who were not fully evaluable. We noticed, however, local reactions (erythema, induration, pruritus) at the intracuta-

Table I. Patients' Characteristics, Status before DC Vaccination, and Response to DC Vaccination

Table 1. Patients Characteristics, Status after 5 th Vaccination												
Patient code	Sex-Age	Onset stage N	Previous therapy	Metastases at study entry ^a							Clinical Response	Survival
				regional		distant					14 days after the 5 th vaccination	
				skin	LN	Skin	LN	Lung	Liver	Other		
Patients with objective tumor regression												
04	M48	1/98	PCI								complete regression of all but 1 lung metastasis, overall progression	10 + >9
06	F81	10/97	CI								complete regression ^b of 1 lung + 4 s.c. ^c metastases, overall progression	8 + >16
07	F48	8/97	C								complete regression ^b of 1 lung ^d + 2 s.c. ^e metastases, overall progression	13 + 12†
08	M67	11/97	PC								complete regression ^b of lung + liver + 4 s.c. ^e metastases, overall progression ^h	8 + 3†
09	F43	5/98	C								Partial regression of 1 lung metastasis, overall progression	4 + >11
12	M54	9/96	CI								partial regression of axillary LN metastases, overall progression	26 + >8
Patients without objective tumor regression												
02	F73	5/98	PCI								continuous progression	18 + 5†
05	F49	10/97	CI								continuous progression	5 + >17
10	M62	8/98	C								continuous progression	1 + 6†
11	F72	7/98	C								continuous progression	4 + 9†
13	M34	12/97	CI								continuous progression	12 + 5†

Treatment centers: three patients (04, 08, and 12) were treated in Wuerzburg, two in Mainz (patients 10 and 13), and the others in Erlangen.

Pretreatment therapy: PCI, polychemoimmunotherapy. Preceding excisions and radiotherapies are not listed.

Metastases at study entry: the number and diameter of the largest metastases present at study entry are listed (number/diameter in millimeters). m, multiple (>3 metastases).

Survival: (since onset of stage IV and as of 5 August 1999) is listed as months since onset stage IV until study entry + number of months since study entry. †Patient deceased.

^aCNS metastases were regressing at study entry after gamma knife treatment.

^bDeveloped (in part) after study entry.

^cDetermined by autopsy.

^dSudden death from bleeding into CNS metastasis on visit 8.

^eThe regressions of lung metastases in patients 06 and 07 were documented at a staging 3 mo after visit 8.

mediast., mediastinum; pancr., pancreas.

Table II. Study Design

Activities	Screen	Leuka pheresis	Vacc. #1 3 Mio s.c. 3 Mio i.d.	Vacc. #2 3 Mio s.c. 3 Mio i.d.	Vacc. #3 3 Mio s.c. 3 Mio i.d.	Vacc. #4 6 Mio i.v.	Vacc. #5 12 Mio i.v.	Final Evaluation
Clinical visit	1	2	3	4	5	6	7	8
Day	-28/-14	-9	+1	+14	+28	+42	+56	+70
Vaccination			X	X	X	X	X	
Multitest Menace	X				X			X
DTH to Mage-3A1 peptide-loaded DC			X		X		X	
Recall antigen proliferation		X						X
CTLp analysis		X				X		X
ELISPOT		X	X	X	X	X	X	X
Mage-3A1 ELISPOT								
recall antigen		x	x	x	x	x	x	x

X, prespecified in the protocol as obligatory; x, optional.

neous vaccination sites that increased with the number of vaccinations. In 9/11 patients, strong DTH reactions (induration >10 mm in diameter) were noted to DCs carrying a recall antigen (Fig. 1). Elevation of body temperature (grade I and II fever) was observed in most (9/11) patients and was also related to pulsing DCs with recall antigen. The most striking example was patient 02, who progressively developed fever (up to 40°C) upon successive vaccinations but did not show a rise in body temperature when TT was omitted for the final (fifth) vaccination. We observed slight lymph node enlargement, clinically in 63% and by sonography in 83% of patients, after the intracutaneous DC injections. Interestingly, these were delayed, being inapparent during the 2 d of monitoring after vaccinations but detected when patients were investigated again the day before the next vaccination (Table II).

Immunological Responses

Boosting of Recall Antigen-specific Immunity. PBMCs that had been frozen before vaccination and 14 d after vaccination 5 were thawed and assayed together, as specified in the protocol (Table II). In most patients, a significant boost of antigen-specific immunity developed to TT (and tuberculin in patient 10) ($P < 0.004$; Fig. 2). Supernatants from the proliferative assays contained large amounts of IFN- γ (mean 1,679 pg/ml, range 846–4,325) but little IL-4 (IFN- γ /IL-4, 317:1). In five patients, we studied the kinetics of the immune response to TT by IFN- γ ELISPOT analysis. We found an increase after the intracutaneous vaccinations ($P < 0.02$) but a peculiar decrease after the intravenous vaccinations ($P < 0.008$; Fig. 3). Thus, comparing recall immunity before and after all five vaccinations (Fig. 2) as prespecified in the protocol (Table II) obviously underestimated the extent of boosting.




Figure 1. Local reactions to DCs carrying Mage-3A1 peptide and TT at the intradermal and subcutaneous vaccination sites in patient 09 (24 h after vaccination 2; top panel) and 02 (48 h after vaccination 3; bottom panel). Erythema at the 10 intradermal (left) and 2 subcutaneous (right) vaccination sites was followed by induration >10 mm in diameter (with secondary purpura in patient 02). These local reactions represent strong DTH reactions to DCs carrying TT, as such strong reactions did not occur in response to unpulsed DCs or DCs pulsed with Mage-3A1 peptide alone in DTH tests I–III (Table II; reactions not shown).




Figure 2. Recall antigen-specific immunity (tuberculin in patient 10; TT in all others) as assayed by antigen-specific proliferation. The cpm values determined after therapy (14 d after vaccination 5) are shown as multiples of pretherapy cpm values. Absolute cpm (cpm with recall antigen minus cpm without antigen) after therapy was 68,917 in patient 02, 85,225 in patient 04, 16,759 in patient 05, 7,913 in patient 06, 18,367 in patient 07, 107,923 in patient 09, 22,790 in patient 10, 4,507 in patient 12, and 1,831 in patient 13 (SEM for all measurements was <20%). Patients 08 and 11 could not be evaluated due to shortage of cells after therapy.

Expansion of Mage-3A1-specific CTLp. Aliquots of PBMCs, frozen before the first and after the third and fifth vaccinations, were thawed at the same time (Table II) and subjected to a semiquantitative recall assay for CTLp (reference 17; Fig. 4). Before vaccination, CTLp frequencies were low or undetectable. In 8/11 patients, we found a significant expansion of Mage-3A1-specific CTLp as indicated by the increase (mean, eightfold; $P < 0.008$) of positive microcultures in the multiple microculture procedure employed for the semiquantitative assessment of CTLp (17). Interestingly, in six patients, the CTLp frequencies were maximal after the three intracutaneous vaccinations ($P < 0.0013$) but then decreased after the two additional intravenous vaccinations in all but one of these patients ($P < 0.026$). Only in 1/11 patients did we observe an increase of CTLp to an irrelevant PB1 influenza peptide that served as a specificity control (not shown).




Figure 3. Kinetic analysis of immunity to recall antigens as assessed by TT-specific IFN- γ ELISPOT (SEM for all measurements was <20%). Blood was drawn (see Table II, Study Design) before the first DC vaccination and then every 14 d just before administration of the next DC vaccination (e.g., pre Vacc # 2 means immediately before vaccination 2, i.e., 14 d after vaccination 1), and finally after therapy. Time points at which vaccinations were not performed lack bars. Note the increase after the intracutaneous vaccinations and the decline upon the two vaccinations after intravenous ones. Patient 10, who received tuberculin-pulsed DCs, exhibited no significant change in the TT-specific IFN- γ ELISPOT as expected.

ELISPOT Analysis for IFN- γ -releasing, Mage-3A1-specific T Cells. We also tried to detect Mage-3A1-specific CTL effectors in uncultured fresh, nonfrozen PBMCs by performing ELISPOT analyses at 14-d intervals on all patients. A significant increase of Mage-3A1-reactive IFN- γ spot-forming cells was apparent only in patients 07 and 09 after the first and second vaccinations, respectively, but the frequency of Mage-3A1-specific effectors was very high ($\sim 5,000$ and $10,500/10^7$ CD8 $^+$ T cells; not shown).

DTH Test to Mage-3A1 Peptide-loaded DCs. Tests of DTH to Mage-3A1 peptide-loaded DCs yielded erythema and/or induration (>5 mm diameter) in 7/11 patients (not shown). The results were, however, equivocal due to the frequently observed background to nonpulsed DCs (up to 10 mm in diameter) and the variability from test site to test site.

Clinical Responses

At the end of the trial, i.e., ~ 2 wk after the fifth vaccination (Table II), we observed temporary growth cessation of some individual metastases, but more intriguingly, in 6/11 patients, complete regression of individual metastases in skin, lymph nodes, lung, and liver (Table I and Fig. 5). Resolution of skin metastases was found in three patients (Table I, patients 06, 07, and 08) and in two of them (06 and 07), it was preceded by local pain, itching, and slight erythema. The six regressing skin lesions of patients 06 and 07 (Table I) were also excised and examined by immunohistology. Clusters of CD8 $^+$ T cells were seen around and in the tumor, the latter often necrotic, suggesting an immune attack (Fig. 6).

In patients 06 and 08, the metastases excised at study entry (four and two, respectively) proved to be Mage-3 mRNA $^+$. However, all of the samples removed at the end (two and six, respectively) were Mage-3 mRNA $^-$, suggesting immunoselection for antigen-negative tumor cells. Remarkably, significant infiltration of CD8 $^+$ T cells was not found in any of these lesions.

Discussion

In deciding on the source of DCs for this phase I trial, we selected mature, monocyte-derived DCs for the follow-




Figure 4. Mage-3A1 CTLp frequency analysis as assessed by semiquantitative recall assay. The y-axis and the numbers above the bars indicate the percentage of positive wells found before vaccination 1, before vaccination 4 (14 d after vaccination 3), and after therapy (usually 14 d after vaccination 5).

ing reasons. Monocyte-derived DCs currently represent the most homogenous and potent DC populations, with several defining criteria and quality controls (12, 13, 21). The method for generating production of these DCs is very reproducible and allows the cryopreservation of large numbers of cells at an identical stage of development (12, 13). Furthermore, these DCs can be produced in the absence of potentially hazardous FCS (12, 13, 21). FCS exposure also leads to large syngeneic T cell responses in culture, so their clinical use (11) might produce nonspecific immunostimulatory effects. Unlike other investigators (9–11), we chose to use mature rather than immature DCs for our first melanoma trial. The DCs that have been used with efficacy in animal experiments were primarily mature (3, 8). Mature DCs are much more potent in inducing CTL and Th1 responses in vitro (reference 22 and Jonuleit, H., A. Gieseke, A. Kandemir, L. Paragnik, J. Knop, and A.H. Enk, manuscript in preparation), and the DCs are also resistant to the immunosuppressive effects of IL-10 (23) that can be produced by tumors (24–26). Mature DCs also display an extended half-life of antigen-presenting MHC class I (26a) and class II molecules (27). Finally, mature DCs have a high migratory activity (21) and express CCR7 (28), a receptor for chemokines produced constitutively in

lymphoid tissues (28). Mature DCs, as used in this cancer therapy trial, have recently also been shown to rapidly generate broad T cell immunity in healthy subjects (28).

Mature DCs were loaded with only one melanoma peptide, Mage-3A1, to avoid uncertainties regarding loading of DCs with multiple peptides (11) of varying affinity and off rate. Successful loading was verified with a Mage-3A1-specific CTL clone and ELISPOT analysis (not shown). The Mage-3A1 peptide (15) was selected for several reasons. It is essentially tumor specific (2) and expressed in tumors other than melanoma (2), and the Mage-3A1 epitope is likely a rejection antigen (14). Moreover, the Mage-3A1 CTLp frequency is exceedingly low in noncancer patients (reference 18; 0.4–3 per 10^7 CD8⁺ T cells) as well as in cancer patients, even after peptide vaccination (14). Thus, any induction or boost of Mage-3A1 CD8⁺ T cell responses would indicate a significant superiority in the adjuvant capacities of DCs.

DTH assays with peptide-pulsed DCs were carried out as described by Nestle et al. (11) to detect Mage-3A1 immunity (not shown). However, we did not detect unequivocal DTH. This was due to the frequently observed background to nonpulsed DCs (possibly due to cytokine production by DCs) and the noteworthy variability from test site to test site. As Mage-3A1-specific T cells are CD8⁺




Figure 5. Regression (arrows) of a globular (13 mm in diameter) lung metastasis in patient 07 that was then no longer detectable in serial 6-mm-thick computed tomography scans.




Figure 6. Regressing subcutaneous metastases in patient 06 display a CD8⁺ lymphocytic infiltrate (alkaline phosphatase/antialkaline phosphatase immunohistochemical staining with anti-CD8 mAb) that surrounds (A) and infiltrates (B) the tumor. Areas of damaged (B, ★) and necrotic (C, ★) melanoma cells are obvious in the vicinity of the CD8⁺ T cell infiltrate. The metastasis expressed Mage-3, as demonstrated by RT-PCR (data not shown). Magnifications: A, 100; B, 250; C, 160.

T cells and DTH assays typically detect primed CD4⁺ T cells, we suspect that DTH to MHC class I peptide-pulsed DCs may also for this reason prove not to be a sensitive or reliable way to monitor specific CD8⁺ T cell-mediated immunity.

In contrast, we found sizable expansions of Mage-3A1-specific CTL precursors in PBMCs from a majority (8/11) of patients ($P < 0.008$; Fig. 4). This is an important proof of the principle of DC-based immunization, and it is also significant from the point of view that tumors can induce tolerance or anergy. It is very promising that CTLp expansions can be induced in far advanced and heavily pretreated stage IV melanoma patients. However, active Mage-3A1-specific effectors were generally not observed in ELISPOT assays, except for in two patients with high frequencies ($>5,000/10^7$ CD8⁺ T cells). Perhaps active CD8⁺ effectors were rapidly sequestered in the numerous metastases, as suggested by the biopsy studies illustrated in Fig. 6. An alternative explanation is that looking for effectors in peripheral blood 14 d after a preceding vaccination might simply be too late.

Interestingly, in six patients, CTLp had increased to their highest levels after the three intracutaneous vaccinations ($P < 0.0013$) and then decreased ($P < 0.026$) with subsequent intravenous immunizations (Fig. 4). The decrease in CTLp might be due to emigration of activated Mage-3-reactive CTLs into tissues, tolerance induction, or clonal exhaustion via the intravenous route. We also observed decreased responses to recall antigens in the five patients that we studied before and after intravenous vaccination (Fig. 3). The effect of the intravenous route requires additional study, as it may be counterproductive. In contrast, our results clearly demonstrate that the intracutaneous route is effective, so that the less practical intranodal injection propagated by other investigators (11) does not seem essential. It will, however, be necessary to compare subcutaneous and intradermal routes to find out if one is superior.

We found regression of individual metastases in 6/11 patients when patients were staged 14 d after the fifth vaccination (Table I). This percentage of responses was unexpected in far advanced stage IV melanoma patients who were all progressive despite standard chemotherapy and even chemolimmunotherapy. In the study by Nestle et al. (11), chemotherapy was only given to 4/16 melanoma patients, and objective tumor responses were observed in 5/16. Therefore, we attribute the regressions to DC-mediated induction of Mage-3A1-specific CTLs. This interpretation is supported by the heavy infiltration with CD8⁺ T cells of regressing but not nonregressing (skin) metastases. The observation that all of the metastases in patients 06 and 08 that were excised at the end of the study were Mage-3 mRNA⁺ (whereas those removed at the onset were uniformly positive) suggests immune escape of and selection for Mage-3 antigen-negative tumors. Immune escape might also have been responsible for the lack of tumor response in those nonresponders that had mounted a Mage-3A1-specific CTL response.

After the end of the trial, surviving patients received further vaccinations with DCs and several tumor peptides (Mage-1, tyrosinase, and Mage-3) that were no longer part of the protocol. It is encouraging that 5/11 patients are still alive (Table I) 9–17 mo after study entry, as the expected median survival in patients progressive after chemo(immuno)therapy is only 4 mo (29, 30). One of the initial responders (patient 06) has recently experienced a complete response and has now been disease free for 2 mo. It is interesting that Marchand et al. (14) have also observed that regressions, once they have started, proceed slowly and may take months to complete.

In conclusion, the use of a defined DC vaccine combined with detailed immunomonitoring provides proof that vaccination with mature DCs expands tumor-specific T cells in advanced melanoma patients. In addition, we have found some evidence for the direct interaction between

CD8⁺ CTLs and tumor cells as well as for escape of antigen-negative metastases. We are convinced that DC-mediated immunization can be intensified further to reveal the presence of expanded populations of effector cells. Efficacy might be increased at the level of the DC, e.g., by optimizing

variables such as DC maturational state, route, dose, and schedule or by improving the short life span of DCs in vivo (31, 32); at the level of the T cell, e.g., by providing melanoma-specific CD4⁺ T cell help (33, 34) or IL-2 (35); and by treating patients earlier in their disease course.

We are grateful to all patients for their confidence and cooperation. We appreciate the support of J. Knop, Head of the Department of Dermatology in Mainz. We thank our colleagues H.B.-R. Balda, H. Hintner, F.S.M. Meurer, and C.R. Neumann for referring patients and T.L. Diepgen for statistical analysis. We are particularly grateful to T. Boon and P. van der Bruggen, who helped us in many ways, and to A. Knuth and T. Woelfel for help in establishing the semiquantitative CTL and ELISPOT assays, respectively. We are obliged to the Protocol Review Committee and Office of Clinical Trials Management of the Ludwig Institute for Cancer Research, in particular H.F. Oettgen and E. Hoffman, for their suggestions on improving the protocol and for supervising the trial.

This work was supported by a grant from the Deutsche Krebshilfe (project #70-2291). B. Thurner was supported by the Training and Mobility of Researchers (TMR) programme of the European Union (EUNIDI).

Address correspondence to Gerold Schuler, Dermatologische Klinik mit Poliklinik, Hartmannstr. 14, D-91052 Erlangen, Germany. Phone: 49-9131-85-0, ext. 33661; Fax: 49-9131-85-6175; E-mail: schuler@derma.med.uni-erlangen.de

Submitted: 1 June 1999 Revised: 21 September 1999 Accepted: 24 September 1999

References

- Schreiber, H. 1999. Tumor Immunology. In *Fundamental Immunology*. W.E. Paul, editor. Lippincott-Raven Publishers, Philadelphia. 1237-1270.
- Van den Eynde, B.J., and P. van der Bruggen. 1997. T cell defined tumor antigens. *Curr. Opin. Immunol.* 9:684-693.
- Schuler, G., and R.M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. *J. Exp. Med.* 8:1183-1187.
- Pardoll, D.M. 1998. Cancer vaccines. *Nat. Med.* 4(Suppl.): 525-531.
- Romero, P., P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. *J. Exp. Med.* 188:1641-1650.
- Rosenberg, S.A. 1998. New opportunities for the development of cancer immunotherapies. *Cancer J. Sci. Am.* 4(Suppl.):S1-4.
- Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature*. 393:245-252.
- Lotze, M.T., H. Farhood, C.W. Wilson, and W.J. Storkus. 1999. Dendritic cell therapy of cancer and HIV infection. In *Dendritic Cells: Biology and Clinical Applications*. M.T. Lotze and A. Thomson, editors. Academic Press, San Diego, CA. 459-485.
- Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taldi, E.G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nat. Med.* 2:52-58.
- Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. *Prostate*. 29:371-380.
- Nestle, F.O., S. Altjagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat. Med.* 4:328-332.
- Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. *J. Immunol. Methods*. 196:137-151.
- Thurner, B., C. Röder, D. Dieckmann, M. Heuer, M. Kruse, A. Glaser, P. Kerkavoussi, E. Kampgen, A. Bender, and G. Schuler. 1999. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. *J. Immunol. Methods*. 223:1-15.
- Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.H. Tessler, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int. J. Cancer*. 80:219-230.
- Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gafotto, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J. Exp. Med.* 179:921-930.
- Herr, W., B. Linn, N. Leister, E. Wandel, K.H. Meyer zum Buschenfelde, and T. Wolfel. 1997. The use of computer-assisted video image analysis for the quantification of CD8⁺ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. *J. Immunol. Methods*. 203:141-152.
- Romero, P., J.C. Cerottini, and G.A. Waanders. 1998. Novel methods to monitor antigen-specific cytotoxic T-cell responses

- in cancer immunotherapy. *Mol. Med. Today*. 4:305-312.
18. Chaux, P., V. Vantomme, P. Coulie, T. Boon, and P. van der Bruggen. 1998. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. *Int. J. Cancer*. 77:538-542.
 19. Zhou, L.J., and T.F. Tedder. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. *J. Immunol.* 154:3821-3835.
 20. Lanzavecchia, A. 1998. Immunology. Licence to kill. *Nature*. 393:413-414.
 21. Jonuleit, H., U. Kuhn, G. Müller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A.H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. *Eur. J. Immunol.* 27:3135-3142.
 22. Dhodapkar, M.V., R.M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V. Cerundolo, D.F. Nixon, et al. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. *J. Clin. Invest.* 104:173-180.
 23. Steinbrink, K., H. Jonuleit, G. Müller, G. Schuler, J. Knop, and A.H. Enk. 1999. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8⁺ T cells resulting in a failure to lyse tumor cells. *Blood*. 93:1634-1642.
 24. Enk, A.H., H. Jonuleit, J. Saloga, and J. Knop. 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. *Int. J. Cancer*. 73:309-316.
 25. Sato, T., P. McCue, K. Masuoka, S. Salwen, E.C. Lattime, M.J. Mastrangelo, and D. Berd. 1996. Interleukin 10 production by human melanoma. *Clin. Cancer Res.* 2:1383-1390.
 26. Dummer, W., J.C. Becker, A. Schwaaf, M. Leverkus, T. Möll, E.B. Bröcker. 1995. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. *Melanoma Res.* 5:67-68.
 - 26a. Keikavoussi, P., C. Carstens, C. Schelcher, F. Koch, W. Fries, E.B. Bröcker, N. Koch, and E. Kämpgen. 1999. Full maturation of human monocyte derived dendritic cells results in stable expression of MHC class I molecules. *Arch. Dermatol. Res.* 291:110. (Abstr.)
 27. Cella, M., A. Engering, V. Pinet, J. Pieters, A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. *Nature*. 388:782-787.
 28. Dieu, M.C., B. Vanbervliet, A. Vicari, J.M. Bridon, E. Oldham, S. Alt-Yahia, F. Briere, A. Zlotnik, S. Lebecque, and C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. *J. Exp. Med.* 188:373-386.
 29. Balch, C.M., A.N. Houghton, A.J. Sober, and S. Soong. 1998. Cutaneous Melanoma. 3rd ed. Quality Medical Publishing Corporation, St. Louis, MO. 596.
 30. Kamanabrou, D., C. Straub, M. Heinsch, C. Lee, and A. Lippold. 1999. Sequential biochemotherapy of INF- α /IL-2, cisplatin (CDDP), dacarbazine (DTIC) and carmustine (BCNU). Result of a monocenter phase II study in 109 patients with advanced metastatic malignant melanoma (MMM). *Proc. Am. Soc. Clin. Oncol.* 18:2044a. (Abstr.)
 31. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. *J. Exp. Med.* 180:1263-1272.
 32. Wong, B.R., R. Josien, S.Y. Lee, B. Sauter, H.L. Li, R.M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. *J. Exp. Med.* 186:2075-2080.
 33. Topalian, S.L., M.I. Gonzales, M. Parkhurst, Y.F. Li, S. Southwood, A. Sette, S.A. Rosenberg, and P.F. Robbins. 1996. Melanoma-specific CD4⁺ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. *J. Exp. Med.* 183:1965-1971.
 34. Chaux, P., V. Vantomme, V. Stroobant, K. Thielemans, J. Corthals, R. Luiten, A.M. Eggermont, T. Boon, and P. van der Bruggen. 1999. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. *J. Exp. Med.* 189:767-778.
 35. Shimizu, K., R.C. Fields, M. Giedlin, and J.J. Mule. 1999. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. *Proc. Natl. Acad. Sci. USA*. 96:2268-2273.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.